

```

chain nodes :
  7  8 16 21 22 23 26
ring nodes :
  1  2  3  4  5  6  9 10 11 12 13 14
chain bonds :
  1-8 3-7 4-21 6-26 22-23
ring bonds :
  1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-14 10-11 11-12 12-13 13-14
exact/norm bonds :
  1-2 1-6 1-8 2-3 3-4 3-7 4-5 4-21 5-6 6-26 22-23
normalized bonds :
  9-10 9-14 10-11 11-12 12-13 13-14
isolated ring systems :
  containing 1 : 9 :
  
```

G1:[*1],[*2]

G2:CN,Hy,[*3]

```

Match level :
  1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom 11:Atom
 12:Atom 13:Atom 14:Atom 16:Atom 21:CLASS 22:CLASS 23:CLASS 26:CLASS
Generic attributes :
  8:
  Saturation : Unsaturated
 16:
  Saturation : Unsaturated
  Number of Carbon Atoms : less than 7
  Type of Ring System : Monocyclic
  
```

```

Element Count :
  Node 16: Limited
    C,C4-5
    N,N1-2
  
```

0,00
S,S0

10/527,391

=>

Uploading C:\Program Files\Stnexp\Queries\10527391.str



chain nodes :

7 8 17 22 23 24 25 29

ring nodes :

1 2 3 4 5 6 10 11 12 13 14 15

chain bonds :

3-7 4-22 23-24

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-15 11-12 12-13 13-14 14-15

exact/norm bonds :

1-2 2-3 3-4 3-7 4-5 4-22 23-24

normalized bonds :

1-6 5-6 10-11 10-15 11-12 12-13 13-14 14-15

isolated ring systems :

containing 1 : 10 :

G1:[*1],[*2]

G2:CN, [*3], [*4]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 17:Atom 22:CLASS 23:CLASS 24:CLASS
25:Atom 29:CLASS 30:Atom

Generic attributes :

17:

Saturation : Unsaturated

Number of Carbon Atoms : less than 7

Type of Ring System : Monocyclic

Element Count :

Node 17: Limited

C, C4-5

N, N1-2

O, O0

S, S0

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 14:49:42 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 24405 TO ITERATE

8.2% PROCESSED 2000 ITERATIONS

0 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 478751 TO 497449

PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 sss ful

FULL SEARCH INITIATED 14:49:51 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 488565 TO ITERATE

100.0% PROCESSED 488565 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.06

L3 0 SEA SSS FUL L1

=>

Uploading C:\Program Files\Stnexp\Queries\10527391 (a).str



```

chain nodes :
7 8 17 22
ring nodes :
1 2 3 4 5 6 10 11 12 13 14 15
chain bonds :
3-7 4-22
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-15 11-12 12-13 13-14 14-15
exact/norm bonds :
1-2 1-6 2-3 3-4 3-7 4-5 4-22 5-6
normalized bonds :
10-11 10-15 11-12 12-13 13-14 14-15
isolated ring systems :
containing 1 : 10 :

```

G1:[*1],[*2]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 17:Atom 22:CLASS

Generic attributes :

8:

Saturation : Unsaturated

17:

Saturation : Unsaturated

Number of Carbon Atoms : less than 7

Type of Ring System : Monocyclic

Element Count :

Node 17: Limited

C,C4-5

N,N1-2

O,O0

S,S0



L4 STRUCTURE UPLOADED

=> d 14

L4 HAS NO ANSWERS

L4 STR

10/527,391



G1 [01],[02]

Hy²

Structure attributes must be viewed using STN Express query preparation.

=> s l4 sss sam

SAMPLE SEARCH INITIATED 14:51:59 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 29684 TO ITERATE

6.7% PROCESSED 2000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

10 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 583375 TO 603985
PROJECTED ANSWERS: 2238 TO 3698

L5 10 SEA SSS SAM L4

=> =>

Uploading C:\Program Files\Stnexp\Queries\10527391 (b).str



```

chain nodes :
7 8 17 22 23 24 27
ring nodes :
1 2 3 4 5 6 10 11 12 13 14 15
chain bonds :
3-7 4-22 23-24
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-15 11-12 12-13 13-14 14-15
exact/norm bonds :
1-2 1-6 2-3 3-4 3-7 4-5 4-22 5-6 23-24
normalized bonds :
10-11 10-15 11-12 12-13 13-14 14-15
isolated ring systems :
containing 1 : 10 :

```


G1:[*1],[*2]

G2:CN,Hy

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 17:Atom 22:CLASS 23:CLASS 24:CLASS
27:CLASS 28:Atom

Generic attributes :

8:

Saturation : Unsaturated

17:

Saturation : Unsaturated

Number of Carbon Atoms : less than 7

Type of Ring System : Monocyclic

Element Count :

Node 17: Limited

C,C4-5

N,N1-2

O,O0

S,S0

L6 STRUCTURE UPLOADED

=> d 16

L6 HAS NO ANSWERS

L6 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s 16 sss sam

SAMPLE SEARCH INITIATED 14:54:00 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 29360 TO ITERATE

6.8% PROCESSED 2000 ITERATIONS

0 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 576951 TO 597449

PROJECTED ANSWERS: 0 TO 0

L7 0 SEA SSS SAM L6

=> s 16 sss ful

10/527,391

FULL SEARCH INITIATED 14:54:15 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 587832 TO ITERATE

100.0% PROCESSED 587832 ITERATIONS
SEARCH TIME: 00.00.07

4 ANSWERS

L8 4 SEA SSS FUL L6

=> =>

Uploading C:\Program Files\Stnexp\Queries\10527391 (c).str



chain nodes :
7 8 16 21 22 23 26
ring nodes :
1 2 3 4 5 6 9 10 11 12 13 14
chain bonds :

10/527,391

3-7 4-21 6-26 22-23
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-14 10-11 11-12 12-13 13-14
exact/norm bonds :
1-2 1-6 2-3 3-4 3-7 4-5 4-21 5-6 6-26 22-23
normalized bonds :
9-10 9-14 10-11 11-12 12-13 13-14
isolated ring systems :
containing 1 : 9 :

G1:[*1],[*2]

G2:CN,Hy

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 16:Atom 21:CLASS 22:CLASS 23:CLASS 26:CLASS
27:CLASS
Generic attributes :
8:
Saturation : Unsaturated
16:
Saturation : Unsaturated
Number of Carbon Atoms : less than 7
Type of Ring System : Monocyclic

Element Count :
Node 16: Limited
C,C4-5
N,N1-2
O,O0
S,S0

L9 STRUCTURE UPLOADED

=> d 19

L9 HAS NO ANSWERS

L9 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s 19 sss sam

SAMPLE SEARCH INITIATED 14:57:13 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 29377 TO ITERATE

6.8% PROCESSED 2000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

10/527,391

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 577288 TO 597792
PROJECTED ANSWERS: 0 TO 0

L10 0 SEA SSS SAM L9

=> s l9 sss ful
FULL SEARCH INITIATED 14:57:24 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 588119 TO ITERATE

100.0% PROCESSED 588119 ITERATIONS 4 ANSWERS
SEARCH TIME: 00.00.07

L11 4 SEA SSS FUL L9

=> => s l11
L12 1 L11

=> d l12 bib,ab,hitstr

L12 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2005:979622 CAPLUS

DN 143:286440

TI Preparation of tetrasubstituted pyrimidin-2-ones as human neutrophil elastase inhibitors

IN Gielen-Haertwig, Heike; Albrecht, Barbara; Keldenich, Joerg; Li, Volkhart; Pernerstorfer, Josef; Schlemmer, Karl-Heinz; Telan, Leila

PA Bayer Healthcare A.-G., Germany

SO PCT Int. Appl., 119 pp.


CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005082863	A2	20050909	WO 2005-EP1487	20050215
	WO 2005082863	A3	20051222		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2557272	A1	20050909	CA 2005-2557272	20050215
	EP 1730121	A2	20061213	EP 2005-707387	20050215
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR			
	JP 2007523931	T	20070823	JP 2007-500100	20050215
	US 20080021053	A1	20080124	US 2007-590786	20070720
PRAI	EP 2004-4315	A	20040226		
	WO 2005-EP1487	W	20050215		
OS	MARPAT 143:286440				
AB	Title compds. I [A = heteroaryl ring; R1-3 = H, halo, NO2, etc.; R4 = CF3CO, alkylcarbonyl, etc.; R5 = alkyl, alkoxy, etc.; R6 = T-U; T = alkanediyl, akenediyl; U = aryl, heteroaryl, etc.; R7 = halo, NO2, CN, etc.; Y1-5 = independently CH, N wherein the ring contains 0-2 N atoms] and analogs are prepared For instance, II is prepared in 6 steps from 2-bromo-5-methylpyridine, allyl 3-oxobutanoate and N-[3-(trifluoromethyl)phenyl]urea. II has an IC50 = 70 nM for human neutrophil elastase (HNE). I are useful for the treatment of chronic obstructive pulmonary diseases, acute coronary syndrome, acute myocardial infarction and heart failure development.				
IT	864150-62-9P 864150-63-0P				
	RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)				
	(preparation of tetrasubstituted pyrimidin-2-ones as human neutrophil elastase inhibitors)				
RN	864150-62-9 CAPLUS				
CN	2-Furancarboxylic acid, 5-[[[5-cyano-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]methyl]-, methyl ester (CA INDEX NAME)				



RN 864150-63-0 CAPLUS

CN 4-Oxazolecarboxylic acid, 2-[[5-cyano-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]methyl]-, methyl ester (CA INDEX NAME)



IT 864150-79-8P 864150-80-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of tetrasubstituted pyrimidin-2-ones as human neutrophil elastase inhibitors)

RN 864150-79-8 CAPLUS

CN 4-Oxazolecarboxylic acid, 2-[[5-cyano-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864150-80-1 CAPLUS

CN 2-Furancarboxylic acid, 5-[[(6R)-5-cyano-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



=> =>

Uploading C:\Program Files\Stnexp\Queries\10527391 (d).str



chain nodes :

7 8 16 21 22 23 26

ring nodes :

1 2 3 4 5 6 9 10 11 12 13 14

chain bonds :

1-8 3-7 4-21 6-26 22-23

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-14 10-11 11-12 12-13 13-14

exact/norm bonds :

1-2 1-6 1-8 2-3 3-4 3-7 4-5 4-21 5-6 6-26 22-23

normalized bonds :

9-10 9-14 10-11 11-12 12-13 13-14

isolated ring systems :

containing 1 : 9 :

G1:[*1],[*2]

G2:CN,Hy,[*3]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 16:Atom 21:CLASS 22:CLASS 23:CLASS 26:CLASS

Generic attributes :

8:
Saturation : Unsaturated
16:
Saturation : Unsaturated
Number of Carbon Atoms : less than 7
Type of Ring System : Monocyclic

Element Count :

Node 16: Limited
C,C4-5
N,N1-2
O,O0
S,S0

L13 STRUCTURE UPLOADED

=> d l13

L13 HAS NO ANSWERS

L13 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l13 sss sam

SAMPLE SEARCH INITIATED 15:03:59 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 29448 TO ITERATE

6.8% PROCESSED 2000 ITERATIONS 2 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 578695 TO 599225
PROJECTED ANSWERS: 263 TO 913

L14 2 SEA SSS SAM L13

=> => d his

(FILE 'HOME' ENTERED AT 14:41:42 ON 20 JUL 2008)

FILE 'REGISTRY' ENTERED AT 14:49:04 ON 20 JUL 2008

```
L1          STRUCTURE UPLOADED
L2          0 S L1 SSS SAM
L3          0 S L1 SSS FUL
L4          STRUCTURE UPLOADED
L5          10 S L4 SSS SAM
L6          STRUCTURE UPLOADED
L7          0 S L6 SSS SAM
L8          4 S L6 SSS FUL
L9          STRUCTURE UPLOADED
L10         0 S L9 SSS SAM
L11         4 S L9 SSS FUL
```

FILE 'CAPLUS' ENTERED AT 14:57:43 ON 20 JUL 2008

```
L12         1 S L11
```

FILE 'REGISTRY' ENTERED AT 15:02:08 ON 20 JUL 2008

```
L13         STRUCTURE UPLOADED
L14         2 S L13 SSS SAM
L15         801 S L13 SSS FUL
```

=> => s l15

```
L16         30 L15
```

=> d l16 1-30 bib,ab,hitstr

L16 ANSWER 1 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2008:6179 CAPLUS

DN 148:121717

TI Preparation of 1,4-diaryldihydropyrimidin-2-ones for treatment of pulmonary arterial hypertension.

IN von Nussbaum, Franz; Gielen-Haertwig, Heike; Klein, Martina; Li, Volkhart; Meibom, Daniel; Sandner, Peter; Lustig, Klemens; Schaefer, Stefan

PA Bayer Healthcare Aktiengesellschaft, Germany

SO Ger. Offen., 34pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 102006031314	A1	20080103	DE 2006-102006031314	20060701
	WO 2008003412	A1	20080110	WO 2007-EP5579	20070625
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, GN, GR, GU, HW, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRAI DE 2006-102006031314 A 20060701

OS MARPAT 148:121717

AB Use of title compds. [I; X = CH, N; R1 = (CH2)nCO2R1 3-CH2C6H4CO2R1a, 4-CH2C6H4CO2R1a; n = 1, 2; R1a = H, alkyl; R2 = cyano, COR2a, CO2R2a; R2a = (substituted) alkyl, cycloalkyl; R3 = H, R4 = H, F, Cl; or R3 = F, Cl and R4 = H] for use in preparation of a drug for treatment of pulmonary arterial hypertension is claimed. Thus, 5-methylhexane-2,4-dione, 4-formylbenzonitrile, and 1-[3-(trifluoromethyl)phenyl]urea were heated with polyphosphoric acid in THF overnight at 80° to give a residue which was subjected to chiral chromatog. to give 8% 4-[(4R)-5-isobutyryl-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidin-4-yl]benzonitrile. I inhibited human neutrophil elastase with IC50 = 0.9-20 nM.

IT 905287-66-3P


RL: PAC (Pharmacological activity); PUR (Purification or recovery); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of diaryldihydropyrimidinones for treatment of pulmonary arterial hypertension)

RN 905287-66-3 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester, (4R)- (CA INDEX NAME)

Absolute stereochemistry.




IT 1000588-65-7P 1000588-69-1P 1000588-72-6P
 RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN
 (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);
 PREP (Preparation); USES (Uses)
 (preparation of diaryldihydropyrimidinones for treatment of pulmonary
 arterial hypertension)
 RN 1000588-65-7 CAPLUS
 CN Benzonitrile, 4-[(4R)-1,2,3,4-tetrahydro-6-methyl-5-(2-methyl-1-oxopropyl)-
 2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1000588-69-1 CAPLUS
 CN Benzonitrile, 4-[(4R)-5-acetyl-1-[4-fluoro-3-(trifluoromethyl)phenyl]-
 1,2,3,4-tetrahydro-6-methyl-2-oxo-4-pyrimidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1000588-72-6 CAPLUS

CN Benzonitrile, 4-[(4R)-5-acetyl-1-[3-fluoro-5-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-4-pyrimidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 1000588-66-8P


RL: PAC (Pharmacological activity); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of diaryldihydropyrimidinones for treatment of pulmonary arterial hypertension)

RN 1000588-66-8 CAPLUS


CN Benzonitrile, 4-[(4R)-5-(cyclobutylcarbonyl)-1-[3-fluoro-5-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




IT 904958-43-6P 956487-28-8P 1000588-67-9P
 1000588-68-0P 1000588-70-4P 1000588-71-5P
 1000588-73-7P 1000588-74-8P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (preparation of diaryldihydropyrimidinones for treatment of pulmonary
 arterial hypertension)
 RN 904958-43-6 CAPLUS
 CN 1(2H)-Pyrimidineacetic acid, 6-(4-cyanophenyl)-5-(ethoxycarbonyl)-3,6-
 dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, (6R)- (CA INDEX
 NAME)

Absolute stereochemistry.



RN 956487-28-8 CAPLUS
 CN 1(2H)-Pyrimidineacetic acid, 6-(4-cyanophenyl)-5-(ethoxycarbonyl)-3,6-
 dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl
 ester, (6R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1000588-67-9 CAPLUS

CN 1(2H)-Pyrimidineacetic acid, 6-(4-cyanophenyl)-5-(cyclobutylcarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester, (6R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1000588-68-0 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2,3-dihydroxypropyl ester, (4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1000588-70-4 CAPLUS

CN 1(2H)-Pyrimidineacetic acid, 6-(4-cyanophenyl)-5-(cyclobutylcarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, (6R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1000588-71-5 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, (4R)-, 2-(dimethylamino)ethyl ester, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 904959-01-9

CMF C24 H23 F3 N4 O3


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 1000588-73-7 CAPLUS

CN 1(2H)-Pyrimidineacetic acid, 6-(4-cyanophenyl)-3,6-dihydro-4-methyl-5-(2-methyl-1-oxopropyl)-2-oxo-3-[3-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester, (6R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1000588-74-8 CAPLUS

CN 1(2H)-Pyrimidineacetic acid, 6-(4-cyanophenyl)-3,6-dihydro-4-methyl-5-(2-methyl-1-oxopropyl)-2-oxo-3-[3-(trifluoromethyl)phenyl]-, (6R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 675103-34-1 675103-36-3 864150-67-4
864150-68-5 864250-45-3

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)


(preparation of diaryldihydropyrimidinones for treatment of pulmonary
arterial hypertension)

RN 675103-34-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-hydroxyethyl ester, (4R)- (CA

INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 675103-36-3 CAPLUS

CN 2-Pyridinecarbonitrile, 5-[(4R)-5-acetyl-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 864150-67-4 CAPLUS

CN Benzoic acid, 3-[[(6R)-5-acetyl-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864150-68-5 CAPLUS

CN Benzoic acid, 4-[[[(6R)-5-acetyl-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864250-45-3 CAPLUS

CN 1(2H)-Pyrimidineacetic acid, 5-[[[2-(carboxymethoxy)ethoxy]carbonyl]-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, (6R)- (CA INDEX NAME)

Absolute stereochemistry.




IT 671775-85-2 864250-60-2

RL: PEP (Physical, engineering or chemical process); PROC (Process)
(preparation of diaryldihydropyrimidinones for treatment of pulmonary
arterial hypertension)


RN 671775-85-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-
2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)



RN 864250-60-2 CAPLUS

CN Benzonitrile, 4-[5-(cyclobutylcarbonyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-
1-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




IT 671776-48-0P

RL: PEP (Physical, engineering or chemical process); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); PROC (Process); RACT (Reactant or reagent)

(preparation of diaryldihydropyrimidinones for treatment of pulmonary arterial hypertension)

RN 671776-48-0 CAPLUS

CN Benzonitrile, 4-[1,2,3,4-tetrahydro-6-methyl-5-(2-methyl-1-oxopropyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




IT 1000588-78-2P

RL: PEP (Physical, engineering or chemical process); SPN (Synthetic preparation); PREP (Preparation); PROC (Process)

(preparation of diaryldihydropyrimidinones for treatment of pulmonary arterial hypertension)

RN 1000588-78-2 CAPLUS

CN Benzonitrile, 4-[5-acetyl-1-[3-fluoro-5-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-4-pyrimidinyl]- (CA INDEX NAME)



IT 1000675-38-6P


RL: PUR (Purification or recovery); PREP (Preparation)

(preparation of diaryldihydropyrimidinones for treatment of pulmonary arterial hypertension)

RN 1000675-38-6 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester, (4S)- (CA INDEX NAME)

Absolute stereochemistry.




IT 864151-33-7 864228-16-0
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of diaryldihydropyrimidinones for treatment of pulmonary
 arterial hypertension)
 RN 864151-33-7 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-
 2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-propen-1-yl ester, (4R)- (CA
 INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 864228-16-0 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-
 2-oxo-1-[3-(trifluoromethyl)phenyl]-, (4R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 1000588-75-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of diaryldihydropyrimidinones for treatment of pulmonary
arterial hypertension)
RN 1000588-75-9 CAPLUS
CN Benzonitrile, 4-[(4R)-1,2,3,4-tetrahydro-5-(1H-imidazol-1-ylcarbonyl)-6-
methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX
NAME)

Absolute stereochemistry.



L16 ANSWER 2 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:1300977 CAPLUS

DN 147:522270

TI Preparation of tetrahydropyrrolopyrimidinediones as human neutrophil elastase (HNE) inhibitors

IN Ray, Nicholas Charles; Finch, Harry; Edwards, Christine; O'Connor, Elizabeth

PA Argenta Discovery Limited, UK

SO PCT Int. Appl., 73pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007129060	A1	20071115	WO 2007-GB1638	20070503
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI GB 2006-8844 A 20060504

GB 2006-12544 A 20060623

OS MARPAT 147:522270

AB Title compds. [I; A = aryl, heteroaryl; D = O, S; R1-R3 = H, OH, halo, NO2, cyano, alkenyl, alkynyl, alkenyloxy, (substituted) alkyl, alkoxy; R, R4 = Xm(A1)pQn(A2)q(X1)kZ; A1, A2 = (substituted) alkylene, alkenylene optionally containing O, S, NRA; Q = O, S, SO, SO2, NRA, NRA SO2, CO2, etc.; X = CO, SO2, CO2, CONRA, SO2NRA; Ra = H, alkyl, cycloalkyl; X1 = O, S, NH; Z = H, (substituted) carbocyclyl, heterocyclyl; k, m, n, p, q = 0, 1], were prepared Thus, title compound (II) was prepared in 3 steps from 3,5-difluorophenylurea, 4-cyanobenzaldehyde, Et acetoacetate, and methylamine. Most I inhibited HNE in the range of 1-50 nM.

IT 956487-06-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of tetrahydropyrrolopyrimidinediones as human neutrophil elastase inhibitors)

RN 956487-06-2 CAPLUS

CN 6H-Pyrrolo[3,4-d]pyrimidine-6-propanaminium, N-[3-[[[(4R)-6-carboxy-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-2-oxo-1-[3-(trifluoromethyl)phenyl]-5-pyrimidinyl]carbonyl]amino]propyl]-4-(4-cyanophenyl)-1,2,3,4,5,7-hexahydro-N,N-dimethyl-2,5-dioxo-1-[3-(trifluoromethyl)phenyl]-, inner salt, (4R)-(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—CF₃


IT 675103-23-8P 956487-08-4P 956487-09-5P
 956487-10-8P 956487-11-9P 956487-12-0P
 956487-13-1P 956487-14-2P 956487-15-3P
 956487-16-4P 956487-17-5P 956487-18-6P
 956487-19-7P 956487-20-0P 956487-21-1P
 956487-22-2P 956487-23-3P 956487-28-8P
 956487-29-9P 956487-38-0P 956487-39-1P
 956487-40-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of tetrahydropyrrolopyrimidinediones as human neutrophil elastase inhibitors)


RN 675103-23-8 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 6-(bromomethyl)-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)




RN 956487-08-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1-(3,5-difluorophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-, ethyl ester (CA INDEX NAME)




RN 956487-09-5 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 1,2,3,4-tetrahydro-4-(4-iodophenyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)




RN 956487-10-8 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 6-(bromomethyl)-1-(3-chlorophenyl)-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-2-oxo-, ethyl ester (CA INDEX NAME)




RN 956487-11-9 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 6-(bromomethyl)-4-(6-cyano-3-pyridinyl)-1,2,3,4-tetrahydro-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)




RN 956487-12-0 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 6-(bromomethyl)-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-1-(3-methylphenyl)-2-oxo-, ethyl ester (CA INDEX NAME)




RN 956487-13-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 6-(bromomethyl)-4-(4-cyanophenyl)-1-(3,5-difluorophenyl)-1,2,3,4-tetrahydro-2-oxo-, ethyl ester (CA INDEX NAME)



RN 956487-14-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 6-(bromomethyl)-1,2,3,4-tetrahydro-4-(4-iodophenyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)




RN 956487-15-3 CAPLUS

CN Piperidinium, 1,1-bis[3-[(6R)-4-(bromomethyl)-6-(4-cyanophenyl)-5-(ethoxycarbonyl)-3,6-dihydro-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]propyl]-, bromide (1:1) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A






PAGE 2-A




RN 956487-16-4 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 1,1'-[2,12-dioxo-7-[(2,2,2-trifluoroacetyl)amino]-3,6,8,11-tetraazatridec-6-ene-1,13-diyl]bis[4-(bromomethyl)-6-(4-cyanophenyl)-1,2,3,6-tetrahydro-2-oxo-3-[3-(trifluoromethyl)phenyl]-, 5,5'-diethyl ester, (6R,6'R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 956487-17-5 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 1,1'-[(methylimino)di-3,1-propanediyl]bis[4-(bromomethyl)-6-(4-cyanophenyl)-1,2,3,6-tetrahydro-2-oxo-3-[3-(trifluoromethyl)phenyl]-, 5,5'-diethyl ester, (6R,6'R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 956487-18-6 CAPLUS

CN 1(2H)-Pyrimidinepropanaminium, 4-(bromomethyl)-N-[3-[(6R)-4-(bromomethyl)-6-(4-cyanophenyl)-5-(ethoxycarbonyl)-3,6-dihydro-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]propyl]-6-(4-cyanophenyl)-5-(ethoxycarbonyl)-3,6-dihydro-N,N-dimethyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, iodide (1:1), (6R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 956487-19-7 CAPLUS

CN 1H-Imidazolium, 1,3-bis[3-[(6R)-4-(bromomethyl)-6-(4-cyanophenyl)-5-(ethoxycarbonyl)-3,6-dihydro-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]propyl]-, bromide (1:1) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 956487-20-0 CAPLUS

CN Pyrrolidinium, 1,1-bis[3-[(6R)-4-(bromomethyl)-6-(4-cyanophenyl)-5-(ethoxycarbonyl)-3,6-dihydro-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]propyl]-, bromide (1:1) (CA INDEX NAME)


Absolute stereochemistry.



RN 956487-21-1 CAPLUS
 CN Ethanaminium, 2-[[2-[(6R)-4-(bromomethyl)-6-(4-cyanophenyl)-5-(ethoxycarbonyl)-3,6-dihydro-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]acetyl]amino]-N-[2-[[2-[(6R)-4-(bromomethyl)-6-(4-cyanophenyl)-5-(ethoxycarbonyl)-3,6-dihydro-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]acetyl]amino]ethyl]-N,N-dimethyl-, iodide (1:1) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—CH₂Br


—OEt

● I⁻

RN 956487-22-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-3-[3-[(1,1-dimethylethoxy)carbonyl]amino]propyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester, (4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 956487-23-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 6-(bromomethyl)-4-(4-cyanophenyl)-3-[3-[[1,1-dimethylethoxy)carbonyl]amino]propyl]-1,2,3,4-tetrahydro-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester, (4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 956487-28-8 CAPLUS

CN 1(2H)-Pyrimidineacetic acid, 6-(4-cyanophenyl)-5-(ethoxycarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester, (6R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 956487-29-9 CAPLUS

CN 1(2H)-Pyrimidineacetic acid, 4-(bromomethyl)-6-(4-cyanophenyl)-5-(ethoxycarbonyl)-3,6-dihydro-2-oxo-3-[3-(trifluoromethyl)phenyl]-,

1,1-dimethylethyl ester, (6R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 956487-38-0 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-3-[5-(methylamino)pentyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester, (4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 956487-39-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-3-[5-[methyl(3-phenoxypropyl)amino]pentyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester, (4R)- (CA INDEX NAME)


Absolute stereochemistry.



10/527,391


RN 956487-40-4 CAPLUS
CN 5-Pyrimidinecarboxylic acid, 6-(bromomethyl)-3-[5-[[3-(4-bromophenoxy)propyl]methylamino]pentyl]-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester, (4R)- (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 3 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2007:230926 CAPLUS
 DN 146:441742
 TI N-substituted ureas and thioureas in Biginelli reaction promoted by
 chlorotrimethylsilane: convenient synthesis of N1-alkyl-, N1-aryl-, and
 N1,N3-dialkyl-3,4-dihydropyrimidin-2(1H)-(thi)ones
 AU Ryabukhin, Sergey V.; Plaskon, Andrey S.; Ostapchuk, Eugeny N.;
 Volochnyuk, Dmitriy M.; Tolmachev, Andrey A.
 CS Enamine Ltd, Kiev, 01103, Ukraine
 SO Synthesis (2007), (3), 417-427
 CODEN: SYNIBF; ISSN: 0039-7881
 PB Georg Thieme Verlag
 DT Journal
 LA English
 OS CASREACT 146:441742
 AB The classical Biginelli reaction has been extended by the use of
 N-substituted ureas and thioureas. A set of N1-alkyl-, N1-aryl-, and
 N1,N3-dialkyl-3,4-dihydropyrimidin-2(1H)-(thi)ones, e.g., I, was readily
 prepared by Biginelli reaction of Et acetoacetate and aryl aldehydes with
 N-substituted ureas or thioureas in excellent yield when
 chlorotrimethylsilane in N,N-dimethylformamide was used as promoter and
 water scavenger.
 IT 300696-72-4P 791107-81-8P 793693-44-4P
 881993-43-7P 924077-69-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of dihydropyrimidinones/thiones via chlorotrimethylsilane-
 promoted Biginelli reaction of acetoacetate, aryl aldehydes, and
 ureas/thioureas)
 RN 300696-72-4 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 1,2,3,4-tetrahydro-6-methyl-2-oxo-1-phenyl-4-
 [2-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)




RN 791107-81-8 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 4-(2-chloro-6-fluorophenyl)-1-(4-
 chlorophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-, ethyl ester (CA INDEX
 NAME)




RN 793693-44-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 1-(4-chlorophenyl)-1,2,3,4-tetrahydro-6-methyl-4-(3-nitrophenyl)-2-oxo-, ethyl ester (CA INDEX NAME)



RN 881993-43-7 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 1-(4-chlorophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-4-phenyl-, ethyl ester (CA INDEX NAME)



RN 924077-69-0 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 1,2,3,4-tetrahydro-6-methyl-2-oxo-1,4-diphenyl-, ethyl ester (CA INDEX NAME)

10/527,391




RE.CNT 61 THERE ARE 61 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 4 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2007:186627 CAPLUS
 DN 147:344045
 TI Synthesis of novel 5-substituted-6-methyl-4-[5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl]-3,4-dihydropyrimidin-2(1H)-ones
 AU Kumar, Rakesh; Malik, Sakshi; Chandra, Ramesh
 CS Department of Chemistry, Kirori Mal College, University of Delhi, Delhi, 110007, India
 SO Organic Preparations and Procedures International (2006), Volume Date 2007, 39(1), 101-106
 CODEN: OPPIAK; ISSN: 0030-4948
 PB Organic Preparations and Procedures, Inc.
 DT Journal
 LA English
 OS CASREACT 147:344045
 AB Pyrazolyl dihydropyrimidinones, e.g., I, was synthesized via three-component coupling reaction of [N-phenyl(chloro)methyl]pyrazolecarboxaldehyde with ureas and β -keto esters or β -diketones in moderate yields.
 IT 948597-55-5P 948597-56-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of pyrazolyl(dihydro)pyrimidinones via three-component coupling reaction of [N-phenyl(chloro)methyl]pyrazolecarboxaldehyde with ureas and β -keto esters or β -diketones)
 RN 948597-55-5 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 4-(5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-phenyl-, ethyl ester (CA INDEX NAME)



RN 948597-56-6 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 4-(5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-phenyl-, methyl ester (CA INDEX NAME)

10/527,391



RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 5 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2006:1356757 CAPLUS
 DN 146:100714
 TI Preparation of dihydropyrimidone multimers as human neutrophil elastase inhibitors
 IN Finch, Harry; Edwards, Christine; Ray, Nicholas Charles; Fitzgerald, Mary Frances
 PA Argenta Discovery Ltd., UK
 SO PCT Int. Appl., 59pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006136857	A1	20061228	WO 2006-GB2337	20060626
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	EP 1893584	A1	20080305	EP 2006-755623	20060626
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	IN 2007DN10018	A	20080711	IN 2007-DN10018	20071224
PRAI	GB 2005-12940	A	20050624		
	WO 2006-GB2337	W	20060626		

OS MARPAT 146:100714

AB Title compds. represented by the formula M-L-M, wherein L is a linker and each M is independently a group of formula I [A = (hetero)aryl; D = O or S; R1-R3 = independently H, halo, nitro, etc.; R4 = OH, alkyl(carbonyl), amino, etc.; Y1-Y5 = independently C or N, with the proviso that the ring in which they are comprised contains no more than 2 N atoms; R5 = (un)substituted alkyl, -O-alkyl-O-alkyl or amino; R6 = halo, nitro, cyano, etc.; and pharmaceutically acceptable salts, solvates or N-oxides thereof], were prepared as human neutrophil elastase (HNE) inhibitors. For example, II was provided in a multi-step synthesis starting from the reaction of 3-(trifluoromethyl)phenylurea with 4-cyanobenzaldehyde. I were tested for inhibitory activity towards HNE with IC50 values of 1-1000 nM. Thus, I and their pharmaceutical compns. are useful as human neutrophil elastase inhibitors for the treatment of respiratory diseases (no data).

IT 917813-88-8P 917813-90-2P 917813-97-9P
 917813-98-0P 917813-99-1P 917814-01-8P
 917814-02-9P 917814-13-2P 917814-15-4P
 917814-17-6P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of dihydropyrimidone multimers as human neutrophil elastase


inhibitors)

RN 917813-88-8 CAPLUS


CN 5-Pyrimidinecarboxamide, N,N'-[(methylimino)di-3,1-propanediyl]bis[4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, (4R,4'R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 917813-90-2 CAPLUS

CN 5-Pyrimidinecarboxamide, N,N'-[(methylimino)di-2,1-ethanediyl]bis[4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, (4R,4'R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


CF₃

RN 917813-97-9 CAPLUS


CN 1(2H)-Pyrimidineacetic acid, 5,5'-[(methylimino)bis(3,1-propanediyliminocarbonyl)]bis[6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, 1,1'-dimethyl ester, (6R,6'R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 917813-98-0 CAPLUS


CN 5-Pyrimidinecarboxamide, N,N'-[1,2-ethanediylbis(imino-2,1-ethanediyl)]bis[4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, (4R,4'R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 917813-99-1 CAPLUS

CN 1(2H)-Pyrimidineacetic acid, 5,5'-[(methylimino)bis(3,1-)]


propanediyliminocarbonyl)]bis[6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, (6R,6'R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





PAGE 1-B



RN 917814-01-8 CAPLUS
 CN 1-Propanaminium, 3-[[[(4R)-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-3-(2-methoxy-2-oxoethyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-5-pyrimidinyl]carbonyl]amino]-N-[3-[[[(4R)-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-3-(2-methoxy-2-oxoethyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-5-pyrimidinyl]carbonyl]amino]propyl]-N,N-dimethyl-, iodide (1:1) (CA INDEX NAME)


Absolute stereochemistry.




RN 917814-02-9 CAPLUS
 CN 1-Propanaminium, 3-[[[(4R)-3-(carboxymethyl)-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-5-pyrimidinyl]carbonyl]amino]-N-[3-[[[(4R)-3-(carboxymethyl)-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-5-pyrimidinyl]carbonyl]amino]propyl]-N,N-dimethyl-, chloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 917814-13-2 CAPLUS
 CN 5-Pyrimidinecarboxamide, N,N'-[(2-thioxo-1,3-imidazolidinediyl)di-2,1-ethanediyl]bis[4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, (4R,4'R)- (CA INDEX NAME)

Absolute stereochemistry.




—CF₃

RN 917814-15-4 CAPLUS


CN 5-Pyrimidinecarboxamide, N,N'-[[[(2,2,2-trifluoroacetyl)carbonimidoyl]bis(imino-2,1-ethanediyl)]bis[4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, (4R,4'R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





RN 917814-17-6 CAPLUS

CN 5-Pyrimidinecarboxamide, N,N'-[[[(2,2,2-trifluoroacetyl)carbonimidoyl]bis(imino-3,1-propanediyl)]bis[4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, (4R,4'R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A






IT 917813-84-4P 917813-85-5P 917813-86-6P
 917813-87-7P 917813-89-9P 917813-91-3P
 917813-92-4P 917813-93-5P 917813-94-6P
 917813-95-7P 917813-96-8P 917814-00-7P
 917814-03-0P 917814-04-1P 917814-05-2P
 917814-06-3P 917814-07-4P 917814-08-5P
 917814-09-6P 917814-10-9P 917814-11-0P
 917814-12-1P 917814-14-3P 917814-16-5P
 917814-18-7P 917814-19-8P 917814-20-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of dihydropyrimidone multimers as human neutrophil elastase
 inhibitors)

RN 917813-84-4 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-
 2-oxo-1-[3-(trifluoromethyl)phenyl]-, 5,5'-(1,10-decanediyl) ester (CA
 INDEX NAME)




RN 917813-85-5 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-
 2-oxo-1-[3-(trifluoromethyl)phenyl]-, 5,5'-[oxybis(2,1-ethanediyl) ester (CA
 INDEX NAME)]


PAGE 1-A



PAGE 1-B




RN 917813-86-6 CAPLUS
 CN 5-Pyrimidinecarboxamide, N,N'-1,10-decanediylbis[4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 917813-87-7 CAPLUS

CN 5-Pyrimidinecarboxamide, N,N'-[1,4-butanediylbis(oxy-3,1-propanediyl)]bis[4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 917813-89-9 CAPLUS


CN 5-Pyrimidinecarboxamide, N,N'-[(methylimino)di-3,1-propanediyl]bis[4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, (4S,4'S)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 917813-91-3 CAPLUS

CN 5-Pyrimidinecarboxamide, N,N'-[(methylimino)di-2,1-ethanediyl]bis[4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, (4S,4'S)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 917813-92-4 CAPLUS


CN 5-Pyrimidinecarboxamide, N,N'-(1,4-piperazinediyldi-3,1-propanediyl)bis[4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, (4R,4'R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 917813-93-5 CAPLUS


CN 5-Pyrimidinecarboxamide, N,N'-(1,5-pentanediyldi-4,1-piperazinediyldi)bis[4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, (4R,4'R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 917813-94-6 CAPLUS
 CN Benzonitrile, 4,4'-[[2,2'-bipyridine]-5,5'-diylbis[carbonyl-4,1-piperazinediylcarbonyl[(4R)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-5,4-pyrimidinediyl]]]bis- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





RN 917813-95-7 CAPLUS

CN Benzonitrile, 4,4'-[3,5-pyridinediylbis[carbonyl-4,1-piperazinediylcarbonyl[(4R)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-5,4-pyrimidinediyl]]]bis- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 917813-96-8 CAPLUS

CN Benzonitrile, 4,4'-[1,2-ethanediylbis[4,1-piperazinediylcarbonyl[(4R)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-5,4-pyrimidinediyl]]]bis- (CA INDEX NAME)

Absolute stereochemistry.




RN 917814-00-7 CAPLUS

CN 1(2H)-Pyrimidineacetamide, 5,5'-[(methylimino)bis(3,1-


propanediyliminocarbonyl)]bis[6-(4-cyanophenyl)-N-[2-(dimethylamino)ethyl]-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, (6R,6'R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B





RN 917814-03-0 CAPLUS
 CN 1-Propanaminium, 3-[[[(4R)-4-(4-cyanophenyl)-3-[2-[[2-(dimethylamino)ethyl]amino]-2-oxoethyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-5-pyrimidinyl]carbonyl]amino]-N-[3-[[[(4R)-4-(4-cyanophenyl)-3-[2-[[2-(dimethylamino)ethyl]amino]-2-oxoethyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-5-pyrimidinyl]carbonyl]amino]propyl]-N,N-dimethyl-, chloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 917814-04-1 CAPLUS


CN 5-Pyrimidinecarboxamide, N,N'-[1,7-heptanediyldis(imino-3,1-propanediyl)]bis[4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, (4R,4'R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 917814-05-2 CAPLUS


CN 5-Pyrimidinecarboxamide, N,N'-[1,5-pentanediy]bis(4,1-piperazinediy-3,1-propanediy)]bis[4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, (4R,4'R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 917814-06-3 CAPLUS


CN 5-Pyrimidinecarboxamide, N,N'-[[2,2'-bipyridine]-5,5'-diylbis(carbonyl-4,1-piperazinediyl-3,1-propanediyl)]bis[4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, (4R,4'R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





RN 917814-07-4 CAPLUS

CN 5-Pyrimidinecarboxamide, N,N'-[3,5-pyridinediylbis(carbonyl-4,1-piperazinediyl-3,1-propanediyl)]bis[4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, (4R,4'R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 917814-08-5 CAPLUS

CN 5-Pyrimidinecarboxamide, N,N'-[1,2-ethanediylbis(4,1-piperazinediyl-3,1-propanediyl)]bis[4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, (4R,4'R)- (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-B




RN 917814-09-6 CAPLUS


CN 5-Pyrimidinecarboxamide, N,N'-[[[1,1'-biphenyl]-4,4'-diylbis(carbonyl-4,1-piperazinediyl-3,1-propanediyl)]bis[4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, (4R,4'R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 917814-10-9 CAPLUS


CN 5-Pyrimidinecarboxamide, N,N'-[oxybis(4,1-phenylenecarbonyl-4,1-piperazinediyl-3,1-propanediyl)]bis[4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, (4R,4'R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 917814-11-0 CAPLUS

CN 5-Pyrimidinecarboxamide, N,N'-[[1,1'-biphenyl]-2,2'-diylbis(carbonyl-4,1-piperazinediyl-3,1-propanediyl)]bis[4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, (4R,4'R)- (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B




CN 5-Pyrimidinecarboxamide, N,N'-[1,4-phenylenebis(carbonyl-4,1-piperazinediyl-3,1-propanediyl)]bis[4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, (4R,4'R)- (CA INDEX NAME)

Page 74

PAGE 1-A




PAGE 1-B



RN 917814-14-3 CAPLUS

CN 5-Pyrimidinecarboxamide, N,N'-[(2-imino-1,3-imidazolidinediyl)di-2,1-ethanediyl]bis[4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, (4R,4'R)- (CA INDEX NAME)

Absolute stereochemistry.




—CF₃

RN 917814-16-5 CAPLUS


CN 5-Pyrimidinecarboxamide, N,N'-[carbonimidoylbis(imino-2,1-ethanediyl)]bis[4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, (4R,4'R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





RN 917814-18-7 CAPLUS

CN 5-Pyrimidinecarboxamide, N,N'-[carbonimidoylbis(imino-3,1-propanediyl)]bis[4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, (4R,4'R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 917814-19-8 CAPLUS

CN 1-Propanaminium, 3-[[[(4R)-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-5-pyrimidinyl]carbonyl]amino]-N-[3-[[[(4R)-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-5-pyrimidinyl]carbonyl]amino]propyl]-N,N-dimethyl-, iodide (1:1) (CA INDEX NAME)

Absolute stereochemistry.






RN 917814-20-1 CAPLUS

CN Ethanaminium, 2-[[[(4R)-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-5-pyrimidinyl]carbonyl]amino]-N-[2-[[[(4R)-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-5-pyrimidinyl]carbonyl]amino]ethyl]-N,N-dimethyl-, iodide (1:1) (CA INDEX NAME)


Absolute stereochemistry.






IT 864228-16-0P
 RL: PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of dihydropyrimidone multimers as human neutrophil elastase inhibitors)
 RN 864228-16-0 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, (4R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 671775-95-4
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of dihydropyrimidone multimers as human neutrophil elastase inhibitors)
 RN 671775-95-4 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




IT 864151-33-7P 904958-42-5P 917814-21-2P
 917814-22-3P 917814-23-4P 917814-24-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of dihydropyrimidone multimers as human neutrophil elastase
inhibitors)

RN 864151-33-7 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-
2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-propen-1-yl ester, (4R)- (CA
INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 904958-42-5 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-
2-oxo-1-[3-(trifluoromethyl)phenyl]-, phenylmethyl ester (CA INDEX NAME)



RN 917814-21-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-cyanophenyl)-N-(3,3-diethoxypropyl)-1,2,3,4-
tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, (4R)- (CA INDEX
NAME)


Absolute stereochemistry.



RN 917814-22-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-N-(3-oxopropyl)-1-[3-(trifluoromethyl)phenyl]-, (4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 917814-23-4 CAPLUS

CN 1(2H)-Pyrimidineacetic acid, 6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-5-[(2-propen-1-yloxy)carbonyl]-3-[3-(trifluoromethyl)phenyl]-, methyl ester, (6R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 917814-24-5 CAPLUS

CN 1(2H)-Pyrimidineacetic acid, 5-carboxy-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, 1-methyl ester, (6R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 917814-25-6P


RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of dihydropyrimidinone multimers as human neutrophil elastase inhibitors)

RN 917814-25-6 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, (4S)- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 6 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2006:796025 CAPLUS

DN 145:211067

TI Multimers of tetrahydropyrimidinone compounds as elastase inhibitors and their preparation, pharmaceutical compositions, and use for treatment of respiratory diseases

IN Finch, Harry; Edwards, Christine; Ray, Nicholas Charles; O'Connor, Elizabeth Anne; Fitzgerald, Mary F.

PA Argenta Discovery Ltd, UK

SO PCT Int. Appl., 132 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006082412	A2	20060810	WO 2006-GB361	20060203
	WO 2006082412	A3	20061012		
	W:	AE, AG, AL, AM, AN, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	AU 2006210730	A1	20060810	AU 2006-210730	20060203
	CA 2595801	A1	20060810	CA 2006-2595801	20060203
	EP 1856059	A2	20071121	EP 2006-709612	20060203
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
	IN 2007DN05905	A	20070817	IN 2007-DN5905	20070727
	CN 101151252	A	20080326	CN 2006-80009856	20070926
PRAI	GB 2005-2258	A	20050203		
	WO 2006-GB361	W	20060203		

OS MARPAT 145:211067


AB A compound of formula I is useful in therapy, e.g. of respiratory diseases. Compds. of formula I wherein L is a linker; each A are independently (un)substituted (hetero)aryl; D is O or S; each Y1 - Y5 are independently CH, CR3, CR6 or N, with the proviso that one of them is CR3, one CR6 and not more than two N per ring; each R3 are independently H, halo, NO2, CN, (un)substituted C1-6 alkyl, OH, or (un)substituted C1-6 alkoxy; each R4 are independently COCF3, (un)substituted C1-6 alkylcarbonyl, (un)substituted C1-6 alkoxy, (un)substituted C1-6 alkenyloxycarbonyl, hydroxycarbonyl, CONH2 and derivs., (un)substituted (hetero)aroyle, etc.; each R5 are independently (un)substituted C1-4 alkyl or amino; each R6 are independently halo, NO2, CN, (un)substituted C1-6 alkyl, OH, or (un)substituted C1-6 alkoxy; and their pharmaceutically acceptable salts, solvates or N-oxides thereof are claimed. Example compound II was prepared by N-alkylation of compound III with 1,12-dibromododecane. The invention compds. were evaluated for their elastase inhibitory activity. The tested compds. were shown to have desirable HNE inhibitory activity (no data).

IT 904957-71-7P 904957-72-8P 904957-86-4P
 904958-07-2P 904958-35-6P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate and intermediate; preparation of multimers of tetrahydropyrimidinone compds. as elastase inhibitors useful in the treatment of respiratory diseases)
 RN 904957-71-7 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-3-[2-[[2-[[2-[[2-[6-(4-cyanophenyl)-5-(ethoxycarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]acetyl]amino]ethyl]methylamino]ethyl]amino]-2-oxoethyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)

PAGE 1-A



PAGE 1-B




RN 904957-72-8 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-3-[2-[[2-[[2-[[2-[(6R)-6-(4-cyanophenyl)-5-(ethoxycarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]acetyl]amino]ethyl]methylamino]ethyl]amino]-2-oxoethyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester, (4R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—CF₃


RN 904957-86-4 CAPLUS
 CN Ethanaminium, 2-[[2-[(6R)-6-(4-cyanophenyl)-5-(ethoxycarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]acetyl]amino]-N-[2-[[2-[(6R)-6-(4-cyanophenyl)-5-(ethoxycarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]acetyl]amino]ethyl]-N,N-dimethyl-, iodide (1:1) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 904958-07-2 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 1,1'-[(methylimino)di-5,1-pentanediy]bis[6-(4-cyanophenyl)-1,2,3,6-tetrahydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, diethyl ester, (6R,6'R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 904958-35-6 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(6-cyano-3-pyridinyl)-3-[2-[[2-[[2-[[2-[6-(6-cyano-3-pyridinyl)-5-(ethoxycarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]acetyl]amino]ethyl]methylamino]ethyl]amino]-2-oxoethyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)

PAGE 1-A






IT 904957-62-6P 904957-63-7P 904957-64-8P
 904957-65-9P 904957-66-0P 904957-67-1P
 904957-68-2P 904957-69-3P 904957-70-6P
 904957-73-9P 904957-74-0P 904957-75-1P
 904957-76-2P 904957-77-3P 904957-78-4P
 904957-79-5P 904957-80-8P 904957-81-9P
 904957-83-1P 904957-84-2P 904957-85-3P
 904957-87-5P 904957-88-6P 904957-89-7P
 904957-90-0P 904957-91-1P 904957-92-2P
 904957-93-3P 904957-94-4P 904957-95-5P
 904957-96-6P 904957-97-7P 904957-98-8P
 904957-99-9P 904958-00-5P 904958-01-6P
 904958-02-7P 904958-03-8P 904958-04-9P
 904958-05-0P 904958-06-1P 904958-08-3P
 904958-09-4P 904958-10-7P 904958-11-8P
 904958-12-9P 904958-13-0P 904958-14-1P
 904958-15-2P 904958-16-3P 904958-17-4P
 904958-18-5P 904958-19-6P 904958-20-9P
 904958-21-0P 904958-22-1P 904958-23-2P
 904958-24-3P 904958-25-4P 904958-26-5P
 904958-27-6P 904958-28-7P 904958-30-1P
 904958-31-2P 904958-32-3P 904958-33-4P
 904958-34-5P 904958-36-7P 904958-37-8P
 904958-39-0P 904958-41-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(drug candidate; preparation of multimers of tetrahydropyrimidinone compds.
 as elastase inhibitors useful in the treatment of respiratory diseases)


RN 904957-62-6 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 1,1'-(1,12-dodecanediyl)bis[6-(4-cyanophenyl)-
 1,2,3,6-tetrahydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, diethyl
 ester (9CI) (CA INDEX NAME)




RN 904957-63-7 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 1,1'-(1,9-nonanediyl)bis[6-(4-cyanophenyl)-1,2,3,6-tetrahydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 904957-64-8 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 1,1'-(1,8-octanediyl)bis[6-(4-cyanophenyl)-1,2,3,6-tetrahydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 904957-65-9 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 1,1'-(1,10-dioxo-1,10-decanediyl)bis[6-(4-cyanophenyl)-1,2,3,6-tetrahydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 904957-66-0 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 1,1'-(1,9-dioxo-1,9-nonanediyl)bis[6-(4-cyanophenyl)-1,2,3,6-tetrahydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 904957-67-1 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 1,1'-(1,12-dioxo-1,12-dodecanediyl)bis[6-(4-cyanophenyl)-1,2,3,6-tetrahydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 904957-68-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 1,1'-[oxybis(2,1-ethanediylloxy-2,1-ethanediyl)]bis[6-(4-cyanophenyl)-1,2,3,6-tetrahydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, diethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 904957-69-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-3-[2-[4-[2-[6-(4-cyanophenyl)-5-(ethoxycarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]acetyl]-1-piperazinyl]-2-oxoethyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)




RN 904957-70-6 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-3-[2-[4-[2-[(6R)-6-(4-cyanophenyl)-5-(ethoxycarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]acetyl]-1-piperazinyl]-2-oxoethyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester, (4R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 904957-73-9 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-3-[2-[[3-[[3-[[2-[6-(4-cyanophenyl)-5-(ethoxycarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]acetyl]amino]propyl]methylamino]propyl]amino]-2-oxoethyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)


PAGE 1-A






RN 904957-74-0 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-3-[2-[4-[2-[4-[2-[6-(4-cyanophenyl)-5-(ethoxycarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]acetyl]-1-piperazinyl]ethyl]-1-piperazinyl]-2-oxoethyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)







RN 904957-75-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-3-[2-[4-[2-[4-[2-[(6R)-6-(4-cyanophenyl)-5-(ethoxycarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]acetyl]-1-piperazinyl]ethyl]-1-piperazinyl]-2-oxoethyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester, (4R)- (CA INDEX NAME)

Absolute stereochemistry.



PAGE 2-A





RN 904957-76-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-3-[2-[[trans-4-[[[5-[[[trans-4-[[2-[6-(4-cyanophenyl)-5-(ethoxycarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]acetyl]amino]cyclohexyl]amino]carbonyl]-2-pyridinyl]carbonyl]amino]cyclohexyl]amino]-2-oxoethyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)

Relative stereochemistry.


PAGE 1-A






RN 904957-77-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 1,1'-[1,5-pentanediy]bis(imino-3,1-propanediyl)]bis[6-(4-cyanophenyl)-1,2,3,6-tetrahydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, diethyl ester, (6R,6'R)- (9CI) (CA INDEX NAME)




RN 904957-78-4 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 1,1'-[1,2-ethanediylbis(4,1-piperazinediyl-3,1-propanediyl)]bis[6-(4-cyanophenyl)-1,2,3,6-tetrahydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, diethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 904957-79-5 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 1,1'-[1,2-ethanediylbis(4,1-piperazinediyl-3,1-propanediyl)]bis[6-(4-cyanophenyl)-1,2,3,6-tetrahydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, diethyl ester, (6R,6'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 904957-80-8 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 1,1'-[(ethylimino)di-8,1-octanediyl]bis[6-(4-cyanophenyl)-1,2,3,6-tetrahydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 904957-81-9 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 1,1'-[(ethylimino)di-8,1-octanediyl]bis[6-(4-cyanophenyl)-1,2,3,6-tetrahydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, diethyl ester, (6R,6'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 904957-83-1 CAPLUS


CN 1H-Imidazolium, 1,3-bis[3-[6-(4-cyanophenyl)-5-(ethoxycarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]propyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 904957-82-0

CMF C53 H49 F6 N8 O6

10/527,391




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 14477-72-6

CMF C2 F3 O2



RN 904957-84-2 CAPLUS

CN 1H-Imidazolium, 1,3-bis[3-[6-(4-cyanophenyl)-5-(ethoxycarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]propyl]-, bromide (1:1) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 904957-85-3 CAPLUS


CN Ethanaminium, 2-[[2-[6-(4-cyanophenyl)-5-(ethoxycarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]acetyl]amino]-N-[2-[[2-[6-(4-cyanophenyl)-5-(ethoxycarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]acetyl]amino]ethyl]-N,N-dimethyl-, iodide (1:1) (CA INDEX NAME)

PAGE 1-A




● I⁻

PAGE 1-B



RN 904957-87-5 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 1,1'-(1,12-dodecanediyl)bis[6-(4-cyanophenyl)-1,2,3,6-tetrahydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, bis(2-hydroxyethyl) ester (9CI) (CA INDEX NAME)




RN 904957-88-6 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-3-[2-[4-[2-[4-[2-[6-(4-cyanophenyl)-3,6-dihydro-5-[(2-hydroxyethoxy)carbonyl]-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]acetyl]-1-piperazinyl]ethyl]-1-piperazinyl]-2-oxoethyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-hydroxyethyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 904957-89-7 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-3-[2-[[2-[[2-[[2-[6-(4-cyanophenyl)-3,6-dihydro-5-[(2-hydroxyethoxy)carbonyl]-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]acetyl]amino]ethyl]methylamino]ethyl]amino]-2-oxoethyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-hydroxyethyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 904957-90-0 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 1,1'-[(ethylimino)di-12,1-dodecanediyl]bis[6-(4-cyanophenyl)-1,2,3,6-tetrahydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, bis(2-hydroxyethyl) ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—CH₂—CH₂—OH

RN 904957-91-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 1,1'-[(ethylimino)di-8,1-octanediyl]bis[6-(4-cyanophenyl)-1,2,3,6-tetrahydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, bis(2-hydroxyethyl) ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B


—CH₂—OH

RN 904957-92-2 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 1,1'-[1,2-ethanediylbis(4,1-piperazinediyl-3,1-propanediyl)]bis[6-(4-cyanophenyl)-1,2,3,6-tetrahydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, bis(2-hydroxyethyl) ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 904957-93-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-3-[[4-[[[2-[[2-[[4-[[6-(4-cyanophenyl)-5-(ethoxycarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]methyl]benzoyl]amino]ethyl]methylamino]ethyl]amino]carbonyl]phenyl]methyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 904957-94-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-3-[[[3-[[[2-[[2-[[3-[[6-(4-cyanophenyl)-5-(ethoxycarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]methyl]benzoyl]amino]ethyl]methylamino]ethyl]amino]carbonyl]phenyl]methyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 904957-95-5 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 1,1'-[carbonimidoylbis(imino-3,1-propanediyl)]bis[6-(4-cyanophenyl)-1,2,3,6-tetrahydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, diethyl ester, (6R,6'R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 904957-96-6 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 1,1'-[carbonimidoylbis(imino-5,1-pentanediy)]bis[6-(4-cyanophenyl)-1,2,3,6-tetrahydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, diethyl ester, (6R,6'R)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 904957-97-7 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 1,1'-(7-imino-2,12-dioxo-3,6,8,11-tetraaza-1,13-tridecanediyl)bis[6-(4-cyanophenyl)-1,2,3,6-tetrahydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, diethyl ester, (6R,6'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 904957-98-8 CAPLUS
 CN Ethanaminium, 2,2'-[(methyldimino)bis[2,1-ethanediyldimino(2-oxo-2,1-ethanediyldimino)][(6R)-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1,5(2H)-pyrimidinediyldimino]carbonyloxy]]bis[N,N,N-trimethyl-, diiodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.






PAGE 1-B



CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-3-[2-[2-[2-[2-[(6R)-6-(4-cyanophenyl)-5-[2-(dimethylamino)ethoxy]carbonyl]-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]acetyl]amino]ethyl]met

PAGE 1-A






RN 904958-00-5 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 3-[2-[[2-[[2-[[2-[(6R)-5-[[2-[(aminoiminomethyl)amino]ethoxy]carbonyl]-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]acetyl]amino]ethyl]methylamino]ethyl]amino]-2-oxoethyl]-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-[(aminoiminomethyl)amino]ethyl ester, (4R)-(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B







RN 904958-01-6 CAPLUS

CN 1(2H)-Pyrimidineacetamide, N,N'-[(methylimino)di-2,1-ethanediyl]bis[6-(4-cyanophenyl)-3,6-dihydro-4-methyl-5-[(4-methyl-1-piperazinyl)carbonyl]-2-oxo-3-[3-(trifluoromethyl)phenyl]-, (6R,6'R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



PAGE 1-B



PAGE 2-A





PAGE 2-B


RN 904958-02-7 CAPLUS

CN 1(2H)-Pyrimidineacetamide, N,N'-[(methyylimino)di-2,1-ethanediyl]bis[6-(4-cyanophenyl)-3,6-dihydro-4-methyl-5-(1-piperazinylcarbonyl)-2-oxo-3-[3-(trifluoromethyl)phenyl]-, (6R,6'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 2-A





RN 904958-03-8 CAPLUS

CN Ethanaminium, 2-[[2-[(6R)-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-5-(1-piperazinylcarbonyl)-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]acetyl]amino]-N-[2-[[2-[(6R)-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-5-(1-piperazinylcarbonyl)-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]acetyl]amino]ethyl]-N,N-dimethyl-, iodide (1:1) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A








RN 904958-04-9 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-3-[22-[(6R)-6-(4-cyanophenyl)-5-(ethoxycarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]-10,13-bis[3-[[2-[[2-[(6R)-6-(4-cyanophenyl)-5-(ethoxycarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]acetyl]amino]ethyl]amino]-3-oxopropyl]-2,7,16,21-tetraoxo-3,6,10,13,17,20-hexaazadocos-1-yl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester, (4R)- (CA INDEX NAME)

Absolute stereochemistry.





PAGE 2-A




NC

PAGE 2-B







RN 904958-05-0 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 3-[2-[[5-[[3,5-bis[[[5-[[2-[6-(4-cyanophenyl)-5-(ethoxycarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]acetyl]amino]pentyl]amino]carbo-nyl]benzoyl]amino]pentyl]amino]-2-oxoethyl]-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)



PAGE 1-B




PAGE 2-A




RN 904958-06-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 3-[2-[[2-[[2-[[2-[3,6-dihydro-5-[(2-hydroxyethoxy)carbonyl]-4-methyl-6-(4-methylphenyl)-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]acetyl]amino]ethyl]methylamino]ethyl]amino]-2-oxoethyl]-1,2,3,4-tetrahydro-6-methyl-4-(4-methylphenyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-hydroxyethyl ester (CA INDEX NAME)

PAGE 1-A



PAGE 1-B




RN 904958-08-3 CAPLUS

CN 1(2H)-Pyrimidinepentanaminium, 6-(4-cyanophenyl)-N-[5-[(6R)-6-(4-cyanophenyl)-5-(ethoxycarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]pentyl]-5-(ethoxycarbonyl)-3,6-dihydro-N,N,4-trimethyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, iodide (1:1), (6R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 904958-09-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-3-[2-[[3-[4-[3-[2-[6-(4-cyanophenyl)-5-(ethoxycarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]acetyl]amino]propyl]-1-piperazinyl]propyl]amino]-2-oxoethyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)

PAGE 1-A

F₃C—


PAGE 1-B




RN 904958-10-7 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-3-[2-[4-[5-[4-[2-[6-(4-cyanophenyl)-5-(ethoxycarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]acetyl]-1-piperazinyl]pentyl]-1-piperazinyl]-2-oxoethyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)


PAGE 1-A





RN 904958-11-8 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 1,1'-(1,4-piperazinediyl)di-3,1-propanediyl]bis[6-(4-cyanophenyl)-1,2,3,6-tetrahydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 904958-12-9 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 1,1'-[1,5-pentanediy]bis(4,1-piperazinediyl-3,1-propanediyl)]bis[6-(4-cyanophenyl)-1,2,3,6-tetrahydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, diethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 904958-13-0 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 1,1'-[[[1,1'-biphenyl]-4,4'-diylbis(carbonyl-4,1-piperazinediyl)-3,1-propanediyl]]bis[6-(4-cyanophenyl)-1,2,3,6-tetrahydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, diethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 904958-14-1 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 1,1'-[oxybis(4,1-phenylenecarbonyl-4,1-piperazinediyl-3,1-propanediyl)]bis[6-(4-cyanophenyl)-1,2,3,6-tetrahydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, diethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 904958-15-2 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 1,1'-[[1,1'-biphenyl]-2,2'-diylbis(carbonyl-4,1-piperazinediyl-3,1-propanediyl)]bis[6-(4-cyanophenyl)-1,2,3,6-tetrahydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, diethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 904958-16-3 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 1,1'-[1,2-phenylenebis(carbonyl-4,1-piperazinediyl-3,1-propanediyl)]bis[6-(4-cyanophenyl)-1,2,3,6-tetrahydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, diethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 904958-17-4 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 1,1'-[[2,2'-bipyridin]-5,5'-diylbis(carbonyl-4,1-piperazinediyl-3,1-propanediyl)]bis[6-(4-cyanophenyl)-1,2,3,6-tetrahydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, diethyl ester (9CI) (CA INDEX NAME)



PAGE 1-A




PAGE 1-B



RN 904958-18-5 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 1,1'-[3,5-pyridinediylbis(carbonyl-4,1-piperazinediyl-3,1-propanediyl)]bis[6-(4-cyanophenyl)-1,2,3,6-tetrahydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 904958-19-6 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 1,1'-[(tetrahydro-1H-1,4-diazepine-1,4(5H)-diyl)di-3,1-propanediyl]bis[6-(4-cyanophenyl)-1,2,3,6-tetrahydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 904958-20-9 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 1,1'-[(methylimino)bis(2,1-ethanediylimino-3,1-propanediyl)]bis[6-(4-cyanophenyl)-1,2,3,6-tetrahydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, diethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 904958-21-0 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 1,1'-[(ethylimino)di-2,1-ethanediyl]bis[6-(4-cyanophenyl)-1,2,3,6-tetrahydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 904958-22-1 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 1,1'-[oxybis[2,1-ethanediyl(methylimino)-3,1-propanediyl]]bis[6-(4-cyanophenyl)-1,2,3,6-tetrahydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, diethyl ester, (6R,6'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





PAGE 2-A




RN 904958-23-2 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 1,1'-(4,13-dimethyl-7,10-dioxa-4,13-diazahexadecane-1,16-diyl)bis[6-(4-cyanophenyl)-1,2,3,6-tetrahydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, diethyl ester, (6R,6'R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 2-A




RN 904958-24-3 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 1,1'-[1,4-butanediylbis[(methylimino)-3,1-propanediyl]]bis[6-(4-cyanophenyl)-1,2,3,6-tetrahydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, diethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 904958-25-4 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 1,1'-[1,8-octanediylbis[(methylimino)-3,1-propanediyl]]bis[6-(4-cyanophenyl)-1,2,3,6-tetrahydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, diethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 904958-26-5 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 1,1'-[(methylimino)di-2,1-ethanediyl]bis[6-(4-cyanophenyl)-1,2,3,6-tetrahydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, diethyl ester, (6R,6'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 904958-27-6 CAPLUS


CN 1(2H)-Pyrimidinepropanaminium, 6-(4-cyanophenyl)-N-[3-[(6R)-6-(4-cyanophenyl)-5-(ethoxycarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]propyl]-5-(ethoxycarbonyl)-3,6-

10/527,391

dihydro-N,N,4-trimethyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, iodide
(1:1), (6R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 904958-28-7 CAPLUS
CN 5-Pyrimidinecarboxylic acid, 1,1'-(1,12-dodecanediyl)bis[6-(4-cyanophenyl)-
1,2,3,6-tetrahydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-,
bis[2-(dimethylamino)ethyl] ester, (6R,6'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 904958-30-1 CAPLUS
 CN Ethanaminium, 2-[[[(4R)-4-(4-cyanophenyl)-3-[12-[(6R)-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-5-[[2-(trimethylammonio)ethoxy]carbonyl]-1(2H)-pyrimidinyl]dodecyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-5-pyrimidinyl]carbonyl]oxy]-N,N,N-trimethyl-, formate (1:2) (CA INDEX NAME)

CM 1

CRN 904958-29-8
 CMF C62 H74 F6 N8 O6


Absolute stereochemistry.



CM 2

CRN 71-47-6

CMF C H O2




RN 904958-31-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 3-[2-[[2-[[2-[[2-[(6R)-5-(butoxycarbonyl)-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]acetyl]amino]ethyl]methylamino]ethyl]amino]-2-oxoethyl]-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, butyl ester, (4R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




—CF₃


RN 904958-32-3 CAPLUS

CN Ethanaminium, 2-[[2-[(6R)-6-(4-cyanophenyl)-5-[[2-(dimethylamino)ethoxy]carbonyl]-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]acetyl]amino]-N-[2-[[2-[(6R)-6-(4-cyanophenyl)-5-[[2-(dimethylamino)ethoxy]carbonyl]-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]acetyl]amino]ethyl]-N,N-dimethyl-, iodide (1:1) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B



RN 904958-33-4 CAPLUS
 CN Pyrrolidinium, 1,1-bis[3-[(6R)-6-(4-cyanophenyl)-5-(ethoxycarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]propyl]-, bromide (1:1) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 904958-34-5 CAPLUS
 CN Piperidinium, 1,1-bis[3-[(6R)-6-(4-cyanophenyl)-5-(ethoxycarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]propyl]-, bromide (1:1) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 904958-36-7 CAPLUS
 CN Ethanaminium, 2-[[2-[6-(6-cyano-3-pyridinyl)-5-(ethoxycarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]acetyl]amino]-N-[2-[[2-[6-(6-cyano-3-pyridinyl)-5-(ethoxycarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]acetyl]amino]ethyl]-N,N-dimethyl-, iodide (1:1) (CA INDEX NAME)

PAGE 1-A





PAGE 1-B



RN 904958-37-8 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-3-[2-[[2-[[2-[[2-[(6R)-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-5-[(phenylmethoxy)carbonyl]-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]acetyl]amino]ethyl]methylamino]ethyl]amino]-2-oxoethyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, phenylmethyl ester, (4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 904958-39-0 CAPLUS
 CN Ethanaminium, 2-[[2-[(6R)-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-5-[(phenylmethoxy)carbonyl]-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]acetyl]amino]-N-[2-[[2-[(6R)-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-5-[(phenylmethoxy)carbonyl]-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]acetyl]amino]ethyl]-N,N-dimethyl-, formate (1:1) (CA INDEX NAME)


CM 1

CRN 904958-38-9

CMF C64 H58 F6 N9 O8

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



CM 2

CRN 71-47-6

CMF C H O2



RN 904958-41-4 CAPLUS

CN Ethanaminium, 2-[[[(6R)-6-(4-cyanophenyl)-5-(ethoxycarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]acetyl]amino]-N-[2-[[[(6R)-6-(4-cyanophenyl)-5-(ethoxycarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]acetyl]amino]ethyl]-N,N-dimethyl-, butanedioate (2:1) (9CI) (CA INDEX NAME)


CM 1

CRN 904958-40-3

CMF C54 H54 F6 N9 O8

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—OEt

CM 2

CRN 56-14-4

CMF C4 H4 O4




IT 864228-16-0P 904958-45-8P

RL: PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of multimers of tetrahydropyrimidinone compds. as elastase inhibitors useful in the treatment of respiratory diseases)

RN 864228-16-0 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, (4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 904958-45-8 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 3-(3-bromopropyl)-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester, (4R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 671776-07-1P 864151-33-7P 904958-42-5P
 904958-43-6P 904958-44-7P 904958-46-9P
 904958-47-0P 904958-48-1P 904958-49-2P
 904958-50-5P 904958-51-6P 904958-52-7P
 904958-53-8P 904958-54-9P 904958-55-0P
 904958-56-1P 904958-57-2P 904958-58-3P
 904958-59-4P 904958-60-7P 904958-61-8P


904958-62-9P 904958-63-0P 904958-64-1P
 904958-65-2P 904958-66-3P 904958-67-4P
 904958-68-5P 904958-69-6P 904958-70-9P
 904958-71-0P 904958-72-1P 904958-73-2P
 904958-74-3P 904958-75-4P 904958-76-5P
 904958-77-6P 904958-78-7P 904958-79-8P
 904958-80-1P 904958-81-2P 904958-83-4P
 904958-97-0P 904958-98-1P 904958-99-2P
 904959-00-8P 904959-01-9P 904959-02-0P
 904959-03-1P 904959-04-2P 904959-05-3P
 904959-06-4P 904959-07-5P 904959-08-6P
 904959-16-6P 905287-66-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(intermediate; preparation of multimers of tetrahydropyrimidinone compds. as
 elastase inhibitors useful in the treatment of respiratory diseases)

RN 671776-07-1 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(6-cyano-3-pyridinyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)



RN 864151-33-7 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-propen-1-yl ester, (4R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 904958-42-5 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, phenylmethyl ester (CA INDEX NAME)




RN 904958-43-6 CAPLUS
 CN 1(2H)-Pyrimidineacetic acid, 6-(4-cyanophenyl)-5-(ethoxycarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, (6R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 904958-44-7 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 3-(3-bromopropyl)-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)




RN 904958-46-9 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-3-[3-(1H-imidazol-1-yl)propyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)



RN 904958-47-0 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-3-[3-(1H-imidazol-1-yl)propyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester, (4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 904958-48-1 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 3-(8-bromooctyl)-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)



RN 904958-49-2 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 3-(8-bromooctyl)-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester, (4R)- (CA INDEX NAME)

Absolute stereochemistry.





RN 904958-50-5 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl ester (CA INDEX NAME)




RN 904958-51-6 CAPLUS


CN 1(2H)-Pyrimidineacetic acid, 6-(4-cyanophenyl)-3,6-dihydro-5-[(2-hydroxyethoxy)carbonyl]-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 904958-52-7 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 1,1'-(1,12-dodecanediyl)bis[6-(4-cyanophenyl)-1,2,3,6-tetrahydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, bis[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl] ester (9CI) (CA INDEX NAME)

PAGE 1-A






RN 904958-53-8 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 3-(12-bromododecyl)-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl ester (CA INDEX NAME)




RN 904958-54-9 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 3-(8-bromooctyl)-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl ester (CA INDEX NAME)



RN 904958-55-0 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 3-(3-bromopropyl)-4-(4-cyanophenyl)-1,2,3,4-


tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-,
2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl ester (CA INDEX NAME)




RN 904958-56-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 1,1'-[1,2-ethanediylbis(4,1-piperazinediyl-3,1-propanediyl)]bis[6-(4-cyanophenyl)-1,2,3,6-tetrahydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, bis[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl] ester (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B



PAGE 2-B




RN 904958-57-2 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 1,1'-[(ethylimino)di-8,1-octanediyl]bis[6-(4-cyanophenyl)-1,2,3,6-tetrahydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, bis[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl] ester (9CI) (CA INDEX NAME)




RN 904958-58-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-3-[[4-(methoxycarbonyl)phenyl]methyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)




RN 904958-59-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 3-[(4-carboxyphenyl)methyl]-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 5-ethyl ester (CA INDEX NAME)




RN 904958-60-7 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-3-[[3-(methoxycarbonyl)phenyl]methyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)



RN 904958-61-8 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 3-[(3-carboxyphenyl)methyl]-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 5-ethyl ester (CA INDEX NAME)



RN 904958-62-9 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-3-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester, (4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 904958-63-0 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 3-(3-aminopropyl)-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester, (4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 904958-64-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-3-[5-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)pentyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester, (4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 904958-65-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 3-(5-aminopentyl)-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester, (4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 904958-66-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 1,1'-[carbonothioylbis(imino-3,1-propanediyl)]bis[6-(4-cyanophenyl)-1,2,3,6-tetrahydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, diethyl ester, (6R,6'R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 904958-67-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 1,1'-[carbonothioylbis(imino-5,1-pentenediyl)]bis[6-(4-cyanophenyl)-1,2,3,6-tetrahydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, diethyl ester, (6R,6'R)-(9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 904958-68-5 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 1,1'-[2,12-dioxo-7-[(trifluoroacetyl)amino]-3,6,8,11-tetraaza-6-tridecene-1,13-diyl]bis[6-(4-cyanophenyl)-1,2,3,6-tetrahydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, diethyl ester, (6R,6'R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 904958-69-6 CAPLUS
 CN 1(2H)-Pyrimidineacetic acid, 6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-5-[(2-propen-1-yloxy)carbonyl]-3-[3-(trifluoromethyl)phenyl]-, (6R)- (CA INDEX NAME)

Absolute stereochemistry.






RN 904958-70-9 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-3-[2-[[2-[[2-[[2-[(6R)-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-5-[(2-propen-1-yloxy)carbonyl]-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]acetyl]amino]ethyl]methylamino]ethyl]amino]-2-oxoethyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-propen-1-yl ester, (4R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A






RN 904958-71-0 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 3-[2-[[2-[[2-[[2-[(6R)-5-carboxy-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]acetyl]amino]ethyl]methylamino]ethyl]amino]-2-oxoethyl]-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, (4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 904958-72-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 3-(5-bromopentyl)-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester, (4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 904958-73-2 CAPLUS

CN Benzonitrile, 4-[(4R)-1,2,3,4-tetrahydro-6-methyl-5-[(4-methyl-1-piperazinyl)carbonyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 904958-74-3 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[[(4R)-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-5-pyrimidinyl]carbonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 904958-75-4 CAPLUS

CN 1(2H)-Pyrimidineacetic acid, 6-(4-cyanophenyl)-3,6-dihydro-4-methyl-5-[(4-methyl-1-piperazinyl)carbonyl]-2-oxo-3-[3-(trifluoromethyl)phenyl]-, (6R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 904958-76-5 CAPLUS

CN 1(2H)-Pyrimidineacetic acid, 6-(4-cyanophenyl)-5-[[4-[(1,1-dimethylethoxy)carbonyl]-1-piperazinyl]carbonyl]-3,6-dihydro-4-methyl-2-

oxo-3-[3-(trifluoromethyl)phenyl]-, (6R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 904958-77-6 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[[[(4R)-4-(4-cyanophenyl)-3-[2-[[2-[[2-[[2-[(6R)-6-(4-cyanophenyl)-5-[[4-[(1,1-dimethylethoxy)carbonyl]-1-piperazinyl]carbonyl]-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]acetyl]amino]ethyl]methylamino]ethyl]amino]-2-oxoethyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-5-pyrimidinyl]carbonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B




PAGE 2-B



RN 904958-78-7 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-
 2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-(phenylmethoxy)ethyl ester (CA
 INDEX NAME)




RN 904958-79-8 CAPLUS
 CN 1(2H)-Pyrimidineacetic acid, 6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-5-[[2-(phenylmethoxy)ethoxy]carbonyl]-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 904958-80-1 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-3-[2-[[2-[[2-[[2-[6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-5-[[2-(phenylmethoxy)ethoxy]carbonyl]-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]acetyl]amino]ethyl]methylamino]ethyl]amino]-2-oxoethyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-(phenylmethoxy)ethyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 904958-81-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-3-[2-[[5-[(1,1-dimethylethoxy)carbonyl]amino]pentyl]amino]-2-oxoethyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)



RN 904958-83-4 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 3-[2-[(5-aminopentyl)amino]-2-oxoethyl]-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 904958-82-3

CMF C29 H32 F3 N5 O4


10/527,391



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 904958-97-0 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-3-[2-(1,3-dioxolan-2-yl)ethyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)



RN 904958-98-1 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-3-(3-oxopropyl)-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)



RN 904958-99-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-3-[2-(1,3-dioxolan-2-yl)ethyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester, (4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 904959-00-8 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-3-(3-oxopropyl)-1-[3-(trifluoromethyl)phenyl]-, ethyl ester, (4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 904959-01-9 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-(dimethylamino)ethyl ester, (4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 904959-02-0 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, butyl ester, (4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 904959-03-1 CAPLUS

CN 1(2H)-Pyrimidineacetic acid, 5-(butoxycarbonyl)-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, (6R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 904959-04-2 CAPLUS

CN Ethanaminium, 2-[[2-[(6R)-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-5-(3-(trifluoromethyl)phenyl)pyrimidin-2-yl]ethyl]carbamoyl]-


[(2-propen-1-yloxy)carbonyl]-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]acetyl]amino]-N-[2-[[2-[(6R)-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-5-[(2-propen-1-yloxy)carbonyl]-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]acetyl]amino]ethyl]-N,N-dimethyl-, iodide (1:1) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 904959-05-3 CAPLUS
 CN Ethanaminium, 2-[[2-[(6R)-5-carboxy-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]acetyl]amino]-N-[2-[[2-[(6R)-5-carboxy-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]acetyl]amino]ethyl]-N,N-dimethyl-, iodide (1:1) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 2-A




RN 904959-06-4 CAPLUS
 CN 1(2H)-Pyrimidineacetic acid, 6-(6-cyano-3-pyridinyl)-5-(ethoxycarbonyl)-
 3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 904959-07-5 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-
 2-oxo-1-[3-(trifluoromethyl)phenyl]-, phenylmethyl ester, (4R)- (CA INDEX
 NAME)


Absolute stereochemistry.



RN 904959-08-6 CAPLUS


CN 1(2H)-Pyrimidineacetic acid, 6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-5-[(phenylmethoxy)carbonyl]-3-[3-(trifluoromethyl)phenyl]-, (6R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 904959-16-6 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-3-(4-penten-1-yl)-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)



RN 905287-66-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester, (4R)- (CA INDEX NAME)

Absolute stereochemistry.




IT 671775-85-2 671776-27-5

RL: RCT (Reactant); RACT (Reactant or reagent)

(starting material; preparation of multimers of tetrahydropyrimidinone compds. as elastase inhibitors useful in the treatment of respiratory diseases)


RN 671775-85-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)



RN 671776-27-5 CAPLUS

CN 1(2H)-Pyrimidineacetic acid, 6-(4-cyanophenyl)-5-(ethoxycarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



IT 671775-95-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(starting material; preparation of multimers of tetrahydropyrimidinone

comps. as elastase inhibitors useful in the treatment of respiratory diseases)

RN 671775-95-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



L16 ANSWER 7 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2006:608538 CAPLUS
 DN 145:58204
 TI Crystal structure of human neutrophil elastase and uses in drug discovery
 IN Reinemer, Peter; Gielen-Haertwig, Heike; Rosentreter, Ulrich; Li, Volkhart; Harrenga, Axel; Schomburg, Dietmar; Niefind, Karsten; Hansen, Guido
 PA Bayer Healthcare AG, Germany
 SO PCT Int. Appl., 123 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006063792	A2	20060622	WO 2005-EP13370	20051213
	WO 2006063792	A3	20070412		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
	CA 2590851	A1	20060622	CA 2005-2590851	20051213
	EP 1828233	A2	20070905	EP 2005-819949	20051213
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU			
PRAI	EP 2004-29768	A	20041216		
	WO 2005-EP13370	W	20051213		


AB This invention relates to crystallized human neutrophil elastase and the use of its three-dimensional structure to design modulators for human neutrophil elastase. The crystal structure and the atomic structural coordinates of human neutrophil elastase and inhibitor complexes is disclosed.

IT 675103-34-1DP, complexes with elastase
 RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of elastase inhibitor; crystal structure of human neutrophil elastase and uses in drug discovery)


RN 675103-34-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-hydroxyethyl ester, (4R)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



IT 671775-85-2P 671775-95-4P 675103-34-1P
 864228-16-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of elastase inhibitor; crystal structure of human neutrophil
 elastase and uses in drug discovery)
 RN 671775-85-2 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-
 2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)




RN 671775-95-4 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-
 2-oxo-1-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 675103-34-1 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-
 2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-hydroxyethyl ester, (4R)- (CA
 INDEX NAME)

10/527,391


Absolute stereochemistry. Rotation (+).




RN 864228-16-0 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, (4R)- (CA INDEX NAME)

Absolute stereochemistry.




L16 ANSWER 8 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:499119 CAPLUS
DN 145:137267
TI Identification and characterization of 4-aryl-3,4-dihydropyrimidin-2(1H)-ones as inhibitors of the fatty acid transporter FATP4
AU Blackburn, Christopher; Guan, Bing; Brown, James; Cullis, Courtney; Condon, Stephen M.; Jenkins, Tracy J.; Peluso, Stephane; Ye, Yingchun; Gimeno, Ruth E.; Punreddy, Sandhya; Sun, Ying; Wu, Hui; Hubbard, Brian; Kaushik, Virendar; Tummino, Peter; Sanchetti, Praveen; Yu Sun, Dong; Daniels, Tom; Tozzo, Effie; Balani, Suresh K.; Raman, Prakash
CS Medicinal Chemistry, Millennium Pharmaceuticals, Inc., 40 Landsdowne St. Cambridge, MA, 02139, USA
SO Bioorganic & Medicinal Chemistry Letters (2006), 16(13), 3504-3509
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier B.V.
DT Journal
LA English
OS CASREACT 145:137267
AB Several potent, cell permeable 4-aryl-dihydropyrimidinones have been identified as inhibitors of FATP4. Lipophilic ester substituents at the 5-position and substitution at the para-position (optimal groups being -NO₂ and CF₃) of the 4-aryl group led to active compds. In two cases racemates were resolved and the S enantiomers shown to have higher potencies.
IT 898798-95-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(aryldihydropyrimidinones as inhibitors of fatty acid transporter FATP4)
RN 898798-95-3 CAPLUS
CN 5-Pyrimidinecarboxylic acid, 1,2,3,4-tetrahydro-6-methyl-4-(4-nitrophenyl)-2-oxo-1-phenyl-, cyclopentyl ester (CA INDEX NAME)




RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 9 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2006:174835 CAPLUS
 DN 144:370036
 TI A convenient synthesis of N(1)-substituted 3,4-dihydropyrimidin-2(1H)-ones by cyclocondensation of α -chlorobenzyl isocyanates with ethyl N-alkyl(aryl)- β -aminocrotonates
 AU Sukach, Volodymyr A.; Bol'but, Andriy V.; Sinitza, Anatoliy D.; Vovk, Mykhaylo V.
 CS Institute of Organic Chemistry, National Academy of Science of Ukraine, Kiev, 02094, Ukraine
 SO Synlett (2006), (3), 375-378
 CODEN: SYNLES; ISSN: 0936-5214
 PB Georg Thieme Verlag
 DT Journal
 LA English
 OS CASREACT 144:370036
 AB A new convenient approach to the synthesis of N(1)-substituted 3,4-dihydropyrimidin-2-(1H)-ones was developed using the regioselective cyclocondensation of α -chlorobenzyl isocyanates with Et N-alkyl(aryl)- β -aminocrotonates. A number of N(1)-aryl and N(1)-alkyl substituted Biginelli compds. difficult to obtain by other methods were prepared with high yields.
 IT 321943-50-4P 331655-46-0P 793693-44-4P
 881993-43-7P 881993-44-8P 881993-45-9P
 881993-46-0P 881993-47-1P 881993-48-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of dihydropyrimidinones by regioselective cyclocondensation of α -chlorobenzyl isocyanates with β -aminocrotonates)
 RN 321943-50-4 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 1,2,3,4-tetrahydro-6-methyl-4-(3-nitrophenyl)-2-oxo-1-phenyl-, ethyl ester (CA INDEX NAME)




RN 331655-46-0 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 1,2,3,4-tetrahydro-6-methyl-4-(4-nitrophenyl)-2-oxo-1-phenyl-, ethyl ester (CA INDEX NAME)




RN 793693-44-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 1-(4-chlorophenyl)-1,2,3,4-tetrahydro-6-methyl-4-(3-nitrophenyl)-2-oxo-, ethyl ester (CA INDEX NAME)




RN 881993-43-7 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 1-(4-chlorophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-4-phenyl-, ethyl ester (CA INDEX NAME)




RN 881993-44-8 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 1-[4-[(difluoromethyl)thio]phenyl]-4-(2-fluorophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-, ethyl ester (CA INDEX NAME)




RN 881993-45-9 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(3-bromophenyl)-1,2,3,4-tetrahydro-1-(4-methoxyphenyl)-6-methyl-2-oxo-, ethyl ester (CA INDEX NAME)



RN 881993-46-0 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(4-chlorophenyl)-1-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-, ethyl ester (CA INDEX NAME)



RN 881993-47-1 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(4-bromophenyl)-1,2,3,4-tetrahydro-1-(4-methoxyphenyl)-6-methyl-2-oxo-, ethyl ester (CA INDEX NAME)

10/527,391



RN 881993-48-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(3,4-dichlorophenyl)-1-(3-fluoro-4-methylphenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-, ethyl ester (CA INDEX NAME)



RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 10 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2005:979623 CAPLUS
 DN 143:286441
 TI Preparation of diaryl-dihydropyrimidin-2-ones as human neutrophil elastase inhibitors
 IN Gielen-Haertwig, Heike; Albrecht, Barbara; Keldenich, Joerg; Li, Volkhart; Pernerstorfer, Josef; Schlemmer, Karl-Heinz; Telan, Leila
 PA Bayer Healthcare A.-G., Germany
 SO PCT Int. Appl., 141 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005082864	A1	20050909	WO 2005-EP1486	20050215
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2557271	A1	20050909	CA 2005-2557271	20050215
	EP 1723121	A1	20061122	EP 2005-707386	20050215
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	JP 2007524696	T	20070830	JP 2007-500099	20050215
	US 20080064704	A1	20080313	US 2007-590770	20070618
PRAI	EP 2004-4314	A	20040226		
	WO 2005-EP1486	W	20050215		

OS CASREACT 143:286441; MARPAT 143:286441

AB Title compds. I [A = aryl or heteroaryl ring; R1, R2 and R3 independently = H, halo, nitro, etc.; R4 = (un)substituted alkyl, cycloalkylcarbonyl, alkylcarbonyl, etc.; R5 = (un)substituted alkyl; R6 = H, formyl, aminocarbonyl, etc.; R7 = cyano, OH, nitro, etc.; V, W, X, Y and Z independently = CH or N wherein the ring contains either 0, 1 or 2 nitrogen atoms] and their pharmaceutically acceptable salts, are prepared and disclosed as human neutrophil elastase (HNE) inhibitors. Thus, e.g., II was prepared by cyclization of N-[3-(trifluoromethyl)phenyl]urea and 4-cyanobenzaldehyde with ethyl-3-oxobutanoate and subsequent reduction using LAH. The activity of I against HNE was evaluated in an in vitro enzyme assay utilizing a fluorogenic peptide substrate and it was revealed that selected compds. of the invention possessed IC50 values in the range of 5 up to 1000 nM. I as inhibitors of human neutrophil elastase should prove useful in the treatment of chronic obstructive pulmonary diseases, acute coronary syndrome, acute myocardial infarction and heart failure development. Pharmaceutical compns. comprising I are disclosed.


IT 864250-62-4P

RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent); USES (Uses)

(preparation of diaryl-dihydropyrimidin-2-ones as human neutrophil elastase inhibitors)

RN 864250-62-4 CAPLUS

CN Benzonitrile, 4-[5-(cyclopropylcarbonyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




IT 864251-32-1P 864251-33-2P

RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)

(preparation of diaryl-dihydropyrimidin-2-ones as human neutrophil elastase inhibitors)

RN 864251-32-1 CAPLUS


CN Benzonitrile, 4-[5-(cyclohexylcarbonyl)-3-[2-(diethylamino)ethyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)



RN 864251-33-2 CAPLUS

CN Benzonitrile, 4-[5-(cyclopropylcarbonyl)-3-[2-(diethylamino)ethyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-

(CA INDEX NAME)



IT 864250-63-5P


RL: PAC (Pharmacological activity); PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of diaryl-dihydropyrimidin-2-ones as human neutrophil elastase inhibitors)

RN 864250-63-5 CAPLUS

CN Benzonitrile, 4-[(4R)-5-(cyclopropylcarbonyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 864251-36-5P 864251-37-6P


RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of diaryl-dihydropyrimidin-2-ones as human neutrophil elastase inhibitors)

RN 864251-36-5 CAPLUS


CN Benzonitrile, 4-[(4R)-5-(cyclopropylcarbonyl)-3-[2-(diethylamino)ethyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 864251-37-6 CAPLUS
 CN Benzonitrile, 4-[(4S)-5-(cyclohexylcarbonyl)-3-[2-(diethylamino)ethyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



IT 864250-60-2P 864250-61-3P 864250-64-6P
 864250-65-7P 864250-66-8P 864250-67-9P
 864250-68-0P 864250-71-5P 864250-72-6P
 864250-73-7P 864250-75-9P 864250-77-1P
 864250-78-2P 864250-82-8P 864250-83-9P
 864250-86-2P 864250-87-3P 864250-94-2P
 864250-95-3P 864250-97-5P 864250-98-6P
 864250-99-7P 864251-05-8P 864251-08-1P
 864251-09-2P 864251-10-5P 864251-21-8P
 864251-22-9P 864251-24-1P 864251-26-3P
 864251-27-4P 864251-29-6P 864251-31-0P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of diaryl-dihydropyrimidin-2-ones as human neutrophil elastase inhibitors)

RN 864250-60-2 CAPLUS
 CN Benzonitrile, 4-[5-(cyclobutylcarbonyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 864250-61-3 CAPLUS

CN Benzonitrile, 4-[5-(cyclohexylcarbonyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 864250-64-6 CAPLUS

CN Benzonitrile, 4-[1,2,3,4-tetrahydro-5-(4-methoxybenzoyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 864250-65-7 CAPLUS

CN Benzonitrile, 4-[5-[(2-amino-4-methyl-5-thiazolyl)carbonyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 864250-66-8 CAPLUS

CN 1(2H)-Pyrimidineacetic acid, 6-(4-cyanophenyl)-5-(cyclobutylcarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864250-67-9 CAPLUS

CN 1(2H)-Pyrimidineacetic acid, 6-(4-cyanophenyl)-5-(cyclopropylcarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864250-68-0 CAPLUS

CN 1(2H)-Pyrimidineacetic acid, 6-(4-cyanophenyl)-5-(cyclohexylcarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864250-71-5 CAPLUS

CN 1(2H)-Pyrimidineacetic acid, 6-(4-cyanophenyl)-5-(cyclopropylcarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 864250-72-6 CAPLUS

CN 1(2H)-Pyrimidineacetic acid, 6-(4-cyanophenyl)-5-(cyclohexylcarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 864250-73-7 CAPLUS

CN 1(2H)-Pyrimidineacetic acid, 6-(4-cyanophenyl)-3,6-dihydro-5-(4-methoxybenzoyl)-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864250-75-9 CAPLUS

CN Benzoic acid, 3-[[6-(4-cyanophenyl)-5-(cyclopropylcarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864250-77-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-5-pyrimidinyl]carbonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864250-78-2 CAPLUS

CN Benzoic acid, 3-[[6-(4-cyanophenyl)-5-(cyclohexylcarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864250-82-8 CAPLUS

CN 2-Furancarboxylic acid, 5-[[6-(4-cyanophenyl)-5-(cyclopropylcarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]methyl]-, methyl ester (CA INDEX NAME)




RN 864250-83-9 CAPLUS

CN 4-Oxazolecarboxylic acid, 2-[[6-(4-cyanophenyl)-5-(cyclopropylcarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]methyl]-, methyl ester (CA INDEX NAME)




RN 864250-86-2 CAPLUS

CN 2-Furancarboxylic acid, 5-[[6-(4-cyanophenyl)-5-(cyclohexylcarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]methyl]-, methyl ester (CA INDEX NAME)




RN 864250-87-3 CAPLUS

CN 4-Oxazolecarboxylic acid, 2-[[6-(4-cyanophenyl)-5-(cyclohexylcarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]methyl]-, methyl ester (CA INDEX NAME)




RN 864250-94-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 2-[[4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-5-pyrimidinyl]carbonyl]-, phenylmethyl ester (CA INDEX NAME)




RN 864250-95-3 CAPLUS

CN 1(2H)-Pyrimidineacetic acid, 6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-5-[[1-[(phenylmethoxy)carbonyl]-2-piperidinyl]carbonyl]-3-[3-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 864250-97-5 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-(phenylmethoxy)-1-[(phenylmethoxy)methyl]ethyl ester (CA INDEX NAME)



RN 864250-98-6 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, (1S)-1-methyl-2-oxo-2-(phenylmethoxy)ethyl ester, (4R)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 864250-99-7 CAPLUS

CN Propanedioic acid, [[4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-5-pyrimidinyl]carbonyl]-, 1,1-dimethylethyl phenylmethyl ester (9CI) (CA INDEX NAME)




RN 864251-05-8 CAPLUS

CN 1(2H)-Pyrimidineacetic acid, 6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-5-[[2-(2-oxo-1-pyrrolidinyl)ethoxy]carbonyl]-3-[3-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864251-08-1 CAPLUS

CN 1(2H)-Pyrimidineacetic acid, 6-(4-cyanophenyl)-3,6-dihydro-4-methyl-5-[[[(methylsulfonyl)amino]carbonyl]-2-oxo-3-[3-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864251-09-2 CAPLUS

CN 1(2H)-Pyrimidineacetic acid, 6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-5-[[[(2,2,2-trifluoroethyl)sulfonyl]amino]carbonyl]-3-[3-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864251-10-5 CAPLUS

CN 1(2H)-Pyrimidineacetic acid, 6-(4-cyanophenyl)-5-[[[4-(trifluoromethyl)phenyl]sulfonyl]amino]carbonyl]-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864251-21-8 CAPLUS

CN Benzonitrile, 4-[5-(4-bromobenzoyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 864251-22-9 CAPLUS

CN 1(2H)-Pyrimidineacetic acid, 5-(4-bromobenzoyl)-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864251-24-1 CAPLUS

CN 1(2H)-Pyrimidineacetic acid, 5-([1,1'-biphenyl]-4-ylcarbonyl)-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864251-26-3 CAPLUS

CN Benzonitrile, 4-[1,2,3,4-tetrahydro-6-methyl-5-(4-nitrobenzoyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)



RN 864251-27-4 CAPLUS


CN 1(2H)-Pyrimidineacetic acid, 6-(4-cyanophenyl)-3,6-dihydro-4-methyl-5-(4-nitrobenzoyl)-2-oxo-3-[3-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 864251-29-6 CAPLUS


CN 1(2H)-Pyrimidineacetic acid, 6-(4-cyanophenyl)-5-(cyclopropylcarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester, (6R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864251-31-0 CAPLUS

CN Benzonitrile, 4-[5-[(2,2-dimethyl-1,3-dioxolan-4-yl)carbonyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)



IT 864250-45-3P 864250-46-4P 864250-47-5P
 864250-48-6P 864250-49-7P 864250-50-0P
 864250-51-1P 864250-52-2P 864250-53-3P
 864250-54-4P 864250-55-5P 864250-56-6P
 864250-57-7P 864250-58-8P 864250-59-9P
 864250-69-1P 864250-70-4P 864250-74-8P
 864250-76-0P 864250-79-3P 864250-80-6P
 864250-84-0P 864250-85-1P 864250-88-4P
 864250-89-5P 864250-90-8P 864250-91-9P
 864250-92-0P 864250-93-1P 864250-96-4P
 864251-00-3P 864251-01-4P 864251-02-5P
 864251-03-6P 864251-04-7P 864251-06-9P
 864251-07-0P 864251-11-6P 864251-12-7P
 864251-13-8P 864251-14-9P 864251-15-0P
 864251-16-1P 864251-23-0P 864251-25-2P
 864251-28-5P 864251-30-9P 864251-34-3P
 864251-35-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of diaryl-dihydropyrimidin-2-ones as human neutrophil elastase
 inhibitors)

RN 864250-45-3 CAPLUS


CN 1(2H)-Pyrimidineacetic acid, 5-[[2-(carboxymethoxy)ethoxy]carbonyl]-6-(4-
 cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-,
 (6R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 864250-46-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-cyanophenyl)-N-cyclopropyl-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 864250-47-5 CAPLUS

CN Benzonitrile, 4-[5-[[4-(3,4-dichlorophenyl)-1-piperazinyl]carbonyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 864250-48-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-N-[1-(phenylmethyl)-4-piperidinyl]-1-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 864250-49-7 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-5-pyrimidinyl]carbonyl]-, methyl ester (CA INDEX NAME)




RN 864250-50-0 CAPLUS

CN Benzonitrile, 4-[1,2,3,4-tetrahydro-6-methyl-2-oxo-5-[[4-(4-pyridinyl)-1-piperazinyl]carbonyl]-1-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 864250-51-1 CAPLUS

CN 5-Pyrimidinecarboxamide, N-[(2-chlorophenyl)methyl]-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 864250-52-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-cyanophenyl)-N-(2-fluorophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 864250-53-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-cyanophenyl)-N-[2-(2-fluorophenyl)ethyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 864250-54-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-cyanophenyl)-N-[(2-fluorophenyl)methyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 864250-55-5 CAPLUS

CN Benzonitrile, 4-[5-([1,4'-bipiperidin]-1'-ylcarbonyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 864250-56-6 CAPLUS

CN Benzonitrile, 4-[1,2,3,4-tetrahydro-6-methyl-2-oxo-5-[(4-propyl-1-piperazinyl)carbonyl]-1-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)



RN 864250-57-7 CAPLUS


CN 4-Piperidinecarboxylic acid, 1-[[4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-5-pyrimidinyl]carbonyl]-, ethyl ester (CA INDEX NAME)



RN 864250-58-8 CAPLUS

CN Benzonitrile, 4-[(4R)-1,2,3,4-tetrahydro-6-methyl-2-oxo-5-[(2R)-1-oxo-2-(phenylmethoxy)propyl]-1-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 864250-59-9 CAPLUS


CN Benzonitrile, 4-[(4R)-1,2,3,4-tetrahydro-6-methyl-2-oxo-5-[(2S)-1-oxo-2-(phenylmethoxy)propyl]-1-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 864250-69-1 CAPLUS

CN 1(2H)-Pyrimidineacetic acid, 5-[(2-amino-4-methyl-5-thiazolyl)carbonyl]-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864250-70-4 CAPLUS

CN 1(2H)-Pyrimidineacetic acid, 6-(4-cyanophenyl)-5-(cyclobutylcarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 864250-74-8 CAPLUS

CN 1(2H)-Pyrimidineacetic acid, 6-(4-cyanophenyl)-3,6-dihydro-5-(4-methoxybenzoyl)-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 864250-76-0 CAPLUS

CN Benzoic acid, 3-[[6-(4-cyanophenyl)-5-(cyclopropylcarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]methyl]- (CA INDEX NAME)




RN 864250-79-3 CAPLUS

CN 1(2H)-Pyrimidineacetic acid, 6-(4-cyanophenyl)-5-[[1-[(1,1-dimethylethoxy)carbonyl]-4-piperidinyl]carbonyl]-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864250-80-6 CAPLUS

CN Benzoic acid, 3-[[6-(4-cyanophenyl)-5-(cyclohexylcarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]methyl]- (CA INDEX NAME)




RN 864250-84-0 CAPLUS

CN 1(2H)-Pyrimidineacetamide, 6-(4-cyanophenyl)-N-[(4-cyanophenyl)sulfonyl]-5-(cyclopropylcarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 864250-85-1 CAPLUS

CN 1(2H)-Pyrimidineacetamide, 6-(4-cyanophenyl)-5-(cyclopropylcarbonyl)-3,6-dihydro-4-methyl-2-oxo-N-[(2,2,2-trifluoroethyl)sulfonyl]-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 864250-88-4 CAPLUS

CN 2-Furancarboxylic acid, 5-[[6-(4-cyanophenyl)-5-(cyclopropylcarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]methyl]- (CA INDEX NAME)




RN 864250-89-5 CAPLUS

CN 1(2H)-Pyrimidineacetamide, 6-(4-cyanophenyl)-N-[(4-cyanophenyl)sulfonyl]-5-(cyclohexylcarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 864250-90-8 CAPLUS

CN 1(2H)-Pyrimidineacetamide, 6-(4-cyanophenyl)-5-(cyclohexylcarbonyl)-3,6-dihydro-4-methyl-2-oxo-N-[(2,2,2-trifluoroethyl)sulfonyl]-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 864250-91-9 CAPLUS

CN 4-Oxazolocarboxylic acid, 2-[6-(4-cyanophenyl)-5-(cyclopropylcarbonyl)-
3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-
pyrimidinyl]methyl]- (CA INDEX NAME)




RN 864250-92-0 CAPLUS

CN 2-Furancarboxylic acid, 5-[[6-(4-cyanophenyl)-5-(cyclohexylcarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]methyl]- (CA INDEX NAME)




RN 864250-93-1 CAPLUS

CN 4-Oxazolecarboxylic acid, 2-[[6-(4-cyanophenyl)-5-(cyclohexylcarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]methyl]- (CA INDEX NAME)




RN 864250-96-4 CAPLUS

CN 1(2H)-Pyrimidineacetic acid, 6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-5-[[1-[(phenylmethoxy)carbonyl]-2-piperidinyl]carbonyl]-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 864251-00-3 CAPLUS


CN 5-Pyrimidinepropanoic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-
 β,2-dioxo-1-[3-(trifluoromethyl)phenyl]-, phenylmethylester (CA
 INDEX NAME)




RN 864251-01-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-
 2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-oxo-2-(phenylmethoxy)ethyl ester,
 (4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 864251-02-5 CAPLUS
 CN 1(2H)-Pyrimidineacetic acid, 6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-5-[[2-(phenylmethoxy)-1-[(phenylmethoxy)methyl]ethoxy]carbonyl]-3-[3-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864251-03-6 CAPLUS
 CN 1(2H)-Pyrimidineacetic acid, 6-(4-cyanophenyl)-3,6-dihydro-4-methyl-5-[[[(1S)-1-methyl-2-oxo-2-(phenylmethoxy)ethoxy]carbonyl]-2-oxo-3-[3-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester, (6R)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 864251-04-7 CAPLUS
 CN 1(2H)-Pyrimidineacetic acid, 6-(4-cyanophenyl)-5-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]ethoxy]carbonyl]-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 864251-06-9 CAPLUS


CN 1(2H)-Pyrimidineacetic acid, 6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-5-[[2-oxo-2-(phenylmethoxy)ethoxy]carbonyl]-3-[3-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 864251-07-0 CAPLUS


CN 1(2H)-Pyrimidineacetic acid, 6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-5-[[2-(2-oxo-1-pyrrolidinyl)ethoxy]carbonyl]-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)

10/527,391




RN 864251-11-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-N-(methylsulfonyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 864251-12-7 CAPLUS



CN 5-Pyrimidinecarboxamide, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-N-[(2,2,2-trifluoroethyl)sulfonyl]-1-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 864251-13-8 CAPLUS
 CN 5-Pyrimidinecarboxamide, 4-(4-cyanophenyl)-N-[(4-cyanophenyl)sulfonyl]-
 1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (CA
 INDEX NAME)





RN 864251-14-9 CAPLUS
 CN 1(2H)-Pyrimidineacetic acid, 6-(4-cyanophenyl)-3,6-dihydro-4-methyl-5-
 [[(methylsulfonyl)amino]carbonyl]-2-oxo-3-[3-(trifluoromethyl)phenyl]-
 (CA INDEX NAME)




RN 864251-15-0 CAPLUS

CN 1(2H)-Pyrimidineacetic acid, 6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-5-[[[(2,2,2-trifluoroethyl)sulfonyl]amino]carbonyl]-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 864251-16-1 CAPLUS

CN 1(2H)-Pyrimidineacetic acid, 6-(4-cyanophenyl)-5-[[[(4-fluorophenyl)sulfonyl]amino]carbonyl]-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 864251-23-0 CAPLUS

CN 1(2H)-Pyrimidineacetic acid, 5-(4-bromobenzoyl)-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 864251-25-2 CAPLUS

CN 1(2H)-Pyrimidineacetic acid, 5-([1,1'-biphenyl]-4-ylcarbonyl)-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 864251-28-5 CAPLUS


CN 1(2H)-Pyrimidineacetic acid, 5-(4-aminobenzoyl)-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 864251-30-9 CAPLUS


CN 1(2H)-Pyrimidineacetic acid, 6-(4-cyanophenyl)-5-(cyclopropylcarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, (6R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 864251-34-3 CAPLUS

CN 1(2H)-Pyrimidineacetic acid, 6-(4-cyanophenyl)-5-[(2,2-dimethyl-1,3-dioxolan-4-yl)carbonyl]-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864251-35-4 CAPLUS


CN 1(2H)-Pyrimidineacetic acid, 6-(4-cyanophenyl)-5-[(2,2-dimethyl-1,3-dioxolan-4-yl)carbonyl]-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, methyl ester (CA INDEX NAME)




IT 671775-86-3P 671775-95-4P 864151-32-6P
 RL: PEP (Physical, engineering or chemical process); PYP (Physical process); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); PROC (Process); RACT (Reactant or reagent)
 (preparation of diaryl-dihydropyrimidin-2-ones as human neutrophil elastase inhibitors)
 RN 671775-86-3 CAPLUS
 CN Benzonitrile, 4-[5-acetyl-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)



RN 671775-95-4 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 864151-32-6 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-propen-1-yl ester (CA INDEX NAME)




IT 671776-55-9P 864151-33-7P 864228-16-0P
 RL: PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of diaryl-dihydropyrimidin-2-ones as human neutrophil elastase inhibitors)
 RN 671776-55-9 CAPLUS
 CN Benzonitrile, 4-[(4R)-5-acetyl-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 864151-33-7 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-propen-1-yl ester, (4R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 864228-16-0 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, (4R)- (CA INDEX NAME)

Absolute stereochemistry.




IT 671775-85-2P 675103-34-1P 864151-39-3P
 864251-40-1P 864251-41-2P 864251-42-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of diaryl-dihydropyrimidin-2-ones as human neutrophil elastase
 inhibitors)
 RN 671775-85-2 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)




RN 675103-34-1 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-hydroxyethyl ester, (4R)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).




RN 864151-39-3 CAPLUS
 CN 1(2H)-Pyrimidineacetic acid, 6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-5-[(2-propen-1-yloxy)carbonyl]-3-[3-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 864251-40-1 CAPLUS
 CN 1(2H)-Pyrimidineacetic acid, 5-carboxy-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, 1-(1,1-dimethylethyl) ester (CA INDEX NAME)




RN 864251-41-2 CAPLUS
 CN 1(2H)-Pyrimidineacetic acid, 6-(4-cyanophenyl)-3,6-dihydro-5-(1H-imidazol-1-ylcarbonyl)-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 864251-42-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 1H-benzotriazol-1-yl ester (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 11 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2005:979622 CAPLUS
 DN 143:286440
 TI Preparation of tetrasubstituted pyrimidin-2-ones as human neutrophil
 elastase inhibitors
 IN Gielen-Haertwig, Heike; Albrecht, Barbara; Keldenich, Joerg; Li, Volkhart;
 Pernerstorfer, Josef; Schlemmer, Karl-Heinz; Telan, Leila
 PA Bayer Healthcare A.-G., Germany
 SO PCT Int. Appl., 119 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005082863	A2	20050909	WO 2005-EP1487	20050215
	WO 2005082863	A3	20051222		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				
	CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				
	GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,				
	LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,				
	NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM,				
	SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,				
	AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,				
	EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,				
	RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,				
	MR, NE, SN, TD, TG				
	CA 2557272	A1	20050909	CA 2005-2557272	20050215
	EP 1730121	A2	20061213	EP 2005-707387	20050215
	R:				
	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,				
	IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	JP 2007523931	T	20070823	JP 2007-500100	20050215
	US 20080021053	A1	20080124	US 2007-590786	20070720
PRAI	EP 2004-4315	A	20040226		
	WO 2005-EP1487	W	20050215		
OS	MARPAT 143:286440				
AB	Title compds. I [A = heteroaryl ring; R1-3 = H, halo, NO2, etc.; R4 = CF3CO, alkylcarbonyl, etc.; R5 = alkyl, alkoxy, etc.; R6 = T-U; T = alkanediyl, akenediyl; U = aryl, heteroaryl, etc.; R7 = halo, NO2, CN, etc.; Y1-5 = independently CH, N wherein the ring contains 0-2 N atoms] and analogs are prepared For instance, II is prepared in 6 steps from 2-bromo-5-methylpyridine, allyl 3-oxobutanoate and N-[3-(trifluoromethyl)phenyl]urea. II has an IC50 = 70 nM for human neutrophil elastase (HNE). I are useful for the treatment of chronic obstructive pulmonary diseases, acute coronary syndrome, acute myocardial infarction and heart failure development.				
IT	864150-42-5P 864150-44-7P 864150-46-9P				
	864150-48-1P 864150-50-5P 864150-52-7P				
	864150-53-8P 864150-54-9P 864150-55-0P				
	864150-56-1P 864150-57-2P 864150-58-3P				
	864150-59-4P 864150-60-7P 864150-61-8P				
	864150-62-9P 864150-63-0P 864150-64-1P				
	864150-81-2P 864150-82-3P 864150-83-4P				
	864150-86-7P 864150-89-0P 864150-93-6P				
	864150-95-8P 864150-97-0P 864151-03-1P				
	864151-05-3P 864151-06-4P 864151-07-5P				

864151-12-2P 864151-29-1P 864151-48-4P


864151-50-8P 864151-51-9P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of tetrasubstituted pyrimidin-2-ones as human neutrophil elastase inhibitors)

RN 864150-42-5 CAPLUS


CN Benzoic acid, 3-[[5-acetyl-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]methyl]-, methyl ester (CA INDEX NAME)



RN 864150-44-7 CAPLUS


CN Benzoic acid, 3-[[(6R)-5-acetyl-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 864150-46-9 CAPLUS

CN Benzeneacetic acid, 4-[[5-acetyl-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]methyl]- α -cyclopentyl-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864150-48-1 CAPLUS

CN Benzoic acid, 4-[[2-[5-acetyl-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]acetyl]methylamino]-, methyl ester (CA INDEX NAME)




RN 864150-50-5 CAPLUS

CN Benzoic acid, 4-[[2-[5-acetyl-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]acetyl]amino]-, methyl ester (CA INDEX NAME)



RN 864150-52-7 CAPLUS


CN Benzoic acid, 4-[[5-acetyl-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 864150-53-8 CAPLUS


CN Benzoic acid, 4-[[[(6R)-5-acetyl-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 864150-54-9 CAPLUS


CN 4-Oxazolecaboxylic acid, 2-[[5-acetyl-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]methyl]-, methyl ester (CA INDEX NAME)



RN 864150-55-0 CAPLUS


CN 4-Oxazolecaboxylic acid, 2-[[6-(4-cyanophenyl)-5-acetyl-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]methyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 864150-56-1 CAPLUS


CN 2-Furancarboxylic acid, 5-[[5-acetyl-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]methyl]-, methyl ester (CA INDEX NAME)



RN 864150-57-2 CAPLUS

CN 2-Furancarboxylic acid, 5-[[5-acetyl-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]methyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 864150-58-3 CAPLUS


CN Benzoic acid, 3-[[5-acetyl-6-(6-cyano-3-pyridinyl)-3,6-dihydro-4-methyl-2-

oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl)methyl]-,
1,1-dimethylethyl ester (CA INDEX NAME)




RN 864150-59-4 CAPLUS

CN Benzeneacetic acid, 4-[[5-acetyl-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl)methyl]- α -(2-methylpropyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864150-60-7 CAPLUS

CN Cyclopropanecarboxylic acid, 1-[5-acetyl-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]-, ethyl ester (CA INDEX NAME)




RN 864150-61-8 CAPLUS

CN 2-Propenoic acid, 3-[5-acetyl-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864150-62-9 CAPLUS

CN 2-Furancarboxylic acid, 5-[[5-cyano-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]methyl]-, methyl ester (CA INDEX NAME)




RN 864150-63-0 CAPLUS

CN 4-Oxazolecarboxylic acid, 2-[[5-cyano-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]methyl]-, methyl ester (CA INDEX NAME)




RN 864150-64-1 CAPLUS

CN Benzoic acid, 4-[[5-acetyl-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]methyl]- (CA INDEX NAME)




RN 864150-81-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 3-[(3-bromophenyl)methyl]-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)



RN 864150-82-3 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 3-[(4-bromophenyl)methyl]-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)



RN 864150-83-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-3-[[3-[(1E)-3-ethoxy-3-oxo-1-propen-1-yl]phenyl]methyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 864150-86-7 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-3-[[4-[(1E)-3-ethoxy-3-oxo-1-propen-1-yl]phenyl]methyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)

Double bond geometry as shown.




RN 864150-89-0 CAPLUS

CN Benzoic acid, 3-[[6-(4-cyanophenyl)-5-(2-furanylcarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864150-93-6 CAPLUS

CN Benzoic acid, 3-[[[6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-5-(3-pyridinylcarbonyl)-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]methyl]-1,1-dimethylethyl ester (CA INDEX NAME)




RN 864150-95-8 CAPLUS

CN 4-Oxazolecarboxylic acid, 2-[[[6-(4-cyanophenyl)-5-(2-furanylcarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]methyl]-, methyl ester (CA INDEX NAME)



RN 864150-97-0 CAPLUS


CN 2-Furancarboxylic acid, 5-[[[6-(4-cyanophenyl)-5-(2-furanylcarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]methyl]-, methyl ester (CA INDEX NAME)



RN 864151-03-1 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-3-[(phenylmethoxy)methyl]-1-[3-(trifluoromethyl)phenyl]-, 2-propen-1-yl ester, (4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 864151-05-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-3-[[4-[(1,1-dimethylethoxy)carbonyl]phenyl]methyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-propen-1-yl ester (CA INDEX NAME)




RN 864151-06-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-3-[[3-[(1,1-dimethylethoxy)carbonyl]phenyl]methyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-propen-1-yl ester (CA INDEX NAME)




RN 864151-07-5 CAPLUS

CN 5(2H)-Pyrimidinecarboxylic acid, 6-(4-cyanophenyl)-1-[1-(ethoxycarbonyl)cyclopropyl]-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, 2-propen-1-yl ester (CA INDEX NAME)




RN 864151-12-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-3-[2-oxo-2-[(2,2,2-trifluoroethyl)sulfonyl]amino]ethyl]-1-[3-(trifluoromethyl)phenyl]-, 2-propen-1-yl ester (CA INDEX NAME)




RN 864151-29-1 CAPLUS

CN 4-Oxazolecarboxylic acid, 2-[[6-(4-cyanophenyl)-3,6-dihydro-4-methyl-5-(2-methyl-1-oxopropyl)-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]methyl]-, methyl ester (CA INDEX NAME)




RN 864151-48-4 CAPLUS

CN Benzonitrile, 4-[1,2,3,4-tetrahydro-6-methyl-2-oxo-5-(3-pyridinylcarbonyl)-1-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 864151-50-8 CAPLUS

CN 1(2H)-Pyrimidineacetic acid, 6-(4-cyanophenyl)-5-(2-furanylcarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 864151-51-9 CAPLUS

CN 1(2H)-Pyrimidineacetic acid, 6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-5-(3-pyridinylcarbonyl)-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




IT 864150-65-2P 864150-66-3P 864150-67-4P
 864150-68-5P 864150-69-6P 864150-70-9P
 864150-71-0P 864150-72-1P 864150-73-2P
 864150-74-3P 864150-75-4P 864150-76-5P
 864150-77-6P 864150-78-7P 864150-79-8P
 864150-80-1P 864150-84-5P 864150-85-6P
 864150-87-8P 864150-88-9P 864150-90-3P
 864150-91-4P 864150-92-5P 864150-94-7P
 864150-96-9P 864150-98-1P 864150-99-2P
 864151-00-8P 864151-01-9P 864151-02-0P
 864151-04-2P 864151-08-6P 864151-09-7P
 864151-10-0P 864151-11-1P 864151-13-3P
 864151-14-4P 864151-15-5P 864151-16-6P
 864151-17-7P 864151-18-8P 864151-19-9P
 864151-20-2P 864151-21-3P 864151-22-4P
 864151-23-5P 864151-24-6P 864151-25-7P
 864151-26-8P 864151-27-9P 864151-28-0P
 864151-30-4P 864151-31-5P 864151-47-3P
 864151-49-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of tetrasubstituted pyrimidin-2-ones as human neutrophil
 elastase inhibitors)


RN 864150-65-2 CAPLUS

CN Benzeneacetic acid, 4-[[5-acetyl-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-
 oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]methyl]- α -(2-
 methylpropyl)- (CA INDEX NAME)



RN 864150-66-3 CAPLUS


CN Benzenecetic acid, 4-[[5-acetyl-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]methyl]- α -cyclopentyl- (CA INDEX NAME)



RN 864150-67-4 CAPLUS

CN Benzoic acid, 3-[[[(6R)-5-acetyl-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864150-68-5 CAPLUS


CN Benzoic acid, 4-[[(6R)-5-acetyl-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 864150-69-6 CAPLUS

CN Benzoic acid, 3-[[5-acetyl-6-(6-cyano-3-pyridinyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]methyl]- (CA INDEX NAME)




RN 864150-70-9 CAPLUS

CN 2-Propenoic acid, 3-[5-acetyl-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]- (CA INDEX NAME)




RN 864150-71-0 CAPLUS

CN 2-Furancarboxylic acid, 5-[[5-acetyl-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]methyl]- (CA INDEX NAME)




RN 864150-72-1 CAPLUS

CN Benzoic acid, 3-[[5-acetyl-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]methyl]- (CA INDEX NAME)




RN 864150-73-2 CAPLUS

CN Benzoic acid, 4-[[2-[5-acetyl-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]acetyl]methylamino]- (CA INDEX NAME)




RN 864150-74-3 CAPLUS

CN Benzoic acid, 4-[[2-[5-acetyl-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]acetyl]amino]- (CA INDEX NAME)



RN 864150-75-4 CAPLUS


CN 4-Oxazolecaboxylic acid, 2-[[5-acetyl-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]methyl]- (CA INDEX NAME)



RN 864150-76-5 CAPLUS

CN 4-Oxazolecaboxylic acid, 2-[[[(6R)-5-acetyl-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864150-77-6 CAPLUS


CN 2-Furancarboxylic acid, 5-[[(6R)-5-acetyl-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 864150-78-7 CAPLUS


CN Cyclopropanecarboxylic acid, 1-[5-acetyl-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]- (CA INDEX NAME)



RN 864150-79-8 CAPLUS

CN 4-Oxazolecaboxylic acid, 2-[[(6R)-5-cyano-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 864150-80-1 CAPLUS


CN 2-Furancarboxylic acid, 5-[[(6R)-5-cyano-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 864150-84-5 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-3-[[3-(2-thienyl)phenyl]methyl]-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)



RN 864150-85-6 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 3-[[3-[(1E)-2-carboxyethenyl]phenyl]methyl]-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 864150-87-8 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 3-[[4-[(1E)-2-carboxyethenyl]phenyl]methyl]-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 864150-88-9 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 3-[[4-[(1E)-2-carboxyethenyl]phenyl]methyl]-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 5-ethyl ester (CA INDEX NAME)

Double bond geometry as shown.




RN 864150-90-3 CAPLUS

CN Benzoic acid, 3-[[6-(4-cyanophenyl)-5-(2-furanylcarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]methyl]- (CA INDEX NAME)




RN 864150-91-4 CAPLUS

CN 1(2H)-Pyrimidineacetamide, 6-(4-cyanophenyl)-N-[(4-cyanophenyl)sulfonyl]-5-(2-furanylcarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 864150-92-5 CAPLUS

CN 1(2H)-Pyrimidineacetamide, 6-(4-cyanophenyl)-5-(2-furanylcarbonyl)-3,6-dihydro-4-methyl-2-oxo-N-[(2,2,2-trifluoroethyl)sulfonyl]-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 864150-94-7 CAPLUS

CN 4-Oxazolecarboxylic acid, 2-[[6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-5-(3-pyridinylcarbonyl)-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]methyl]-, methyl ester (CA INDEX NAME)




RN 864150-96-9 CAPLUS

CN 2-Furancarboxylic acid, 5-[[6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-5-(3-pyridinylcarbonyl)-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]methyl]-, methyl ester (CA INDEX NAME)




RN 864150-98-1 CAPLUS

CN 2-Furancarboxylic acid, 5-[[6-(4-cyanophenyl)-5-(2-furanylcabonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]methyl]- (CA INDEX NAME)




RN 864150-99-2 CAPLUS

CN 4-Oxazolecarboxylic acid, 2-[[6-(4-cyanophenyl)-5-(2-furanylcarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]methyl]- (CA INDEX NAME)




RN 864151-00-8 CAPLUS

CN Benzoic acid, 3-[[6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-5-(3-pyridinylcarbonyl)-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]methyl]- (CA INDEX NAME)




RN 864151-01-9 CAPLUS

CN 1(2H)-Pyrimidineacetamide, 6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-5-(3-pyridinylcarbonyl)-N-[(2,2,2-trifluoroethyl)sulfonyl]-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 864151-02-0 CAPLUS

CN 1(2H)-Pyrimidineacetamide, 6-(4-cyanophenyl)-N-[(4-cyanophenyl)sulfonyl]-3,6-dihydro-4-methyl-2-oxo-5-(3-pyridinylcarbonyl)-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 864151-04-2 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-3-[(phenylmethoxy)methyl]-1-[3-(trifluoromethyl)phenyl]-, (4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 864151-08-6 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 3-[(3-carboxyphenyl)methyl]-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 5-(2-propen-1-yl) ester (CA INDEX NAME)




RN 864151-09-7 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 3-[(4-carboxyphenyl)methyl]-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 5-(2-propen-1-yl) ester (CA INDEX NAME)




RN 864151-10-0 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 3-(1-carboxycyclopropyl)-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 5-ethyl ester (9CI) (CA INDEX NAME)




RN 864151-11-1 CAPLUS

CN 5(2H)-Pyrimidinecarboxylic acid, 1-(1-carboxycyclopropyl)-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 864151-13-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-3-[2-oxo-2-[[[4-(trifluoromethyl)phenyl]sulfonyl]amino]ethyl]-1-[3-(trifluoromethyl)phenyl]-, 2-propen-1-yl ester (CA INDEX NAME)




RN 864151-14-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-3-[2-[[[4-(trifluoromethyl)phenyl]sulfonyl]amino]-2-oxoethyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-propen-1-yl ester (CA INDEX NAME)




RN 864151-15-5 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-3-[2-[[[4-(trifluoromethyl)phenyl]sulfonyl]amino]-2-oxoethyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-propen-1-yl ester (CA INDEX NAME)




RN 864151-16-6 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-3-[2-(hydroxyamino)-2-oxoethyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-propen-1-yl ester (CA INDEX NAME)




RN 864151-17-7 CAPLUS

CN 1(2H)-Pyrimidineacetamide, 5-acetyl-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-N-[(2,2,2-trifluoroethyl)sulfonyl]-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 864151-18-8 CAPLUS


CN 1(2H)-Pyrimidineacetamide, 5-acetyl-6-(4-cyanophenyl)-N-[(4-cyanophenyl)sulfonyl]-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 864151-19-9 CAPLUS

CN 1(2H)-Pyrimidineacetamide, 5-acetyl-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-N-[(2,2,2-trifluoroethyl)sulfonyl]-3-[3-(trifluoromethyl)phenyl]-, (6R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 864151-20-2 CAPLUS


CN 1(2H)-Pyrimidineacetamide, 5-acetyl-6-(4-cyanophenyl)-N-[(4-cyanophenyl)sulfonyl]-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, (6R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 864151-21-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-3-[2-oxo-2-[[2,2,2-trifluoroethyl)sulfonyl]amino]ethyl]-1-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 864151-22-4 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-3-[2-oxo-2-[[2,2,2-trifluoroethyl)sulfonyl]amino]ethyl]-1-[3-(trifluoromethyl)phenyl]-, 2-hydroxyethyl ester (CA INDEX NAME)




RN 864151-23-5 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 3-[(4-carboxyphenyl)sulfonyl]-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 5-(2-propen-1-yl) ester (CA INDEX NAME)



RN 864151-24-6 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-3-[2-[[(1,1-dimethylethoxy)carbonyl]amino]acetyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-propen-1-yl ester (CA INDEX NAME)




RN 864151-25-7 CAPLUS
 CN 1,5(2H)-Pyrimidinedicarboxylic acid, 6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, 1-[2-oxo-2-(phenylmethoxy)ethyl] 5-(2-propen-1-yl) ester (CA INDEX NAME)




RN 864151-26-8 CAPLUS

CN 1(2H)-Pyrimidinecarboxylic acid, 5-acetyl-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, 2-oxo-2-(phenylmethoxy)ethyl ester (CA INDEX NAME)




RN 864151-27-9 CAPLUS

CN Benzonitrile, 4-[5-acetyl-1,2,3,4-tetrahydro-6-methyl-2-oxo-3-(2-propen-1-yl)-1-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 864151-28-0 CAPLUS

CN Carbamic acid, [2-[5-acetyl-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 864151-30-4 CAPLUS

CN 1(2H)-Pyrimidineacetamide, 6-(4-cyanophenyl)-3,6-dihydro-4-methyl-5-(2-methyl-1-oxopropyl)-2-oxo-N-[(2,2,2-trifluoroethyl)sulfonyl]-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 864151-31-5 CAPLUS

CN 4-Oxazolecarboxylic acid, 2-[[6-(4-cyanophenyl)-3,6-dihydro-4-methyl-5-(2-methyl-1-oxopropyl)-2-oxo-3-[3-(trifluoromethyl)phenyl]-1(2H)-pyrimidinyl]methyl]- (CA INDEX NAME)



RN 864151-47-3 CAPLUS


CN 5-Pyrimidinecarbonitrile, 4-(6-cyano-3-pyridinyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 864151-49-5 CAPLUS

CN 1(2H)-Pyrimidineacetic acid, 5-acetyl-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester, (6R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 671776-55-9P 675103-36-3P 864151-33-7P


864151-34-8P

RL: PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of tetrasubstituted pyrimidin-2-ones as human neutrophil elastase inhibitors)

RN 671776-55-9 CAPLUS

CN Benzonitrile, 4-[(4R)-5-acetyl-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 675103-36-3 CAPLUS

CN 2-Pyridinecarbonitrile, 5-[(4R)-5-acetyl-1,2,3,4-tetrahydro-6-methyl-2-oxo-

1-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 864151-33-7 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-propen-1-yl ester, (4R)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 864151-34-8 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, (4R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




IT 671775-85-2P 671775-86-3P 671775-93-2P

671775-95-4P 671776-48-0P 671776-50-4P
 671776-53-7P 675103-35-2P 864151-32-6P
 864151-35-9P 864151-36-0P 864151-37-1P
 864151-38-2P 864151-39-3P 864151-40-6P
 864151-41-7P 864151-42-8P 864151-43-9P
 864151-44-0P 864151-45-1P 864151-46-2P
 864228-16-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of tetrasubstituted pyrimidin-2-ones as human neutrophil
 elastase inhibitors)


RN 671775-85-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-
 2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)




RN 671775-86-3 CAPLUS

CN Benzonitrile, 4-[5-acetyl-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 671775-93-2 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-
 oxo-1-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 671775-95-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 671776-48-0 CAPLUS

CN Benzonitrile, 4-[1,2,3,4-tetrahydro-6-methyl-5-(2-methyl-1-oxopropyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)



RN 671776-50-4 CAPLUS


CN Benzonitrile, 4-[5-(2-furanylcarbonyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)



RN 671776-53-7 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-

oxo-1-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 675103-35-2 CAPLUS

2-Pyridinecarbonitrile, 5-[5-acetyl-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 864151-32-6 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-propen-1-yl ester (CA INDEX NAME)




RN 864151-35-9 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(6-cyano-3-pyridinyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-propen-1-yl ester (CA INDEX NAME)




RN 864151-36-0 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(6-cyano-3-pyridinyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 864151-37-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(6-cyano-3-pyridinyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 864151-38-2 CAPLUS

CN 1(2H)-Pyrimidineacetic acid, 5-acetyl-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, methyl ester (CA INDEX NAME)




RN 864151-39-3 CAPLUS

CN 1(2H)-Pyrimidineacetic acid, 6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-5-[(2-propen-1-yloxy)carbonyl]-3-[3-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)





RN 864151-40-6 CAPLUS

CN 1(2H)-Pyrimidineacetic acid, 5-acetyl-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 864151-41-7 CAPLUS


CN 1(2H)-Pyrimidineacetic acid, 6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-5-[(2-propen-1-yloxy)carbonyl]-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 864151-42-8 CAPLUS


CN 1(2H)-Pyrimidineacetic acid, 5-acetyl-6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, (6R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 864151-43-9 CAPLUS

CN 1(2H)-Pyrimidineacetic acid, 6-(4-cyanophenyl)-5-(2-furanylcarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864151-44-0 CAPLUS

CN 1(2H)-Pyrimidineacetic acid, 6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-5-(3-pyridinylcarbonyl)-3-[3-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 864151-45-1 CAPLUS

CN 1(2H)-Pyrimidineacetic acid, 6-(4-cyanophenyl)-3,6-dihydro-4-methyl-5-(2-methyl-1-oxopropyl)-2-oxo-3-[3-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 864151-46-2 CAPLUS


CN 1(2H)-Pyrimidineacetic acid, 6-(4-cyanophenyl)-3,6-dihydro-4-methyl-5-(2-methyl-1-oxopropyl)-2-oxo-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 864228-16-0 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, (4R)- (CA INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2004:689107 CAPLUS
 DN 142:198006
 TI Synthesis of functionalised pyrimidin-2-one derivatives
 AU Abd El-Nabi, Hisham A.; Nour El-Din, A. M.; Fahmi, Magda S.
 CS Dep. Chem., Fac. Sci., El-Minia Univ., El-Minia, Egypt
 SO Journal of Chemical Research, Synopses (2003), (8), 514-515
 CODEN: JRPSDC; ISSN: 0308-2342
 PB Science Reviews
 DT Journal
 LA English
 OS CASREACT 142:198006
 AB Pyrimidin-2-one and pyrimidine-2-thione derivs. were obtained in 40-65% and 60-75% yields when 4-ethoxycarbonyl-5-phenylfuran-2,3-dione (1) reacts with semicarbazones and thiosemicarbazones $H_2NC(X)NHN:CHC_6H_4R-4$ [$X = O$, $R = H$ (2a), Me (2b), MeO (2c), Cl (2d); $X = S$, $R = Cl$ (2e), NMe_2 (2f)], or urea and thiourea derivs. $H_2NC(X)NHR_1$ [$X = O$, $R_1 = Me$ (6a), Ph (6b); $X = S$, $R_1 = Me$ (6c), Ph (6d)] through loss of H_2O and CO_2 .
 IT 839674-02-1P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of pyrimidinone and pyrimidinethione derivs. by cyclocondensation reaction of ethoxycarbonyl(phenyl)furandione with (thio)semicarbazones and (thio)ureas)
 RN 839674-02-1 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 1,2-dihydro-2-oxo-1,4-diphenyl-, ethyl ester (CA INDEX NAME)



RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L16 ANSWER 13 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2004:253147 CAPLUS
 DN 140:287406
 TI Preparation of pyrimidinones as human neutrophil elastase (HNE) inhibitors
 IN Gielen, Heike; Li, Volkhart; Rosentreter, Ulrich; Schlemmer, Karl-heinz;
 Allerheiligen, Swen; Telan, Leila; Baerfacker, Lars; Keldenich, Joerg;
 Fitzgerald, Mary F.; Nash, Kevin; Albrecht, Barbara; Meurer, Dirk
 PA Bayer Healthcare Ag, Germany
 SO PCT Int. Appl., 121 pp.
 CODEN: PIXXD2
 DT Patent Applicant's
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004024700	A1	20040325	WO 2003-EP9525	20030828
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	GB 2392910	A	20040317	GB 2003-15870	20030707
	CA 2498051	A1	20040325	CA 2003-2498051	20030828
	AU 2003282006	A1	20040430	AU 2003-282006	20030828
	EP 1546113	A1	20050629	EP 2003-773613	20030828
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003014186	A	20050809	BR 2003-14186	20030828
	JP 2006507355	T	20060302	JP 2004-571738	20030828
	NZ 538670	A	20070126	NZ 2003-538670	20030828
	MX 2005PA02644	A	20050920	MX 2005-PA2644	20050309
	NO 2005001726	A	20050407	NO 2005-1736	20050407
	US 20060160801	A1	20060720	US 2005-527391	20051021
PRAI	GB 2002-20962	A	20020910		
	GB 2002-26609	A	20021114		
	GB 2003-15870	A	20030707		
	WO 2003-EP9525	W	20030828		


OS MARPAT 140:287406
 AB Title compds. I [wherein A = hetero/aryl; R1, R2, R3 = independently H, halo, NO2, CN, OH and derivs., (un)substituted alkyl, R4 = CN, trifluoromethylcarbonyl, alkenoxycarbonyl, hydroxycarbonyl, aryl/alkylaminocarbonyl, (un)substituted heteroarylcarbonyl, heterocyclylcarbonyl, heteroaryl, heterocyclyl, alkylcarbonyl, alkoxy carbonyl, mono- and dialkylaminocarbonyl; R5 = NH2, (un)substituted alkyl; R6 = H, formyl, N-(alkylsulfonyl)/N-(alkylsulfonyl)-N-(alkyl)/aminocarbonyl, heteroarylcarbonyl, heterocyclylcarbonyl, cycloalkylcarbonyl, (un)substituted alkyl, mono- and dialkylaminocarbonyl, alkylcarbonyl, alkoxy carbonyl, heteroaryl, heterocyclyl, etc.; R7 = halo, NO2, CN, OH, (un)substituted alkyl, alkoxy; Y1, Y2, Y3, Y4, Y5 = independently CH or N; and their salts, hydrates, and/or solvates, and their tautomeric forms] were prepared as human neutrophil elastase (HNE) inhibitors. For example, II was prepared, in 91% yield, by

cyclocondensation of N-[3-(trifluoromethyl)phenyl]urea with 4-cyanobenzaldehyde and Et 3-oxobutanoate. In an in vitro assay, II displayed an IC₅₀ value of 8 nM for HNE inhibition. Thus, I are useful for treatment of acute and chronic inflammation, ischemic and remodelling processes, in particular chronic obstructive pulmonary diseases.

- IT 671775-85-2P, Ethyl 4-(4-cyanophenyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-5-pyrimidinecarboxylate
 671775-95-4P, 4-(4-Cyanophenyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-5-pyrimidinecarboxylic acid
 RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent); USES (Uses) (human neutrophil elastase inhibitor; preparation of pyrimidinones as human neutrophil elastase inhibitors)
 RN 671775-85-2 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)




- RN 671775-95-4 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



- IT 675103-35-2P, 5-[5-Acetyl-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-4-pyrimidinyl]-2-pyridinecarbonitrile
 RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses) (human neutrophil elastase inhibitor; preparation of pyrimidinones as human neutrophil elastase inhibitors)
 RN 675103-35-2 CAPLUS

CN 2-Pyridinecarbonitrile, 5-[5-acetyl-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)



IT 864228-16-0P


RL: PAC (Pharmacological activity); PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(human neutrophil elastase inhibitor; preparation of pyrimidinones as human neutrophil elastase inhibitors)

RN 864228-16-0 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, (4R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 675103-36-3P


RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(human neutrophil elastase inhibitor; preparation of pyrimidinones as human neutrophil elastase inhibitors)


RN 675103-36-3 CAPLUS

CN 2-Pyridinecarbonitrile, 5-[(4R)-5-acetyl-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



IT 671775-98-7P, Ethyl 4-(4-cyanophenyl)-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-5-pyrimidinecarboxylate
 671776-27-5P 671776-53-7P, 4-(4-Cyanophenyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-5-pyrimidinecarboxamide 671776-58-2P, 4-(4-Cyanophenyl)-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-5-pyrimidinecarboxylic acid 675103-23-8P, Ethyl 6-(bromomethyl)-4-(4-cyanophenyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-5-pyrimidinecarboxylate 675103-26-1P
 675103-28-3P, 4-[5-(1H-Imidazol-1-ylcarbonyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-4-pyrimidinyl]benzonitrile 675103-34-1P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (human neutrophil elastase inhibitor; preparation of pyrimidinones as human neutrophil elastase inhibitors)
 RN 671775-98-7 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)




RN 671776-27-5 CAPLUS
 CN 1(2H)-Pyrimidineacetic acid, 6-(4-cyanophenyl)-5-(ethoxycarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 671776-53-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 671776-58-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 675103-23-8 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 6-(bromomethyl)-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)



RN 675103-26-1 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester, (+)- (CA INDEX NAME)

Rotation (+).



RN 675103-28-3 CAPLUS


CN Benzonitrile, 4-[1,2,3,4-tetrahydro-5-(1H-imidazol-1-ylcarbonyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)



RN 675103-34-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-hydroxyethyl ester, (4R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




IT 671775-86-3P, 4-[5-Acetyl-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-4-pyrimidinyl]benzonitrile
 671775-87-4P, Ethyl 4-(4-bromophenyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-5-pyrimidinecarboxylate
 671775-88-5P, Ethyl 4-(4-cyanophenyl)-6-methyl-2-oxo-1-(4-fluorophenyl)-1,2,3,4-tetrahydro-5-pyrimidinecarboxylate
 671775-89-6P, Ethyl 4-(4-cyanophenyl)-6-methyl-2-oxo-1-(3-chlorophenyl)-1,2,3,4-tetrahydro-5-pyrimidinecarboxylate
 671775-90-9P 671775-91-0P, 4-[6-Methyl-5-(4-morpholinylcarbonyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-4-pyrimidinyl]benzonitrile 671775-92-1P,
 4-(4-Cyanophenyl)-N,N-diethyl-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-5-pyrimidinecarboxamide 671775-93-2P,
 4-(4-Cyanophenyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carbonitrile 671775-94-3P, Ethyl
 4-(4-cyanophenyl)-3-formyl-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-5-pyrimidinecarboxylate 671775-96-5P,
 4-(4-Cyanophenyl)-6-methyl-2-oxo-N-propyl-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-5-pyrimidinecarboxamide 671775-97-6P,
 4-(4-Cyanophenyl)-N-(2-methoxyethyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-5-pyrimidinecarboxamide
 671775-99-8P, Ethyl 3-acetyl-4-(4-cyanophenyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-5-pyrimidinecarboxylate
 671776-00-4P, Diethyl 6-(4-cyanophenyl)-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-3,6-dihydro-1,5(2H)-pyrimidinedicarboxylate
 671776-01-5P, Ethyl 4-(4-cyanophenyl)-6-methyl-1-(3-methylphenyl)-2-oxo-1,2,3,4-tetrahydro-5-pyrimidinecarboxylate 671776-02-6P,
 Ethyl 4-(4-chlorophenyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-5-pyrimidinecarboxylate 671776-07-1P, Ethyl
 4-(6-cyano-3-pyridinyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-5-pyrimidinecarboxylate 671776-14-0P
 671776-15-1P 671776-16-2P 671776-17-3P
 671776-18-4P 671776-19-5P 671776-20-8P
 671776-21-9P 671776-22-0P 671776-23-1P
 671776-24-2P 671776-25-3P 671776-26-4P
 671776-28-6P 671776-29-7P 671776-30-0P
 671776-31-1P 671776-32-2P 671776-33-3P
 671776-34-4P 671776-35-5P 671776-36-6P
 671776-37-7P 671776-38-8P 671776-39-9P
 671776-40-2P 671776-41-3P 671776-42-4P, Ethyl
 4-(4-cyanophenyl)-6-methyl-3-[2-(4-morpholinyl)-2-oxoethyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-5-pyrimidinecarboxylate
 671776-43-5P 671776-44-6P 671776-45-7P

671776-46-8P 671776-47-9P 671776-48-0P
 671776-49-1P 671776-50-4P 671776-51-5P
 671776-52-6P 671776-54-8P, 2-Hydroxyethyl
 4-(4-cyanophenyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-
 tetrahydro-5-pyrimidinecarboxylate 671776-56-0P
 671776-57-1P 671776-59-3P 671776-60-6P
 671776-61-7P 671776-62-8P 671776-63-9P
 671776-64-0P 671776-65-1P 671776-66-2P
 671776-67-3P 671776-68-4P 671776-69-5P
 671776-70-8P 671776-71-9P 671776-72-0P
 671776-73-1P 671776-74-2P 671776-75-3P
 671776-76-4P 671776-77-5P 671776-78-6P
 671776-79-7P 671776-80-0P 671776-81-1P
 671776-82-2P, Ethyl 4-(4-cyanophenyl)-1-(3,5-dichlorophenyl)-6-
 methyl-2-oxo-1,2,3,4-tetrahydro-5-pyrimidinecarboxylate
 671776-83-3P, Ethyl 6-methyl-4-(3-nitrophenyl)-2-oxo-1-[3-
 (trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-5-pyrimidinecarboxylate
 671776-84-4P 671776-85-5P 671776-86-6P
 671776-87-7P 671776-88-8P, 4-(4-Cyanophenyl)-6-methyl-2-
 oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-
 carboxylic acid 2-cyanoethyl ester 671776-89-9P, Ethyl
 6-methyl-4-(4-nitrophenyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-
 tetrahydropyrimidine-5-carboxylate 671776-90-2P,
 5-Acetyl-6-methyl-4-(4-nitrophenyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]-
 1,2,3,4-tetrahydropyrimidine 671776-99-1P 675103-22-7P
 , 6-Amino-4-(4-cyanophenyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-
 tetrahydro-5-pyrimidinecarbonitrile 675103-24-9P, Ethyl
 4-(4-cyanophenyl)-6-[(diethylamino)methyl]-2-oxo-1-[3-
 (trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-5-pyrimidinecarboxylate
 675103-25-0P, Ethyl 6-(anilinomethyl)-4-(4-cyanophenyl)-2-oxo-1-[3-
 (trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-5-pyrimidinecarboxylate
 675103-27-2P 675103-29-4P, 2-(Dimethylamino)ethyl
 4-(4-cyanophenyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-
 tetrahydro-5-pyrimidinecarboxylate 675103-30-7P
 675103-31-8P 675103-32-9P, 2-(2-Oxo-1-pyrrolidinyl)ethyl
 4-(4-cyanophenyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-
 tetrahydro-5-pyrimidinecarboxylate
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)


(human neutrophil elastase inhibitor; preparation of pyrimidinones as human
 neutrophil elastase inhibitors)

RN 671775-86-3 CAPLUS


CN Benzonitrile, 4-[5-acetyl-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-
 (trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 671775-87-4 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 4-(4-bromophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)



RN 671775-88-5 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1-(4-fluorophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-, ethyl ester (CA INDEX NAME)




RN 671775-89-6 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 1-(3-chlorophenyl)-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-, ethyl ester (CA INDEX NAME)




RN 671775-90-9 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, (1S)-2-methoxy-1-methyl-2-oxoethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 671775-91-0 CAPLUS

CN Benzonitrile, 4-[1,2,3,4-tetrahydro-6-methyl-5-(4-morpholinylcarbonyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 671775-92-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-cyanophenyl)-N,N-diethyl-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 671775-93-2 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 671775-94-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-3-formyl-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)




RN 671775-96-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-N-propyl-1-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 671775-97-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-N-(2-methoxyethyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 671775-99-8 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 3-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)




RN 671776-00-4 CAPLUS

CN 1,5(2H)-Pyrimidinedicarboxylic acid, 6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, 1,5-diethyl ester (CA INDEX NAME)




RN 671776-01-5 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-1-(3-methylphenyl)-2-oxo-, ethyl ester (CA INDEX NAME)




RN 671776-02-6 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-chlorophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)




RN 671776-07-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(6-cyano-3-pyridinyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)




RN 671776-14-0 CAPLUS

CN 1(2H)-Pyrimidineacetic acid, 6-(4-cyanophenyl)-5-(ethoxycarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)




RN 671776-15-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-3-(cyclopropylcarbonyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)



RN 671776-16-2 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-3-ethyl-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)



RN 671776-17-3 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-

3-(4-morpholinylcarbonyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)




RN 671776-18-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-3-[(dimethylamino)carbonyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)





RN 671776-19-5 CAPLUS


CN 1,5(2H)-Pyrimidinedicarboxylic acid, 6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, 5-ethyl 1-methyl ester (CA INDEX NAME)




RN 671776-20-8 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-3-(phenylmethyl)-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)




RN 671776-21-9 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-3-(1-oxopropyl)-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)




RN 671776-22-0 CAPLUS
 CN 1,5(2H)-Pyrimidinedicarboxylic acid, 6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, 5-ethyl 1-(2-methoxyethyl) ester (CA INDEX NAME)




RN 671776-23-1 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-3-(2-methyl-1-oxopropyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)




RN 671776-24-2 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-3-[(diethylamino)carbonyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)




RN 671776-25-3 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-3-[[methyl(methylsulfonyl)amino]carbonyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)



RN 671776-26-4 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 3-(2-amino-2-oxoethyl)-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)




RN 671776-28-6 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 3-(2-aminoethyl)-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)




RN 671776-29-7 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-3-(2-pyridinylmethyl)-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)




RN 671776-30-0 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-3-[2-(diethylamino)ethyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)




RN 671776-31-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-3-[2-(methylanino)-2-oxoethyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)




RN 671776-32-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-3-(3-pyridinylmethyl)-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)




RN 671776-33-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-3-(4-pyridinylmethyl)-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)





RN 671776-34-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-3-(1H-imidazol-2-ylmethyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)




RN 671776-35-5 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 3-(cyanomethyl)-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)




RN 671776-36-6 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-3-[2-[(2-methoxyethyl)amino]-2-oxoethyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)




RN 671776-37-7 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, methyl ester (CA INDEX NAME)



RN 671776-38-8 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, cyclopropylmethyl ester (CA INDEX NAME)




RN 671776-39-9 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 1-methylethyl ester (CA INDEX NAME)




RN 671776-40-2 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, (1R)-2-methoxy-1-methyl-2-oxoethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 671776-41-3 CAPLUS
 CN 5-Pyrimidinecarboxamide, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-N,N,6-trimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 671776-42-4 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-3-[2-(4-morpholinyl)-2-oxoethyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)




RN 671776-43-5 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-3-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)




RN 671776-44-6 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-3-[2-[[2-(dimethylamino)ethyl]amino]-2-oxoethyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)




RN 671776-45-7 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-3-[2-(dimethylamino)-2-oxoethyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)



RN 671776-46-8 CAPLUS


CN Benzonitrile, 4-[1,2,3,4-tetrahydro-6-methyl-5-(3-methyl-1,2,4-oxadiazol-5-yl)-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)



RN 671776-47-9 CAPLUS


CN Benzonitrile, 4-[5-(2-benzothiazolyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-

[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 671776-48-0 CAPLUS

CN Benzonitrile, 4-[1,2,3,4-tetrahydro-6-methyl-5-(2-methyl-1-oxopropyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 671776-49-1 CAPLUS

CN Benzonitrile, 4-[1,2,3,4-tetrahydro-5-(2-methoxyacetyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 671776-50-4 CAPLUS

CN Benzonitrile, 4-[5-(2-furanylcarbonyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 671776-51-5 CAPLUS

CN Benzonitrile, 4-[5-benzoyl-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)



RN 671776-52-6 CAPLUS


CN Benzonitrile, 4-[1,2,3,4-tetrahydro-6-methyl-2-oxo-5-(2,2,2-trifluoroacetyl)-1-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)



RN 671776-54-8 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-hydroxyethyl ester (CA INDEX NAME)

NAME)




RN 671776-56-0 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-pyridinylmethyl ester (CA INDEX NAME)




RN 671776-57-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-(3-pyridinyl)ethyl ester (CA INDEX NAME)




RN 671776-59-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 3-pyridinylmethyl ester (CA INDEX NAME)




RN 671776-60-6 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-amino-2-oxoethyl ester (CA INDEX NAME)




RN 671776-61-7 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-(formylmethylamino)ethyl ester (CA INDEX NAME)



RN 671776-62-8 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, (1-methyl-1H-imidazol-5-yl)methyl ester (CA INDEX NAME)



RN 671776-63-9 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-(1H-pyrazol-1-yl)ethyl ester (CA INDEX NAME)

INDEX NAME)




RN 671776-64-0 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-(1H-1,2,4-triazol-1-yl)ethyl ester
(CA INDEX NAME)




RN 671776-65-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-ethoxy-2-oxoethyl ester (CA INDEX NAME)




RN 671776-66-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-(dimethylamino)-2-methylpropyl ester (CA INDEX NAME)




RN 671776-67-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 3-(dimethylamino)propyl ester (CA INDEX NAME)




RN 671776-68-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-(1-pyrrolidinyl)ethyl ester (CA INDEX NAME)




RN 671776-69-5 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-(3-pyridinyl)ethyl ester (CA INDEX NAME)




RN 671776-70-8 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 3-pyridinylmethyl ester (CA INDEX NAME)




RN 671776-71-9 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-amino-2-oxoethyl ester (CA INDEX NAME)



RN 671776-72-0 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-(formylmethylamino)ethyl ester (CA INDEX NAME)



RN 671776-73-1 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-(acetylamino)ethyl ester

(CA INDEX NAME)




RN 671776-74-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, (1-methyl-1H-imidazol-5-yl)methyl ester (CA INDEX NAME)




RN 671776-75-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-(1H-pyrazol-1-yl)ethyl ester (CA INDEX NAME)




RN 671776-76-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-(1H-1,2,4-triazol-1-yl)ethyl ester (CA INDEX NAME)




RN 671776-77-5 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-ethoxy-2-oxoethyl ester (CA INDEX NAME)




RN 671776-78-6 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-(dimethylamino)-2-methylpropyl ester (CA INDEX NAME)




RN 671776-79-7 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 3-(dimethylamino)propyl ester (CA INDEX NAME)




RN 671776-80-0 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-(1-pyrrolidinyl)ethyl ester (CA INDEX NAME)




RN 671776-81-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-pyridinylmethyl ester (CA INDEX NAME)




RN 671776-82-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1-(3,5-dichlorophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-, ethyl ester (CA INDEX NAME)




RN 671776-83-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 1,2,3,4-tetrahydro-6-methyl-4-(3-nitrophenyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)




RN 671776-84-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-chlorophenyl)-1,2,3,4-tetrahydro-6-methyl-1-(3-nitrophenyl)-2-oxo-, ethyl ester (CA INDEX NAME)




RN 671776-85-5 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 1,2,3,4-tetrahydro-6-methyl-1,4-bis(3-nitrophenyl)-2-oxo-, ethyl ester (CA INDEX NAME)




RN 671776-86-6 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-fluorophenyl)-1,2,3,4-tetrahydro-6-methyl-1-(3-nitrophenyl)-2-oxo-, ethyl ester (CA INDEX NAME)




RN 671776-87-7 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-bromophenyl)-1,2,3,4-tetrahydro-6-methyl-1-(3-nitrophenyl)-2-oxo-, ethyl ester (CA INDEX NAME)




RN 671776-88-8 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-cyanoethyl ester (CA INDEX NAME)




RN 671776-89-9 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 1,2,3,4-tetrahydro-6-methyl-4-(4-nitrophenyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)




RN 671776-90-2 CAPLUS

CN 2(1H)-Pyrimidinone, 5-acetyl-3,4-dihydro-6-methyl-4-(4-nitrophenyl)-1-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 671776-99-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-(acetamino)ethyl ester (CA INDEX NAME)




RN 675103-22-7 CAPLUS

CN 5-Pyrimidinecarbonitrile, 6-amino-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-2-oxo-1-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)





RN 675103-24-9 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-6-[(diethylamino)methyl]-1,2,3,4-tetrahydro-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)



RN 675103-25-0 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-2-oxo-6-[(phenylamino)methyl]-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)



RN 675103-27-2 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester, (-)- (CA INDEX NAME)

Rotation (-).




RN 675103-29-4 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-(dimethylamino)ethyl ester (CA INDEX NAME)



RN 675103-30-7 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-(4-pyridinyl)ethyl ester (CA INDEX NAME)




RN 675103-31-8 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-(2-pyridinyl)ethyl ester (CA INDEX NAME)



RN 675103-32-9 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-(2-oxo-1-pyrrolidinyl)ethyl ester (CA INDEX NAME)

10/527,391



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 14 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2004:213317 CAPLUS
 DN 140:253573
 TI Preparation of 2-oxopyrimidines as human leukocyte elastase (HNE)
 inhibitors
 IN Gielen, Heike; Li, Volkhart Min-jian; Rosentreter, Ulrich; Schlemmer,
 Karl-heinz; Allerheiligen, Swen; Telan, Leila; Baerfacker, Lars;
 Keldenich, Joerg; Albrecht, Barbara; Meurer, Dirk; Fitzgerald, Mary; Nash,
 Kevin
 PA Bayer Ag, Germany
 SO Brit. UK Pat. Appl., 117 pp.
 CODEN: BAXXDU
 DT Patent
 LA English

Applicant's

FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2392910	A	20040317	GB 2003-15870	20030707
CA 2498051	A1	20040325	CA 2003-2498051	20030828
WO 2004024700	A1	20040325	WO 2003-EP9525	20030828
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003282006	A1	20040430	AU 2003-282006	20030828
EP 1546113	A1	20050629	EP 2003-773613	20030828
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003014186	A	20050809	BR 2003-14186	20030828
CN 1732159	A	20060208	CN 2003-824983	20030828
JP 2006507355	T	20060302	JP 2004-571738	20030828
NZ 538670	A	20070126	NZ 2003-538670	20030828
ZA 2005001964	A	20060531	ZA 2005-1964	20050308
MX 2005PA02644	A	20050920	MX 2005-PA2644	20050309
NO 2005001726	A	20050407	NO 2005-1726	20050407
US 20060160801	A1	20060720	US 2005-527391	20051021
PRAI GB 2002-20962	A	20020910		
GB 2002-26609	A	20021114		
GB 2003-15870	A	20030707		
WO 2003-EP9525	W	20030828		
OS MARPAT 140:253573				
AB	Title compds. [I; A = aryl, heteroaryl; R1-R3 = H, OH, halo, NO2, cyano, (substituted) alkyl, alkoxy; R4 = F3CCO, (substituted) alkylcarbonyl, alkoxy carbonyl, alkenyloxycarbonyl, CO2H, arylcarbonyl, heteroaryl, heterocyclyl, cyano, etc.; R5 = (substituted) alkyl, amino; R6 = H, CHO, CONH2, (substituted) alkyl, alkoxy carbonyl, alkylsulfonaminocarbonyl, heteroaryl, heterocyclyl, etc.; R7 = halo, NO2, cyano, OH, (substituted) alkyl, alkoxy; Y1-Y5 = CH, N, wherein the ring contains 0-2 N], were prepared Thus, 3-trifluoromethylphenylurea, 4-cyanobenzaldehyde, Et 3-oxobutyrate, and polyphosphoric acid Et ester were refluxed 18 h in THF to give 91% Et 4-(4-cyanophenyl)-6-methyl-2-oxo-1-[3-			

(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-5-pyrimidinecarboxylate. The latter inhibited HNE with IC50 = 8 nM.


IT 671775-85-2P 671775-86-3P 671775-87-4P
 671775-88-5P 671775-89-6P 671775-90-9P
 671775-91-0P 671775-92-1P 671775-93-2P
 671775-94-3P 671775-95-4P 671775-96-5P
 671775-97-6P 671775-98-7P 671775-99-8P
 671776-00-4P 671776-01-5P 671776-02-6P
 671776-03-7P 671776-04-8P 671776-05-9P
 671776-06-0P 671776-07-1P 671776-08-2P
 671776-09-3P 671776-10-6P 671776-11-7P
 671776-12-8P 671776-13-9P 671776-14-0P
 671776-15-1P 671776-16-2P 671776-17-3P
 671776-18-4P 671776-19-5P 671776-20-8P
 671776-21-9P 671776-22-0P 671776-23-1P
 671776-24-2P 671776-25-3P 671776-26-4P
 671776-27-5P 671776-28-6P 671776-29-7P
 671776-30-0P 671776-31-1P 671776-32-2P
 671776-33-3P 671776-34-4P 671776-35-5P
 671776-36-6P 671776-37-7P 671776-38-8P
 671776-39-9P 671776-40-2P 671776-41-3P
 671776-42-4P 671776-43-5P 671776-44-6P
 671776-45-7P 671776-46-8P 671776-47-9P
 671776-48-0P 671776-49-1P 671776-50-4P
 671776-51-5P 671776-52-6P 671776-53-7P
 671776-54-8P 671776-55-9P 671776-56-0P
 671776-57-1P 671776-58-2P 671776-59-3P
 671776-60-6P 671776-61-7P 671776-62-8P
 671776-63-9P 671776-64-0P 671776-65-1P
 671776-66-2P 671776-67-3P 671776-68-4P
 671776-69-5P 671776-70-8P 671776-71-9P
 671776-72-0P 671776-73-1P 671776-74-2P
 671776-75-3P 671776-76-4P 671776-77-5P
 671776-78-6P 671776-79-7P 671776-80-0P
 671776-81-1P 671776-82-2P 671776-83-3P
 671776-84-4P 671776-85-5P 671776-86-6P
 671776-87-7P 671776-88-8P 671776-89-9P
 671776-90-2P 671776-99-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2-oxopyrimidines as human leukocyte elastase inhibitors)


RN 671775-85-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)




RN 671775-86-3 CAPLUS

CN Benzonitrile, 4-[5-acetyl-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 671775-87-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-bromophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)




RN 671775-88-5 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1-(4-fluorophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-, ethyl ester (CA INDEX NAME)



RN 671775-89-6 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 1-(3-chlorophenyl)-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-, ethyl ester (CA INDEX NAME)



RN 671775-90-9 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, (1S)-2-methoxy-1-methyl-2-oxoethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 671775-91-0 CAPLUS

CN Benzonitrile, 4-[1,2,3,4-tetrahydro-6-methyl-5-(4-morpholinylcarbonyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 671775-92-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-cyanophenyl)-N,N-diethyl-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 671775-93-2 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 671775-94-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-3-formyl-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)




RN 671775-95-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 671775-96-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-N-propyl-1-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 671775-97-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-N-(2-methoxyethyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 671776-01-5 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-1-(3-methylphenyl)-2-oxo-, ethyl ester (CA INDEX NAME)




RN 671776-02-6 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-chlorophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)




RN 671776-03-7 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 6-(bromomethyl)-4-(4-chlorophenyl)-1,2,3,4-tetrahydro-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)





RN 671776-04-8 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-chlorophenyl)-6-[(diethylamino)methyl]-1,2,3,4-tetrahydro-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)



RN 671776-05-9 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(4-chlorophenyl)-1,2,3,4-tetrahydro-2-oxo-6-[(phenylamino)methyl]-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)



RN 671776-06-0 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(4-chlorophenyl)-1,2,3,4-tetrahydro-3,6-

dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)




RN 671776-07-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(6-cyano-3-pyridinyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)




RN 671776-08-2 CAPLUS

CN 2-Pyridinecarbonitrile, 5-[1,2,3,4-tetrahydro-5-(1H-imidazol-1-ylcarbonyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 671776-09-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(6-cyano-3-pyridinyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-hydroxyethyl ester (CA INDEX NAME)




RN 671776-10-6 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(6-cyano-3-pyridinyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-(dimethylamino)ethyl ester (CA INDEX NAME)



RN 671776-11-7 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(6-cyano-3-pyridinyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-(4-pyridinyl)ethyl ester (CA INDEX NAME)



RN 671776-12-8 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(6-cyano-3-pyridinyl)-1,2,3,4-tetrahydro-6-

methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-(2-pyridinyl)ethyl ester
(CA INDEX NAME)




RN 671776-13-9 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(6-cyano-3-pyridinyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-(2-oxo-1-pyrrolidinyl)ethyl ester (CA INDEX NAME)




RN 671776-14-0 CAPLUS

CN 1(2H)-Pyrimidineacetic acid, 6-(4-cyanophenyl)-5-(ethoxycarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)




RN 671776-15-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-3-(cyclopropylcarbonyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)



RN 671776-16-2 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-3-ethyl-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)



RN 671776-17-3 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-

3-(4-morpholinylcarbonyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)




RN 671776-18-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-3-[(dimethylamino)carbonyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)





RN 671776-19-5 CAPLUS

CN 1,5(2H)-Pyrimidinedicarboxylic acid, 6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, 5-ethyl 1-methyl ester (CA INDEX NAME)




RN 671776-20-8 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-3-(phenylmethyl)-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)




RN 671776-21-9 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-3-(1-oxopropyl)-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)




RN 671776-22-0 CAPLUS
 CN 1,5(2H)-Pyrimidinedicarboxylic acid, 6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, 5-ethyl 1-(2-methoxyethyl) ester (CA INDEX NAME)




RN 671776-23-1 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-3-(2-methyl-1-oxopropyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)




RN 671776-24-2 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-3-[(diethylamino)carbonyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)




RN 671776-25-3 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-3-[[methyl(methylsulfonyl)amino]carbonyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)



RN 671776-26-4 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 3-(2-amino-2-oxoethyl)-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)




RN 671776-27-5 CAPLUS
 CN 1(2H)-Pyrimidineacetic acid, 6-(4-cyanophenyl)-5-(ethoxycarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 671776-28-6 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 3-(2-aminoethyl)-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)




RN 671776-29-7 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-3-(2-pyridinylmethyl)-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)




RN 671776-30-0 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-3-[2-(diethylamino)ethyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)




RN 671776-31-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-3-[2-(methylamino)-2-oxoethyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)




RN 671776-32-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-3-(3-pyridinylmethyl)-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)




RN 671776-33-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-3-(4-pyridinylmethyl)-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)





RN 671776-34-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-3-(1H-imidazol-2-ylmethyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)




RN 671776-35-5 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 3-(cyanomethyl)-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)




RN 671776-36-6 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-3-[2-[(2-methoxyethyl)amino]-2-oxoethyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)




RN 671776-37-7 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, methyl ester (CA INDEX NAME)




RN 671776-38-8 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, cyclopropylmethyl ester (CA INDEX NAME)



RN 671776-39-9 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 1-methylethyl ester (CA INDEX NAME)



RN 671776-40-2 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, (1R)-2-methoxy-1-methyl-2-oxoethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 671776-41-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-N,N,6-trimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 671776-42-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-3-[2-(4-morpholinyl)-2-oxoethyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)




RN 671776-43-5 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-3-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)




RN 671776-44-6 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-3-[2-[[2-(dimethylamino)ethyl]amino]-2-oxoethyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)




RN 671776-45-7 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-3-[2-(dimethylamino)-2-oxoethyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)



RN 671776-46-8 CAPLUS


CN Benzonitrile, 4-[1,2,3,4-tetrahydro-6-methyl-5-(3-methyl-1,2,4-oxadiazol-5-yl)-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)



RN 671776-47-9 CAPLUS


CN Benzonitrile, 4-[5-(2-benzothiazolyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-

[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 671776-48-0 CAPLUS

CN Benzonitrile, 4-[1,2,3,4-tetrahydro-6-methyl-5-(2-methyl-1-oxopropyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 671776-49-1 CAPLUS

CN Benzonitrile, 4-[1,2,3,4-tetrahydro-5-(2-methoxyacetyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 671776-50-4 CAPLUS

CN Benzonitrile, 4-[5-(2-furanylcarbonyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 671776-51-5 CAPLUS

CN Benzonitrile, 4-[5-benzoyl-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 671776-52-6 CAPLUS

CN Benzonitrile, 4-[1,2,3,4-tetrahydro-6-methyl-2-oxo-5-(2,2,2-trifluoroacetyl)-1-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 671776-53-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 671776-54-8 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-hydroxyethyl ester (CA INDEX NAME)



RN 671776-55-9 CAPLUS


CN Benzonitrile, 4-[(4R)-5-acetyl-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 671776-56-0 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-pyridinylmethyl ester (CA INDEX NAME)




RN 671776-57-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-(3-pyridinyl)ethyl ester (CA INDEX NAME)



RN 671776-58-2 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 671776-59-3 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-

2-oxo-1-[3-(trifluoromethyl)phenyl]-, 3-pyridinylmethyl ester (CA INDEX NAME)




RN 671776-60-6 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-amino-2-oxoethyl ester (CA INDEX NAME)




RN 671776-61-7 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-(formylmethylamino)ethyl ester (CA INDEX NAME)




RN 671776-62-8 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, (1-methyl-1H-imidazol-5-yl)methyl ester (CA INDEX NAME)



RN 671776-63-9 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-(1H-pyrazol-1-yl)ethyl ester (CA INDEX NAME)




RN 671776-64-0 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-(1H-1,2,4-triazol-1-yl)ethyl ester (CA INDEX NAME)




RN 671776-65-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-ethoxy-2-oxoethyl ester (CA INDEX NAME)



RN 671776-66-2 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-(dimethylamino)-2-methylpropyl ester (CA INDEX NAME)



RN 671776-67-3 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 3-(dimethylamino)propyl ester (CA INDEX NAME)

INDEX NAME)




RN 671776-68-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-(1-pyrrolidinyl)ethyl ester (CA INDEX NAME)




RN 671776-69-5 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-(3-pyridinyl)ethyl ester (CA INDEX NAME)




RN 671776-70-8 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 3-pyridinylmethyl ester (CA INDEX NAME)




RN 671776-71-9 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-amino-2-oxoethyl ester (CA INDEX NAME)




RN 671776-72-0 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-(formylmethylamino)ethyl ester (CA INDEX NAME)




RN 671776-73-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-(acetylamino)ethyl ester (CA INDEX NAME)




RN 671776-74-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, (1-methyl-1H-imidazol-5-yl)methyl ester (CA INDEX NAME)




RN 671776-75-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-(1H-pyrazol-1-yl)ethyl ester (CA INDEX NAME)




RN 671776-76-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-(1H-1,2,4-triazol-1-yl)ethyl ester (CA INDEX NAME)




RN 671776-77-5 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-ethoxy-2-oxoethyl ester (CA INDEX NAME)



RN 671776-78-6 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-(dimethylamino)-2-methylpropyl ester (CA INDEX NAME)



RN 671776-79-7 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 3-(dimethylamino)propyl

ester (CA INDEX NAME)




RN 671776-80-0 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-(1-pyrrolidinyl)ethyl ester (CA INDEX NAME)




RN 671776-81-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-pyridinylmethyl ester (CA INDEX NAME)




RN 671776-82-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1-(3,5-dichlorophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-, ethyl ester (CA INDEX NAME)




RN 671776-83-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 1,2,3,4-tetrahydro-6-methyl-4-(3-nitrophenyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)




RN 671776-84-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-chlorophenyl)-1,2,3,4-tetrahydro-6-methyl-1-(3-nitrophenyl)-2-oxo-, ethyl ester (CA INDEX NAME)




RN 671776-85-5 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 1,2,3,4-tetrahydro-6-methyl-1,4-bis(3-nitrophenyl)-2-oxo-, ethyl ester (CA INDEX NAME)




RN 671776-86-6 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-fluorophenyl)-1,2,3,4-tetrahydro-6-methyl-1-(3-nitrophenyl)-2-oxo-, ethyl ester (CA INDEX NAME)




RN 671776-87-7 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-bromophenyl)-1,2,3,4-tetrahydro-6-methyl-1-(3-nitrophenyl)-2-oxo-, ethyl ester (CA INDEX NAME)




RN 671776-88-8 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-cyanoethyl ester (CA INDEX NAME)



RN 671776-89-9 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 1,2,3,4-tetrahydro-6-methyl-4-(4-nitrophenyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)



RN 671776-90-2 CAPLUS


CN 2(1H)-Pyrimidinone, 5-acetyl-3,4-dihydro-6-methyl-4-(4-nitrophenyl)-1-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)

10/527,391




RN 671776-99-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-(acetamino)ethyl ester (CA INDEX NAME)




RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 15 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2003:350926 CAPLUS
 DN 139:230707
 TI Synthesis and antimicrobial activity of some pyrimidine derivatives
 AU Padhy, A. K.; Bardhan, M.; Panda, C. S.
 CS National Institute of Science and Technology, Berhampur, 761 008, India
 SO Indian Journal of Chemistry, Section B: Organic Chemistry Including
 Medicinal Chemistry (2003), 42B(4), 910-915
 CODEN: IJSBDB; ISSN: 0376-4699
 PB National Institute of Science Communication
 DT Journal
 LA English
 OS CASREACT 139:230707
 AB 4-Aryl-5-carbethoxy-6-methyl-1,2,3,4-tetrahydropyrimidin-2-ones have been synthesized from easily available starting materials. The carbethoxy group at the C5-position of the pyrimidine ring is converted to hydrazide, which in turn is condensed with cyclizing agents such as aromatic aldehydes, CS₂, etc. to give heterocycles. The heterocycles are then subjected to phenacylation to give (N3-phenacylpyrimidinyl)-heterocycles, e.g., I, in excellent yield. In a slightly modified way, uracil derivs. are condensed with Et bromoacetate to give N3-[(ethoxycarbonyl)methyl] derivs. The hydrazide derivs. of these N3-[(ethoxycarbonyl)methyl] derivs. subsequently react with 1,2-diketones to give pyrimidylpyridazines, e.g., II.
 IT 593283-68-2P 593283-71-7P 593283-73-9P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and antimicrobial activity of pyrimidine derivs.)
 RN 593283-68-2 CAPLUS
 CN 5-Pyrimidinecarbonitrile, 1-(2,3-dihydro-3-oxo-5,6-diphenyl-4-pyridazinyl)-1,2,3,6-tetrahydro-2,6-dioxo-4-phenyl- (CA INDEX NAME)




RN 593283-71-7 CAPLUS
 CN 5-Pyrimidinecarbonitrile, 4-(4-chlorophenyl)-1-(2,3-dihydro-3-oxo-5,6-diphenyl-4-pyridazinyl)-1,2,3,6-tetrahydro-2,6-dioxo- (CA INDEX NAME)

10/527,391



RN 593283-73-9 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1-(2,3-dihydro-3-oxo-5,6-diphenyl-4-pyridazinyl)-
4-[4-(dimethylamino)phenyl]-1,2,3,6-tetrahydro-2,6-dioxo- (CA INDEX NAME)



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 16 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2001:779582 CAPLUS

DN 136:183781

TI Investigation of the chemical reactivity of positions N-3, C-5 and C6-methyl group in Biginelli type compounds and synthesis of new dihydropyrimidine derivatives

AU Namazi, H.; Mirzaei, Y. R.; Azamat, H.

CS Lab of Carbohydrates and Biopolymers, Faculty of Chemistry, University of Tabriz, Tabriz, Iran

SO Journal of Heterocyclic Chemistry (2001), 38(5), 1051-1054
CODEN: JHTCAD; ISSN: 0022-152X

PB HeteroCorporation

DT Journal

LA English

OS CASREACT 136:183781

AB Biginelli-type compds. (I; R = Me, Ph) were prepared and converted to eight N-3 substituted dihydropyrimidines using NaH and various electrophiles (ClCO₂Et, TsCl, Ac₂O, AcCl and PhCOCl). I (R = Ph) was monobrominated at the C6-Me group using bromine solution. Reaction of the bromo derivative with amino nucleophiles, such as MeNH₂ and cyclohexylamine, produced two pyrrolopyrimidine derivs. (II; R₁ = Me, cyclohexyl). The structures of all the new compds. were confirmed using FTIR, ¹H NMR, and ¹³C NMR spectral and elemental analyses.


IT 321943-50-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(chemical reactivity of positions N-3, C-5 and C6-Me group in Biginelli type compds. and synthesis of new dihydropyrimidine derivs.)

RN 321943-50-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 1,2,3,4-tetrahydro-6-methyl-4-(3-nitrophenyl)-2-oxo-1-phenyl-, ethyl ester (CA INDEX NAME)




IT 398456-89-8P 398456-90-1P 398456-91-2P
398456-96-7P

RL: SPN (Synthetic preparation); PREP (Preparation)

(chemical reactivity of positions N-3, C-5 and C6-Me group in Biginelli type compds. and synthesis of new dihydropyrimidine derivs.)


RN 398456-89-8 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 3-acetyl-1,2,3,4-tetrahydro-6-methyl-4-(3-nitrophenyl)-2-oxo-1-phenyl-, ethyl ester (CA INDEX NAME)




RN 398456-90-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 3-benzoyl-1,2,3,4-tetrahydro-6-methyl-4-(3-nitrophenyl)-2-oxo-1-phenyl-, ethyl ester (CA INDEX NAME)



RN 398456-91-2 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 1,2,3,4-tetrahydro-6-methyl-3-[(4-methylphenyl)sulfonyl]-4-(3-nitrophenyl)-2-oxo-1-phenyl-, ethyl ester (CA INDEX NAME)



RN 398456-96-7 CAPLUS


CN 1,5(2H)-Pyrimidinedicarboxylic acid, 3,6-dihydro-4-methyl-6-(3-nitrophenyl)-2-oxo-3-phenyl-, 1,5-diethyl ester (CA INDEX NAME)

10/527,391




RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 17 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 1998:795884 CAPLUS
 DN 130:125043
 TI A Combinatorial Approach to Recognition of Chirality: Preparation of
 Highly Enantioselective Aryl-Dihydropyrimidine Selectors for Chiral HPLC
 AU Lewandowski, Kevin; Murer, Peter; Svec, Frantisek; Frechet, Jean M. J.
 CS Department of Chemistry, University of California, Berkeley, CA,
 94720-1460, USA
 SO Journal of Combinatorial Chemistry (1999), 1(1), 105-112
 CODEN: JCCHFF; ISSN: 1520-4766
 PB American Chemical Society
 DT Journal
 LA English
 AB A parallel library of 108 4-aryl-1,4-dihydropyrimidine (DHPM) enantiomers,
 which are potential selectors for chiral HPLC sepns., was synthesized
 using the single-step Biginelli multicomponent condensation. The
 individual compds. were screened by observing the enantioselectivity for
 resolution on a brush-type L-(3,5-dinitrobenzoyl)leucine-based chiral
 stationary phase, and separation factors α up to 12 were achieved. The
 best candidates from the library contained an ortho-substituted aromatic
 group at C-4 of the pyrimidine ring and an alkyl substituent at N-1.
 Resolution of the enantiomers of the lead compound, 4-(9-phenanthryl)-1,4-
 dihydropyrimidine, using semipreparative chiral HPLC followed by
 attachment to monodisperse macroporous aminomethacrylate beads, provided a
 novel polymer based chiral stationary phase with good enantioselectivities
 in the resolution of several π -acidic aryldihydropyrimidines and
 derivatized profens. In addition, 3,5-dinitrobenzamido derivs. of
 α -amino acids could be resolved under normal phase HPLC conditions
 with separation factors up to 8.
 IT 219814-96-7P 219814-97-8P
 RL: PEP (Physical, engineering or chemical process); SPN (Synthetic
 preparation); PREP (Preparation); PROC (Process)
 (combinatorial synthesis and resolution of aryldihydropyrimidinecarboxylat
 es for use as chiral stationary phases)
 RN 219814-96-7 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 1,2,3,4-tetrahydro-6-methyl-4-(1-
 naphthalenyl)-2-oxo-1-phenyl-, ethyl ester (CA INDEX NAME)




RN 219814-97-8 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 1-(3,5-dimethylphenyl)-1,2,3,4-tetrahydro-6-
 methyl-4-(1-naphthalenyl)-2-oxo-, ethyl ester (CA INDEX NAME)

10/527,391



RE.CNT 69 THERE ARE 69 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L16 ANSWER 18 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 1998:594082 CAPLUS
 DN 129:269481
 OREF 129:54755a,54758a
 TI Synthesis and characterization of metal chelates with new pyrimidine derivatives
 AU Siddiqi, K. S.; Nishat, N.
 CS Department of Chemistry, University of Bahrain, Isa Town, Bahrain
 SO Synthesis and Reactivity in Inorganic and Metal-Organic Chemistry (1998), 28(8), 1353-1369
 CODEN: SRIMCN; ISSN: 0094-5714
 PB Marcel Dekker, Inc.
 DT Journal
 LA English
 AB The ligands 4-phenyl-5-ethoxycarbonyl-6-methyl-3,4-dihydropyrimidin-2-one (L1), 1,3-diacetamido(4-phenyl-5-ethoxycarbonyl-6-methyl-3,4-dihydropyrimidin-2-one) (L2) and 1,3-dipyrimidinyl(4-phenyl-5-ethoxycarbonyl-6-methyl-3,4-dihydropyrimidin-2-one) (L3) and their metal chelates with 3d metal ions were synthesized. The conductivity measurements suggest that $[M(L1)2Cl2]$, $[M2(L2)Cl4]$, $[M'2(L2)Cl6]$ and $[M(L3)2Cl2]$ are nonelectrolytes in DMSO and MeCN while $[M'(L1)2Cl2]Cl$ and $[M'(L3)2Cl2]Cl$ are 1:1 electrolytes, where $M = Mn(II)$, $Co(II)$, $Ni(II)$, $Cu(II)$ and $Zn(II)$ and $M' = Cr(III)$ and $Fe(III)$. Spectroscopic studies show that L1 coordinates through NH and the O atom of the pyrimidinyl ring, L2 coordinates through the N and O atoms of the amide group while L3 coordinates via the two N atoms of the pyrimidinone ring. The electronic spectra and the magnetic moments reveal that all metal complexes of L1, L3 and complexes of trivalent metal ions with L2 are octahedral while those of the divalent metal ions with L2 probably have a tetrahedral structure except for the $Cu(II)$ complex which appears to be square-planar. The β values suggest a considerable degree of orbital overlap in the metal-ligand bond.
 IT 213592-25-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and complexation with first-row transition-metal ions)
 RN 213592-25-7 CAPLUS
 CN [2,1'(2'H):3'(4'H),2''-Terpyrimidine]-5'-carboxylic acid, 4'-methyl-2'-oxo-6'-phenyl-, ethyl ester (9CI) (CA INDEX NAME)




IT 213592-48-4P 213592-50-8P 213592-52-0P
 213592-54-2P 213592-56-4P 213592-58-6P
 213592-60-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of)
 RN 213592-48-4 CAPLUS
 CN Chromium(1+), dichlorobis[ethyl 6'-methyl-2'-oxo-4'-
 phenyl[2,1'(2'H):3'(4'H),2''-terpyrimidine]-5'-carboxylate-κN1]-,
 chloride, (T-4)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 213592-50-8 CAPLUS
 CN Manganese, dichlorobis[ethyl 6'-methyl-2'-oxo-4'-
 phenyl[2,1'(2'H):3'(4'H),2''-terpyrimidine]-5'-carboxylate-κN1]-
 (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 213592-52-0 CAPLUS
 CN Iron(1+), dichlorobis[ethyl 6'-methyl-2'-oxo-4'-phenyl[2,1'(2'H):3'(4'H),2''-terpyrimidine]-5'-carboxylate-κN1]-, chloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 213592-54-2 CAPLUS
 CN Cobalt, dichlorobis[ethyl 6'-methyl-2'-oxo-4'-phenyl[2,1'(2'H):3'(4'H),2''-terpyrimidine]-5'-carboxylate-κN1]-, (T-4)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 213592-56-4 CAPLUS
 CN Nickel, dichlorobis[ethyl 6'-methyl-2'-oxo-4'-phenyl[2,1'(2'H):3'(4'H),2''-terpyrimidine]-5'-carboxylate-κN1]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 213592-58-6 CAPLUS
 CN Copper, dichlorobis[ethyl 6'-methyl-2'-oxo-4'-phenyl[2,1'(2'H):3'(4'H),2''-terpyrimidine]-5'-carboxylate-κN1]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 213592-60-0 CAPLUS
 CN Zinc, dichlorobis[ethyl 6'-methyl-2'-oxo-4'-phenyl[2,1'(2'H):3'(4'H),2''-terpyrimidine]-5'-carboxylate-κN1]-, (T-4)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1993:560311 CAPLUS

DN 119:160311

OREF 119:28737a,28740a

TI Preparation of pyrimidines as pesticides.

IN Ishii, Shigeru; Nakayama, Kazuya; Yagi, Kazuo; Akimoto, Kazuhiko; Umehara, Toshuki; Kudo, Masaki; Inoe, Yoichi

PA Nissan Chemical Ind Ltd, Japan

SO Jpn. Kokai Tokkyo Koho, 32 pp.


CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 05025144	A	19930202	JP 1991-82380	19910415
PRAI	JP 1991-82380		19910415		
OS	MARPAT 119:160311				
AB	The title compds. [R1 = H, alkyl, alkenyl, alkynyl, etc.; R2 = H, halo, alkyl, haloalkyl, etc.; Z1, Z2 = O, S, imino; A, B = substituted phenyl], useful as miticides, insecticides, etc., (no data), are prepared E.g., Et 3-amino-3-(2-chlorophenyl)-2-propenoate was cyclocondensed with Et 4-(2-pyrimidinylloxy)phenylcarbamate at 100° for 3 h to give the title compound 3-[4-(2-pyrimidinylloxy)phenyl]-6-(o-chlorophenyl)-2,4(1H,3H)-pyrimidinedione. I [R1 = R2 = H, A = 2-fluorophenyl, B = 3,4-dichlorophenyl, Z1 = Z2 = O] at 1000 ppm had 100% kill when applied to Spodoptera litura.				
IT	149908-69-0P 149908-70-3P RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as pesticide)				
RN	149908-69-0 CAPLUS				
CN	5-Pyrimidinecarbonitrile, 4-(2-fluorophenyl)-1,2,3,6-tetrahydro-2,6-dioxo-1-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)				



RN 149908-70-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(2-fluorophenyl)-1,2,3,6-tetrahydro-2,6-dioxo-1-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)

10/527,391



L16 ANSWER 20 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1993:517269 CAPLUS

DN 119:117269

OREF 119:21099a,21102a

TI Preparation of 6-phenylpyrimidine derivatives as pesticides

IN Ishii, Shigeru; Nakayama, Kazuya; Akimoto, Kazuhiko; Umehara, Toshuki; Kudo, Masaki; Inoe, Yoichi

PA Nissan Chemical Ind Ltd, Japan

SO Jpn. Kokai Tokkyo Koho, 29 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 05025142	A	19930202	JP 1991-172720	19910712
PRAI	JP 1991-172720		19910712		
OS	MARPAT 119:117269				


AB The title compds. [I; R1 = H, alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, CHO, alkylcarbonyl, alkoxyalkyl, cyanoalkyl, (un)substituted Ph, PhCH₂, alkylsulfonyl, (un)substituted NH₂, etc.; R2 = H, halo, alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, alkylthioalkyl, thiol, alkylthio, alkylsulfinyl, alkylsulfonyl, HO, alkoxy, NO₂, etc.; X = halo, alkyl, alkoxy, alkylthio, haloalkyl, haloalkoxy, haloalkylthio, NH₂, cyano, NO₂; l = 0-5; Z1, Z2 = O, S, NH; B = (un)substituted Ph, (W)nAr (where n = 0,1); W = O, S(O)q (where q = 0-2), (un)substituted NH or CH₂, CO, (un)substituted CHON:CH, OCH₂, CH₂O, or NHCH₂, etc.; Ar = (un)substituted Ph, naphthyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, etc.], having excellent insecticidal and acaricidal activity particularly against spider mites, are prepared Thus, a solution of 0.70 g Et 3-amino-3-(2,6-difluorophenyl)-2-propenoate in 1,4-dioxane was added dropwise to a stirred mixture of 0.15 g 55% NaH and 1,4-dioxane with ice-cooling and after stirring 15 min at room temperature 0.8 g Et 4-(trifluoromethylthio)phenylcarbamate was added and the mixture was refluxed for 2 h to give 0.15 3-(4-trifluoromethylthiophenyl)-6-(2,6-difluorophenyl)-2,4(1H,3H)-pyrimidinedione (II). I including II killed 100% larvae of *Nilaparvata lugens*, *Henosepilachna vigintioctopunctata*, *Spodoptera litura*, and *Tetranychus urticae*.

IT 148785-95-9P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as insecticide and acaricide)

RN 148785-95-9 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,2,3,4-tetrahydro-4-imino-2-oxo-6-phenyl-3-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



10/527,391

L16 ANSWER 21 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1992:59388 CAPLUS

DN 116:59388

OREF 116:10281a,10284a

TI Preparation of 3-phenyl pyrimidine-2,4-diones as pesticides

IN Ishii, Shigeru; Nakayama, Kazunari; Yagi, Kazuo; Satow, Jun; Fukuda, Kenzou; Itoh, Kaoru; Umehara, Toshiyuki; Kudo, Masaki; Nawamaki, Tsutomu; et al.

PA Nissan Chemical Industries, Ltd., Japan

SO Eur. Pat. Appl., 379 pp.

CODEN: EPXXDW


DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 438209	A1	19910724	EP 1991-300035	19910102
	EP 438209	B1	19940921		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	JP 03287578	A	19911218	JP 1990-327671	19901128
	JP 3038903	B2	20000508		
	AU 9168587	A	19910725	AU 1991-68587	19910103
	AU 636186	B2	19930422		
	ZA 9100094	A	19911030	ZA 1991-94	19910104
	US 5116404	A	19920526	US 1991-638811	19910108
	CA 2034404	A1	19910719	CA 1991-2034404	19910117
	KR 149513	B1	19981015	KR 1991-756	19910118
PRAI	JP 1990-8826	A	19900118		
	JP 1990-53450	A	19900305		
	JP 1990-327671	A	19901128		
OS	MARPAT 116:59388				
AB	Title compds. [I; R1 = H, CHO, alkyl, alkenyl, alkynyl, alkylcarbonyl, alkoxy carbonyl, cyanoalkyl, Ph, PhCh2, alkoxy carbonylthio, alkali metal, alkaline earth metal, etc.; R2 = H, halo (halo)alkyl, hydroxyalkyl, alkoxyalkyl, alkylthioalkyl, SH, (halo)alkylthio, (halo)alkylsulfinyl, (halo)alkylsulfonyl, OH, (halo)alkoxy, CHO, cyano, NO2, thiocyanato; A, B = (substituted) Ph, naphthyl, furyl, thienyl, pyrrolyl, pyrazolyl, pyrimidyl, halo, cyano, NO2, haloalkyl, (halo)alkylthio, (halo)alkoxy, (halo)alkylsulfonyl, etc; Z1, Z2 = O, S, imino], were prepared Thus, a mixture of Et 3-amino-4,4,4-trifluorocrotonate, Et 2,3,4-trifluorophenylcarbonate, and NaH was stirred in DMF for 4 h at 90° to give title compound II. II at 0.16 kg/hal postemergent gave complete control of Abutilon avidennae, Amaranthus retroflexus, etc.				
IT	136728-92-2P				
	RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as pesticide)				
RN	136728-92-2 CAPLUS				
CN	5-Pyrimidinecarbonitrile, 1,2,3,6-tetrahydro-2,6-dioxo-4-phenyl-1-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)				

10/527,391




L16 ANSWER 22 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 1989:57604 CAPLUS
 DN 110:57604
 OREF 110:9536h,9537a
 TI Pyrimidine-5-carbonitriles from methyl N-(aminocarbonyl)- or
 N-(aminothiocabonyl)imidates
 AU Krechl, Jiri; Perez, Miguel A.; Cuadrado, Francisco J.; Soto, Jose L.
 CS Dep. Org. Chem., Prague Inst. Chem. Technol., Prague, CS-166 28, Czech.
 SO Synthesis (1988), (2), 122-4
 CODEN: SYNTBF; ISSN: 0039-7881
 DT Journal
 LA English
 OS CASREACT 110:57604
 AB Cyclization of MeOC(R1):NC(X)NHR2 (I, R1 = Et, Ph, p-tolyl, p-ClC6H4; R2 =
 Et, Ph; X = O, S) with CH2(CN)2 gave 20-89% 8 pyrimidines II. Similarly,
 I and CNCH2CO2Me or CH2(CO2Et)2 gave III (R = CN, CO2Et).
 IT 118543-61-6P 118543-62-7P 118543-63-8P
 118543-64-9P 118543-65-0P 118543-66-1P
 118543-67-2P 118579-64-9P
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
 (preparation and spectra of)
 RN 118543-61-6 CAPLUS
 CN 5-Pyrimidinecarbonitrile, 6-amino-1,2-dihydro-4-(4-methylphenyl)-2-oxo-1-
 phenyl- (CA INDEX NAME)




In claims the R7 on phenyl is not hydrogen


RN 118543-62-7 CAPLUS
 CN 5-Pyrimidinecarbonitrile, 6-amino-4-(4-chlorophenyl)-1,2-dihydro-2-oxo-1-
 phenyl- (CA INDEX NAME)




RN 118543-63-8 CAPLUS
 CN 5-Pyrimidinecarbonitrile, 1,2,3,6-tetrahydro-2,6-dioxo-1,4-diphenyl- (CA
 INDEX NAME)




RN 118543-64-9 CAPLUS
 CN 5-Pyrimidinecarbonitrile, 1,2,3,6-tetrahydro-4-(4-methylphenyl)-2,6-dioxo-1-phenyl- (CA INDEX NAME)



RN 118543-65-0 CAPLUS
 CN 5-Pyrimidinecarbonitrile, 4-(4-chlorophenyl)-1,2,3,6-tetrahydro-2,6-dioxo-1-phenyl- (CA INDEX NAME)




RN 118543-66-1 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 1,2,3,6-tetrahydro-2,6-dioxo-1,4-diphenyl-, ethyl ester (CA INDEX NAME)




RN 118543-67-2 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 1,2,3,6-tetrahydro-4-(4-methylphenyl)-2,6-dioxo-1-phenyl-, ethyl ester (CA INDEX NAME)

10/527,391




RN 118579-64-9 CAPLUS


CN 5-Pyrimidinecarbonitrile, 6-amino-1,2-dihydro-2-oxo-1,4-diphenyl- (CA
INDEX NAME)




L16 ANSWER 23 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 1988:112373 CAPLUS
 DN 108:112373
 OREF 108:18405a,18408a
 TI Amination of pyridinium betaines. Synthesis of substituted
 pyridino[5,6-c]-1-azaquinolizine and its dihydro analogs
 AU Kochkanyan, R. O.; Lukanyuk, S. S.
 CS Inst. Fiz.-Org. Khim. Uglekhim., Donetsk, 340114, USSR
 SO Khimiya Geterotsiklicheskikh Soedinenii (1987), (5), 677-80
 CODEN: KGSSAQ; ISSN: 0453-8234
 DT Journal
 LA Russian
 OS CASREACT 108:112373
 AB Amination of betaines I (R = Ph, p-tolyl, p-MeO, R1 = H; R = Ph, R1 = D5)
 by aqueous NH₃ or (NH₄)₂CO₃ gave 42-52% pyrimidoquinazolines II which (R = Ph,
 R1 = H) was treated with chloranil in DMF to give 78% dehydrogenated III
 (R = Ph, R1 = H). Amination of I (R = Ph, R1 = 3-Me) by aqueous NH₃ gave 40%
 III (R = Ph, R1 = 3-Me).
 IT 69457-39-2 69457-40-5 69457-41-6
 113271-94-6 113271-95-7
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (amination of, by aqueous ammonia or ammonium carbonate)
 RN 69457-39-2 CAPLUS
 CN Pyridinium, 1-(5-formyl-1,2,3,6-tetrahydro-2,6-dioxo-1-phenyl-4-
 pyrimidinyl)-, inner salt (CA INDEX NAME)



RN 69457-40-5 CAPLUS
 CN Pyridinium, 1-[5-formyl-1,2,3,6-tetrahydro-1-(4-methoxyphenyl)-2,6-dioxo-4-
 pyrimidinyl]-, inner salt (CA INDEX NAME)




RN 69457-41-6 CAPLUS
 CN Pyridinium, 1-[5-formyl-1,2,3,6-tetrahydro-1-(4-methylphenyl)-2,6-dioxo-4-
 pyrimidinyl]-, inner salt (CA INDEX NAME)




RN 113271-94-6 CAPLUS

CN Pyridinium, 1-(5-formyl-1,2,3,6-tetrahydro-2,6-dioxo-1-phenyl-4-pyrimidinyl)-3-methyl-, inner salt (CA INDEX NAME)




RN 113271-95-7 CAPLUS

CN Pyridinium-2,3,4,5,6-d5, 1-(5-formyl-1,2,3,6-tetrahydro-2,6-dioxo-1-phenyl-4-pyrimidinyl)-, inner salt (9CI) (CA INDEX NAME)



L16 ANSWER 24 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 1987:439737 CAPLUS
 DN 107:39737
 OREF 107:6647a,6650a
 TI Synthesis and properties of derivatives of 1,4-dihydro-5-pyrimidinecarboxylic acid
 AU Khanina, E. L.; Muceniece, D.; Kadysh, V. P.; Dubur, G. Ya.
 CS Inst. Org. Sint., Riga, USSR
 SO Khimiya Geterotsiklicheskikh Soedinenii (1986), (9), 1223-7
 CODEN: KGSSAQ; ISSN: 0453-8234
 DT Journal
 LA Russian
 OS CASREACT 107:39737
 AB Heating aryltetrahydropyrimidinethionecarboxylic acid derivs. I (R = Ph, 4-MeOC₆H₄; R₁ = CO₂Et, CONH₂, cyano; R₂ = Me, Ph) with Raney nickel in acetone at reflux for 2 h yielded the title compds. II.
 IT 108958-88-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and dehydration of)
 RN 108958-88-9 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 1,2,3,4-tetrahydro-2-hydroxy-4-(4-methoxyphenyl)-6-methyl-1-phenyl-, ethyl ester (CA INDEX NAME)



L16 ANSWER 25 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1985:422653 CAPLUS

DN 103:22653

OREF 103:3739a,3742a

TI Controlled orientation of substitution in betaines. Synthesis and conformational analysis of new heterocyclic compounds with phosphorus

AU Kochkanyan, R. O.; Lukanyuk, S. S.; Dmitruk, T. A.; Korzhenevskaya, N. G.

CS Inst. Fiz.-Org. Khim. Uglekhim., Donetsk, USSR

SO Zhurnal Obshchei Khimii (1985), 55(1), 195-200

CODEN: ZOKHA4; ISSN: 0044-460X

DT Journal

LA Russian

OS CASREACT 103:22653


AB Heterocyclic compds. [I, (E)- and (Z)-II, III and IV, X = NPh, S] were prepared from betaines. Thus, refluxing azoles V with Ph₃P in AcOH gave 56, 67% III. Treating III with HClO₄ in Me₂CHOH gave (E)-II (X = NPh). The conformation of (E)- and (Z)-II (X = NPh) was studied by NMR.

IT 69457-39-2


RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with triphenylphosphine)

RN 69457-39-2 CAPLUS

CN Pyridinium, 1-(5-formyl-1,2,3,6-tetrahydro-2,6-dioxo-1-phenyl-4-pyrimidinyl)-, inner salt (CA INDEX NAME)



L16 ANSWER 26 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 1983:539833 CAPLUS
 DN 99:139833
 OREF 99:21481a,21484a
 TI Synthesis and structural features of betaine aldehydes with polynuclear heteroaromatic cations
 AU Kochkanyan, R. O.; Spitsyn, N. V.; Baranov, S. N.
 CS Inst. Fiz.-Org. Khim. Uglekhim., Donetsk, 340048, USSR
 SO Khimiya Geterotsiklicheskikh Soedinenii (1983), (4), 505-7
 CODEN: KGSSAQ; ISSN: 0453-8234
 DT Journal
 LA Russian
 OS CASREACT 99:139833
 AB Heating I with pyridine, 4,4'-dipyridyl, quinoline, isoquinoline, or acridine gave 5-94% II (het = heterocyclyl) with betaine structures, e.g., III. Analogously obtained from 3,6-bis(dimethylamino)acridine were IV (Z = S, PhN, PhNCO).
 IT 87243-15-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 87243-15-0 CAPLUS
 CN Acridinium, 3,6-bis(dimethylamino)-10-(5-formyl-1,2,3,6-tetrahydro-2,6-dioxo-1-phenyl-4-pyrimidinyl)-, chloride (9CI) (CA INDEX NAME)




● Cl⁻

```


L16 ANSWER 27 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1982:85503 CAPLUS
DN 96:85503
OREF 96:14039a,14042a
TI Reaction of enamines with isocyanates. A new uracil synthesis
AU Capuano, Lilly; Kussler, Manfred; Kirn, H. Reiner
CS Fachrichtung 14.1 Org. Chem., Univ. Saarlandes, Saarbruecken, D-6600, Fed.
Rep. Ger.
SO Annales Universitatis Saraviensis, Reihe: Mathematisch-
Naturwissenschaftliche Fakultaet (1981), 16, 7-18
CODEN: AUSVAN; ISSN: 0080-5165
DT Journal
LA German
AB Uracils I (R1 = H, 4-MeOC6H4, Ph; R2 = CONHPh, CONHC6H4Cl-4, CONHC6H4Me,
H, Ph, Me, CN; R1R2 = o-C6H4CH2CH2; R3, R4 = H, Me, Cl; Z = O) were prepared
by base-catalyzed condensation of R1C(:CHR)NR25 [R = H, Ph, OMe; R25 =
Et2, (CH2)2O(CH2)2, (CH2)5, Me2, (CH2)4] with R3C6H4NCO. Cyclic enamines
II [R25 = (CH2)2O(CH2)2, (CH2)4] gave iminopyrimidones I (R1R2 =
o-C6H4CH2CH2, R3 = R4 = H, Z = NPh, NC6H4Cl-4, 1-naphthyl) because of
steric hindrance. I (R1 = R3 = R4 = H, R2 = CONHPh; R1 = H, R2 =
CONHC6H4Cl-4, R3 = R4 = 4-Cl; R1 = Ph, R2 = CONHPh, R3 = R4 = H; Z = O)
rearranged quant. into alkylidenobarbituric acids III in the presence of
bases.
IT 80767-96-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 80767-96-0 CAPLUS
CN 5-Pyrimidinecarboxamide, 1,2,3,4-tetrahydro-6-(4-methylphenyl)-2,4-dioxo-
N,1,3-triphenyl- (CA INDEX NAME)

```




In claims R7 on the phenyl is not hydrogen


L16 ANSWER 28 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 1981:3982 CAPLUS
 DN 94:3982
 OREF 94:743a,746a
 TI Reaction of heterocyclic betaines. Synthesis of a new heterocyclic system
 AU Kochkanyan, R. O.; Lukanyuk, S. S.
 CS Inst. Fiz.-Org. Khim. Uglekhim., Donetsk, USSR
 SO Khimiya Geterotsiklicheskikh Soedinenii (1980), (7), 992-5
 CODEN: KGSSAQ; ISSN: 0453-8234
 DT Journal
 LA Russian
 OS CASREACT 94:3982
 AB The new heterocyclic compound, pyrimidopyrimidooxazine I, was obtained by the cycloaddn. of III with the betaine II. III was obtained in 88% yield from II by treatment with Me₂NH.HCl and NaOAc in AcOH. Treatment of II with Me₂NH.HCl gave IV.
 IT 69457-39-2
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reaction of, with dimethylaminomethylene barbituric acid derivative)
 RN 69457-39-2 CAPLUS
 CN Pyridinium, 1-(5-formyl-1,2,3,6-tetrahydro-2,6-dioxo-1-phenyl-4-pyrimidinyl)-, inner salt (CA INDEX NAME)




L16 ANSWER 29 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 1979:137912 CAPLUS
 DN 90:137912
 OREF 90:21876h,21877a
 TI Synthesis of pyrimidine betaines with phosphonium and cycloammonium cations
 AU Kochkanyan, R. O.; Radkova, S. S.; Klyuev, N. L.; Petrovskaya, L. Yu.; Baranov, S. N.
 CS Inst. Fiz.-Org. Khim. Uglekhim., Donetsk, USSR
 SO Khimiya Geterotsiklicheskikh Soedinenii (1978), (12), 1687-90
 CODEN: KGSSAQ; ISSN: 0453-8234
 DT Journal
 LA Russian
 AB Chloroformylation of I gave II which on treatment with N heterocycles or Ph₃P gave III (R = Ph, p-MeC₆H₄, p-MeOC₆H₄, Me; R₁ = C₅H₅N⁺, C₉H₇N⁺, Ph₃P⁺, etc.).
 IT 69457-38-1P 69457-39-2P 69457-40-5P
 69457-41-6P 69457-44-9P 69457-45-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 69457-38-1 CAPLUS
 CN Pyridinium, 1-(5-formyl-1,2,3,6-tetrahydro-2,6-dioxo-1-phenyl-4-pyrimidinyl)-, perchlorate (9CI) (CA INDEX NAME)
 CM 1
 CRN 69457-37-0
 CMF C16 H12 N3 O3



CM 2
 CRN 14797-73-0
 CMF Cl O4




RN 69457-39-2 CAPLUS
 CN Pyridinium, 1-(5-formyl-1,2,3,6-tetrahydro-2,6-dioxo-1-phenyl-4-pyrimidinyl)-, inner salt (CA INDEX NAME)




RN 69457-40-5 CAPLUS

CN Pyridinium, 1-[5-formyl-1,2,3,6-tetrahydro-1-(4-methoxyphenyl)-2,6-dioxo-4-pyrimidinyl]-, inner salt (CA INDEX NAME)




RN 69457-41-6 CAPLUS

CN Pyridinium, 1-[5-formyl-1,2,3,6-tetrahydro-1-(4-methylphenyl)-2,6-dioxo-4-pyrimidinyl]-, inner salt (CA INDEX NAME)



RN 69457-44-9 CAPLUS


CN Quinolinium, 1-(5-formyl-1,2,3,6-tetrahydro-2,6-dioxo-1-phenyl-4-pyrimidinyl)-, inner salt (CA INDEX NAME)



RN 69457-45-0 CAPLUS

CN Isoquinolinium, 2-(5-formyl-1,2,3,6-tetrahydro-2,6-dioxo-1-phenyl-4-pyrimidinyl)-, inner salt (CA INDEX NAME)

10/527,391



L16 ANSWER 30 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1976:592595 CAPLUS

DN 85:192595

OREF 85:30799a,30802a

TI Formation of heterocyclic compounds by use of N'-diphenylmethyle-N-phenyl-N-trimethylsilylurea

AU Matsuda, Isamu; Yamamoto, Sakae; Ishii, Yoshio

CS Fac. Eng., Nagoya Univ., Nagoya, Japan

SO Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) (1976), (14), 1523-8
CODEN: JCPRB4; ISSN: 0300-922X

DT Journal

LA English


AB The reactions of the title urea (I) with acceptor mols. were studied. With cyclohexyl isocyanide, MeNCO, MeO2CC.tplbond.CC(=O)OMe, or Cl3CCN followed by desilylation I underwent [4+1] or [4+2] cycloaddn.; imidazolidinone, triazinone, and pyrimidinone derivs. were formed. E.g., I with MeNCO gave the triazinone II. I reacted with RCN (R = CC13, NMe2) to give the triazinone III and Ph2C:NC(NMe2):NPh, resp., by decomposition of the intermediate silyloxytriphenyltriazine with MeOH or under the reaction conditions, resp. Reaction of I with RR1CO (RR1 = Ph2C; R = H, R1 = CC13) gave the insertion products Ph2C:NCONPhCRR1OSiMe3. Diketene reacted with I to give the oxazinone IV.

IT 61032-91-5P 61033-58-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and desilylation of)


RN 61032-91-5 CAPLUS

CN 4,5-Pyrimidinedicarboxylic acid, 1,2,3,6-tetrahydro-2-oxo-3,6,6-triphenyl-1-(trimethylsilyl)-, dimethyl ester (9CI) (CA INDEX NAME)



RN 61033-58-7 CAPLUS

CN 4,5-Pyrimidinedicarboxylic acid, 3,6-dihydro-3,6,6-triphenyl-2-[(trimethylsilyl)oxy]-, dimethyl ester (9CI) (CA INDEX NAME)




IT 61033-49-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 61033-49-6 CAPLUS

CN 4,5-Pyrimidinedicarboxylic acid, 1,2,3,6-tetrahydro-2-oxo-3,6,6-triphenyl-, dimethyl ester (9CI) (CA INDEX NAME)



10/527,391

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

169.26

900.93

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-24.00

-24.80

STN INTERNATIONAL LOGOFF AT 15:12:21 ON 20 JUL 2008